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Abstract 
Tumour necrosis factor  (TNF) is an essential pro-inflammatory cytokine predominantly 
secreted by macrophages that regulates the inflammatory response to infection. Macrophages 
are essential phagocytic innate immune cells resident in all tissues. In response to distinct 
stimuli, macrophages are polarized into classically activated macrophages (CAM) or 
alternatively activated macrophages (AAM). CAM have a pro-inflammatory phenotype with a 
strong ability in killing invading pathogens whereas AAM display an anti-inflammatory 
phenotype and promote tissue repair. The enzymes iNOS and Arginase-1 are signature 
molecules expressed by CAM and AAM, respectively, and they use the same substrate L-
arginine competitively. TNF plays a central role in restricting AAM differentiation in parasitic 
infection with Leishmania (L.) major and a tumour model and we hypothesized that it would 
be applicable generally. Therefore, this thesis investigated the role of TNF in the activation of 
macrophages during an infection with the gram-positive bacterium Listeria (L.) monocytogenes.  
Wild-type and B6.TNF-/- mice were infected with L. monocytogenes and macrophage 
differentiation in spleen (Chapter 3) and peritoneum (Chapter 4) was analysed. TNF deficiency 
resulted in high susceptibility of infected mice to L. monocytogenes with high bacterial loads 
in spleen and liver. In addition, there was a strong expression of Arginase-1 and an intact 
presence of iNOS in splenic and peritoneal macrophages, indicating a regulation of AAM 
differentiation during L. monocytogenes infection by TNF. Furthermore, in response to the 
alternative activation of macrophages in B6.TNF-/- mice, the number of splenic neutrophils and 
the titre of the pro-inflammatory cytokine IL-1 increased. This indicates that TNF also 
orchestrates immune responses to bacterial infection and indicates that its role in the 
suppression of central molecules of the AAM signature such as Arg1 is a general phenomenon. 
In addition, this thesis investigated the role of TNF in phagocytosis of L. monocytogenes and 
Devil Facial Tumour Disease (DFTD) cells by macrophages (Chapter 5). We examined 
macrophage phagocytosis of L. monocytogenes and DFTD cells by macrophages from wild-
type and B6.TNF-/- mice. Under steady state conditions there was no difference in phagocytosis 
efficiency. However, the treatment of macrophages with IFN plus LPS or LPS alone increased 
phagocytosis in macrophages from B6.TNF-/- mice, to a greater degree than macrophages from 
wild type mice. It is likely that TNF regulates phagocytosis of DFTD cells by activated 
macrophages.  
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In summary, these results indicate a key role for TNF in orchestrating innate immune responses 
through modulating the macrophage differentiation and phagocytosis. The AAM bias in the 
absence of TNF leads to the high susceptibility to bacterial infection, suggesting an essential 
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Chapter 1: Literature review 
1.1 Tumour necrosis factor  
1.1.1 TNF in pathology 
Tumour necrosis factor α (TNF) is an important inflammatory cytokine, which was first named 
in 1975 for its ability to induce tumour cell hemorrhagic necrosis in mice [5]. TNF has also 
been reported to play a role in a central endogenous mediator of endotoxic shock [5]. 
Additionally, as a pro-inflammatory cytokine, TNF is essential in initiation and resolution of 
inflammation. Overproduction of TNF is involved in many inflammatory diseases. Studies in 
TNF- or TNFR- deficient mice have indicated the essential role of TNF in host defence against 
bacterial and viral infections [5]. TNF is synthesised rapidly after infection and orchestrates 
pro-inflammatory cytokine production, which suggests its importance in the development of 
many inflammatory diseases including Rheumatoid arthritis (RA) and Crohn’s disease [6]. For 
instance, high concentrations of TNF have been found in the joints and synovial fluid from RA 
patients [7]. Thus, drugs targeting TNF have been developed for treatment of RA and Crohn’s 
disease. These include anti-TNF antibody (Remicade), and anti-TNF receptors Fc fusion 
protein (Etanercept, Lenercept) [8].   
 
1.1.2 TNF expression 
TNF is one of the 19 TNF family members which also includes TNFβ, FAS ligand (FasL) and 
CD40 ligand (CD40L) [5]. TNF genes are located within the cluster of major histocompatibility 
complex (MHC) genes on the murine chromosome 17 and the short arm of human chromosome 
6 [9]. There is a 20-30% identity in protein sequence between family members and they share 
the conserved region referred to as the TNF homology domain (THD) [10]. THD is required 
for TNF family members to bind to the TNF receptors at conserved cysteine rich regions to 
activate downstream pathways. TNF is sourced from macrophages, mast cells, T cells and B 
cells [11]. Lipopolysaccharide (LPS) or TNF itself is the potent stimuli to TNF synthesis [11]. 
Several transcription factors regulate TNF expression including nuclear factor kappa B (NF-
κB), activating protein-1(AP-1) and AP-2 [12]. There are two forms of TNF in cells: 
transmembrane (mTNF) and soluble TNF (sTNF) [13]. TNF is initially produced as a 27kD 
mTNF anchored by a N-terminal hydrophobic domain [14]. TNF is subsequently cleaved into 
17kD sTNF, by the metalloprotease TNFα-converting enzyme (TACE) [15]. The expression 
of TNF is also regulated at the post-transcriptional level, with mRNA stability regulated by 
Tristetraprolin (TTP) [16].  
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1.1.3 TNF signal transduction  
TNF acts through binding with the receptors, TNF receptor 1 (TNFR1) and TNF receptor 2 
TNFR2, in a trimeric manner [6]. TNFR1 and TNFR2 are expressed in most mammalian cells 
[17]. TNF binds to TNFR1 with higher affinity than TNFR2 [18], suggesting the predominant 
role of TNFR1 in TNF induced cellular responses. The trigger of TNF signaling pathway leads 
to various responses, including cell survival, apoptosis and necrosis.   
 
1.1.3.1 Activation of the NF-κB and MAPK pathways  
Following TNF binding, TNFR1 provides a docking site and interacts with the TNF receptor 
associated death domain (TRADD) [5]. TRADD then recruits TNFR-associated factors 
(TRAFs), which include TRAF2, TRAF5, receptor interacting protein-1 (RIP-1) and cellular 
inhibitor of apoptosis proteins 1 and 2 (cIAP-1 and 2), to form the TNF receptor signalling 
complex [5]. TRAF2 and TRAF5 double knockout cells demonstrated that TRAF2 and TRAF5 
are required in TNF-induced NF-κB activation [19]. RIP-1 is a unique serine/threonine kinase 
with a death domain in the C-terminus [20]. The recruitment of RIP1 and TRAF2 are 
independent during the process of forming the signalling complex [21]. In addition, the lipid 
rafts provide the micro domain for the ubiquitylation of TNFR1 and RIP-1, as inhibition of the 
organization of lipid rafts impaired the NF-κB activation [22]. After formation of the TNF 
receptor signalling complex, RIP1 is polyubiquitinated by cIAP-1 and cIAP-2. This triggers 
activation of TGF-β activated kinase (TAK1) [22]. TAK1 then activates NF-κB which leads to 
NF-κB translocation into the cell nucleus, where it activates the transcription of genes such as 
cytokines, chemokines, growth factors and survival genes [23]. TAK1 activation also results 
in the activation of MAPK pathway which includes JNK and p38 [24]. The activation of MAPK 
pathway results in the activation of AP-1, it has similar activity to NF-κB in regulation of gene 
expression [5].   
 
1.1.3.2 Induction of apoptosis and necrosis 
TNF induces cells to undergo apoptosis. The Fas-associated protein-containing death domain 
(FADD) is also recruited by TRADD and subsequently RIP-1 is deubiquitinated. FADD and 
RIP-1 activate pro-caspase 8 and in turn results in the release of cytochrome c from 
chondriosome [25]. The released cytochrome c leads to apoptosis through activating caspase-
3/7 [25]. The activation of NF-κB inhibits TNF induced apoptosis, suggesting there is a balance 
between apoptosis and cell survival signals in response to TNF [26]. In the initiation of necrosis, 
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RIP-1 interact with RIP-3 to form the RIP-1/RIP-3 necrosome. RIP-3 then phosphorylate 
phosphoglycerate mutase family member 5 (PGAM5), which dephosphorylates dynamin-
related protein 1 (Drp1) and leads to necrosis [27]. Knockdown of PGAM5 or Drp1 impairs 
TNF induced necrosis [5]. In addition, the generation of reactive oxygen species (ROS) also 
plays a role in PGAM5/Drp1 dependent TNF activated necrosis [28].    
 
Figure 1.1: Overview of TNF signaling pathway. TNF binds with TNFR1 and then TNFR1 recruits 
TRADD. TRADD activates the formation of TNF receptor signalling complex, RIP-1 is subsequently 
triggers TAK-1 activation and leads to the activation of NF-B and MAPK pathway. FADD interacts 
with RIP-1 and leads to the activation of caspase-8, then triggers the induction of apoptosis. RIP-1/RIP-
3 necrosome formation leads to the phosphorylation of PGAM5S and subsequent necrosis. Adapted 
from [6].  
 
1.1.4 TNF and macrophages 
Macrophages are the dominant source of TNF during infection and injury [6]. TNF activates 
macrophages in an autocrine manner as a positive feedback loop to induce further activation 
of macrophages [29]. Macrophages are a population of innate immune cells that form the first 
line of defense against bacterial infection [6]. They are also essential in tissue homeostasis, 
tissue repair, regulation of adaptive immune response and inflammation [6]. Macrophages are 
a major defense system against invading microorganisms through phagocytosis, destruction of 
organisms, antigen presentation, and synthesis of a range of products, including enzymes, 
complement components, chemokines and cytokines [6]. The released cytokines and 
chemokines also activate macrophages in an autocrine/paracrine manner to further regulate the 
inflammatory response [6]. Because of the essential role of macrophages in physiological and 
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pathophysiological processes, mechanisms of TNF activities in macrophage have been 
investigated.  
 
TNFR1 deficient mice are susceptible to the infection by pathogens, including Leishmania 
major [30], Listeria. monocytogenes [31]. It indicates the requirement of TNF signaling in host 
defense against parasite and bacterium. TNF is known in the activation of macrophages. In 
combination with IFNγ, TNF activates macrophages of classically activated macrophage 
phenotypes with a high capacity for microbicidal or tumoricidal, secreting pro-inflammatory 
cytokines [6]. Typically, TLR ligands trigger macrophages in a MyD88-dependent pathway to 
produce TNF, which cooperates with IFNγ to activate macrophages in an autocrine manner 
[32]. Some TLR ligands can also trigger the production of IFN by regulating the IFN-
regulatory factor 3 (IRF3) pathway [33]. The IFN replaces IFNγ and combines with TNF to 
induce the classically activated macrophages [33]. In addition to the role of promoting 
differentiation of classically activated macrophages, TNF has been shown to inhibit 
alternatively activated macrophage differentiation [34, 35]. In infection by L. major, 
macrophages from TNF-/- mice were indicated to exhibit the phenotype of AAM, with high 
expression of AAM markers, such as Arginase-1, CD206, Ym1 and Fizz1 [35]. TNF inhibits 
AAM markers expression in IL-4 induced macrophages [35]. The role of TNF in inhibiting 
AAM differentiation in other model needs to be investigated.  
 
1.2 Macrophages  
Macrophages are resident in all tissues of adult mammals and they are heterogeneous in 
function in particular microenvironment. They have different names in different tissue, such as 
microglial cells in nervous system, Kupffer cells in liver, alveolar macrophages in lung, and 
Langerhans cells in skin [36]. Macrophages play key roles in maintance of tissue homeostasis 
by clearing apoptotic cells, tissue development, and immune response to pathogens by 
initiating and resolving inflammation [37]. Tissue resident macrophages regulate homeostasis 
by responding to changes to physiology and challenges from microenvironment. Macrophages 
can also be recruited from bone marrow or tissue resident progenitors by local proliferation in 
the situation of infection. Macrophages are important therapeutic targets in many diseases and 
related to many disease state. It makes the investigation of diverse phenotype in macrophages 
to be important.  
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1.2.1 Tissue resident macrophage origins 
Tissue resident macrophages have at least three lineages in mice, which arise at different 
developmental stages and persist to adulthood [38]. Macrophages are generated from the yolk 
sac in the embryo and colonise in the tissue where they persist in the adult [39]. The fetal liver 
is responsible for a second linage and gives rise to circulating monocytes during embryogenesis 
[40]. After birth, bone marrow is the main source of circulating monocytes and tissue resident 
macrophages [40]. Bone marrow derived monocytes originate from hematopoietic stem cells 
(HSC) with self-renewing ability [41]. After a series of differentiations, HSC become 
granulocyte and monocyte progenitors (GMP) [42]. GMPs then differentiate into monocyte 
and dendritic cell progenitors (MDP) [42]. These generate DCs and macrophages and lose the 
ability to differentiate into granulocytes [43]. Yolk sac and fetal liver are the main contributers 
of tissue resident macrophages in homeostasis. It is evident that adult microglial cells are 
generated from yolk sac and Langerhans cells in skin are derived from the yolk sac and fetal 
liver [37]. These yolk sac derived macrophages express high levels of the F4/80 marker 
(F4/80hi) in spleen, peritoneum, liver, skin and brain [44]. Under inflammatory conditions, 
bone marrow derived monocytes are recruited into inflammation sites and give rise to 
inflammatory dendritic cells (DC) and macrophages [41]. Due to the limitations of 





Figure 1.2: Tissue resident macrophage origins in mice. The tissue resident macrophages in 
adults originate from three sources. Before birth, yolk sac generates progenitors and populates the 
spleen and peritoneum. The second is fetal liver through progenitors generated from yolk sac. After 
birth, bone marrow is the main origin of tissue resident macrophages. The circulating Ly6Chi and 
Ly6Clow monocytes give rise to macrophages and DCs in the tissue. Adapted from [1].  
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1.2.1.1 Splenic macrophages 
The spleen is a key organ for pathogen filtration, erythrocyte homeostasis and iron metabolism. 
It has all the major types of phagocytes such as monocytes, macrophages, and DCs [45]. These 
phagocytes are essential protectors in identifying cellular stress, pathogens, and phagocytosing 
dying cells [45]. The spleen is organized as red pulp, white pulp and marginal zones (MZ) [46]. 
Red pulp filters blood and recycles iron from old erythrocytes through phagocytosis by red 
pulp macrophages. White pulp has T cell and B cell follicles and protects the hosts against 
blood-borne pathogen infections and generates antigen specific immune responses [45]. The 
phenotype of red pulp macrophages is F4/80+CD206+CD11blo/-, and white pulp macrophages 
are identified by the pan-macrophage marker CD68 [47]. MZ surrounds the white pulp and 
promotes T cell responses by capturing antigens to white pulp [46]. MZ macrophages are 
characterized by the expression of MARCO (Macrophage receptor with collagenous structure), 
CD204 (Scavenger receptor A) and SINGR1 [47]. These MZ macrophages are efficient in 
trapping blood-borne antigens and pathogens. For example, SINGR1 recognizes 
polysaccharide antigens of Mycobacterium tuberculosis efficiently, then degrade these 
pathogens by phagocytosis [48].   
 
1.2.1.2 Resident macrophages in peritoneum and central nervous system 
The peritoneal cavity has the cell composition of B cells, T cells, NK cells, macrophages, 
eosinophils and DCs [1]. There are two subsets in peritoneal macrophages, large peritoneal 
macrophages (LPMs) and small peritoneal macrophages (SPMs) [1]. LPMs are 
F4/80highCD11b+ and SPMs are characterized as F4/80lowCD11b+ phenotype [49]. CD11b 
belongs to the integrin family and it forms the complement receptor 3 heterodimer together 
Table 1.1 | Phenotypic profile of LPMs and SPMs[1]   
Surface molecule LPMs  SPMs 
F4/80  +++ + 
CD11b  +++ + 
MHC-II  + ++ 
Ly6C - - 
CD62L - ++ 
CD80 ++ + 
CD86 +++ + 
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with CD18 [50]. CD11b is expressed not only on macrophages, but also DCs, T and B cells 
[50]. It is required for monocyte adhesion with other immune cells, as the deficiency of CD11b 
leads to impaired myeloid cell recruitment in inflammation [51].  F4/80 has been used as a 
specific mouse macrophage marker and it is a glycoprotein that belongs to epidermal growth 
factor-transmembrane7 (TM7) family [1]. It is expressed in tissue resident macrophages 
(Kupffer cells, microglia, Langerhans cells), eosinophils and DCs, but not on fibroblasts or 
lymphocytes [51]. 
LPMs are the more abundant peritoneal macrophages in homeostasis [1]. LPMs and SPMs are 
present in the peritoneal cavity from several mouse strains, such as C57Bl/6, BALB/c, 129/S6, 
SJL/J, FVB/N [1]. These two peritoneal macrophage subsets have distinct morphologies and 
phenotypes. LPMs have abundant vacuoles in the cytoplasm, whereas SPMs exhibit dendrites 
with a polarized morphology in culture [52]. In addition, LPMs and SPMs express different 
levels of surface molecules (Table 1.1). LPMs and SPMs exhibit different phagocytic abilities, 
cytokines synthesis and nitric oxide production [49]. Phagocytosis analysis showed that SPMs 
appear to have higher efficiency in phagocytosis of zymosan and E. coli [49, 52]. SPMs and 
LPMs don't produce significant levels of inflammatory cytokines in steady-state conditions. 
SPMs secrete increased levels of pro-inflammatory cytokines such as TNF, IL-1β and IL-12 
following stimulation with Staphylococcus epidermidis cell-free (SES) supernatant [53]. 
During stimulation with LPS in vitro, SPMs produce TNF, MIP-1α whereas LPMs secrete G-
CSF, GM-CSF [53]. SPMs from Trypanoso macruzi, zymosan-inoculated mice produce high 
levels of NO in response to LPS in vitro [52]. In the LPS inoculated mice, SPMs produce larger 
amounts of NO than LPMs [49].  
After inflammatory stimulations, peritoneal cell subsets are altered dramatically, such as 
recruited monocytes, increased number of SPMs, and disappearing LPMs [54]. These 
responses are described as ‘Macrophage disappearance reactions’ [54]. The macrophage 
disappearance reactions is attributed to cell death, migration to lymph nodes or increased tissue 
adherence [1]. LPMs are generated from yolk sac and maintained by self-renewal. SPMs 
originate from bone marrow derived inflammatory monocytes in homeostasis [1]. Yolk sac 
generated macrophages in general are F4/80hi phenotype, which correlates with the LPM 
phenotype. During inflammatory conditions, SPMs differentiate from bone marrow derived 
Ly6C+ monocytes [1]. Confirming that impaired inflammatory monocyte recruitment in CCR2-
/- mice leads to reduced numbers of SPMs in inflammation [55]. After inoculation with LPS or 
thioglycollate, monocytes shift towards the SPM phenotype, suggesting a monocyte origin of 
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SPM [49]. LPMs undergo proliferation in homeostasis to maintain the number of F4/80hi 
peritoneal macrophages [1]. The proliferation ability of LPM is decreased in 12-week-old mice 
compared with newborn mice [56]. The transcription factor GATA-binding protein 6 (GATA6) 
is essential in LPM proliferation [55]. GATA6 is specifically expressed in LPMs and GATA-
6 deficiency in macrophages leads to reduced number of LPMs in the peritoneal cavity [55]. 
Moreover, vitamin A induced retinoic acid induces the specific gene expression of GATA-6 in 
LPMs [55]. The self-proliferation of LPMs is a phenotype of AAMs which is related to tissue 
repair after resolution of the infection [57]. The macrophages in central nervous system, 
including microglia also have the ability to proliferate. Microglia are derived from yolk sac 
macrophages during early embryogenesis and express macrophage-associated markers, 
including CD11b and CD14 [58]. The self-proliferation of microglia is essential in infection, 
injury and irradiation throughout life. The transcription factor PU.1 and interferon regulatory 
factor 8 (IRF8) are implicated in microglia differentiation and development [59].  
 
1.2.2 Molecules related to monocyte development 
Monocyte development requires the stimulation of growth factors. Macrophage colony- 
stimulating factor-1 receptor (M-CSFR) is crucial for monocyte development. M-CSFR is a 
class III transmembrane tyrosine kinase receptor and it is expressed on most mononuclear 
phagocytic cells [41]. Macrophages are severely depleted in many tissues in M-CSFR deficient 
mice [60]. One of the M-CSFR ligands is M-CSF, the administration of M-CSF increases the 
proliferation of tissue resident macrophages, and expansion of the monocyte pool in tissues 
[61]. The other ligand of M-CSFR is IL-34, which is required for the development of microglia 
and Langerhans cells [62]. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is 
the other growth factor that regulates macrophage development, as shown by GM-CSF 
deficient mice having defects in tissue macrophages (except for alveolar macrophages) [38]. 
In addition, the development of monocytes is regulated by several transcription factors. The 
transcription factor PU.1, belonging to Ets family, is required for monocyte generation [63]. 
PU.1 deficiency leads to a general myeloid lineage defect in mice [64]. PU.1 drives GMP 
development into monocytes through interaction with transcription factor C/EBPα [65], Gata-
1 and Gata-2 [66]. The transcription factor Gata-6 is required for the local proliferation of 
resident macrophages [67]. Gata-6 deficiency leads to dysregulation of peritoneal macrophage 
proliferation in homeostasis and inflammation [67].  
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1.2.3 Monocyte heterogeneity in mouse 
Monocytes are a population of innate immune cells which are highly heterogeneous in 
phenotype and function [41]. There are two subsets of monocytes in mice: Ly6Chi inflammatory 
and Ly6Clow non-inflammatory monocytes [68]. Ly6Chi inflammatory monocytes express high 
level of CC- chemokine receptor 2 (CCR2) and low level of CX3C- chemokine receptor 
1(CX3CR1) [68]. The Ly6Clow non-inflammatory monocytes have low expression of CCR2 
and high level of CX3CR1 [68]. The Ly6Chi monocytes and Ly6Clow monocytes exhibit distinct 
functions with Ly6Chi monocytes being pro-inflammatory and Ly6Clow monocytes having anti-
inflammatory activities.  
In bacterial (L. monocytogenes [69]) and protozoal (Leishmania major [70]) infections, Ly6Chi 
monocytes are recruited to the infected sites with a high capacity for producing TNF and 
inducible nitric oxide (iNOS). Conversely, Ly6Clow monocytes patrol blood vessels to 
scavenge dead cells, oxidized lipids, and pathogens in homeostasis [71]. To carry out these 
roles, Ly6Clow monocytes require integrin LFA-1 and chemokine receptor CX3CR1 [71]. 
During L. monocytogenes infection, Ly6Clow monocytes are recruited in the very early stage of 
infection and mediate early responses to bacterial infection [71]. In the spinal cord injury model, 
Ly6Clow monocytes are essential in wound recovery with high expression of IL-10 and arginase 
1 [72]. Some studies have indicated that Ly6Chi monocytes are progenitors of Ly6Clow 
monocytes with decreasing expression of Ly6C [73]. Ly6Chi monocytes differentiate into 
Ly6Clow monocytes in homeostasis as demonstrated by a fate mapping study [40]. The M-
CSFR antibody blockade results in an increased number of Ly6Chi monocytes and reduced 
number of Ly6Clow monocytes [74]. The decrease of Ly6Clow monocytes is balanced by the 
increase of Ly6Chi monocytes which suggested the requirement of M-CSF in the maturation of 
Ly6Chi to Ly6Clow monocytes [74].  
  
1.2.4 Monocyte migration in infection 
Chemokines are small molecules required for the trafficking of monocytes into inflammatory 
sites. According to the sequence of cysteine residues in the ligands, chemokines are classified 
into four subsets: CC, CX3C, CXC and C; Where C represents a cysteine and X represents a 
noncysteine amino acid [75]. CCR2 is essential for the migration of Ly6Chi monocytes to the 
sites infected with L. monocytogenes [76], M. tuberculosis [77] and L. major [78]. The 
recruitment of Ly6Chi monocytes in response to L. monocytogenes infection was dampened in 
the CCR2 deficient mice [76].  CC-chemokines ligand 2 (CCL2) and CCL7 are ligands of 
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CCR2 and mediate the recruitment of Ly6Chi monocytes [79]. L. monocytogenes infection 
induces CCL2 and CCL7 production in the serum, liver, spleen and lung [79]. The enhanced 
CCL2, CCL7 expression in tissue results in the recruitment of inflammatory cells to infection 
sites [79]. The mechanism of CCL2 action in monocyte migration remains unclear. One idea 
is that the dimerization and glycosaminoglycan of CCL2 in specific tissues are required for  
gradient establishment and monocyte migration [75, 80]. The prevention of CCL2 dimerization 
or glycosaminoglycan leads to the impairment of monocyte recruitment. The recruitment of 
Ly6Clow monocytes is mediated through CX3CR1 [81]. Deficiency of  CX3CR1 leads to 
diminished Ly6Clow monocyte recruitment [71]. The ligand of CX3CR1, CX3CL1 is 
upregulated in the marginal zone of the spleen in response to L. monocytogenes infection. It 
mediates early migration of Ly6Clow monocytes into spleen [81]. Moreover, CX3CR1 has some 
roles in Ly6Chi monocyte migration as CX3CR1 deficiency also leads to the reduced migration 
of Ly6Chi monocytes to the spleen following bacterial infection [81].  
 
1.2.5 Macrophage polarization and functional phenotypes 
Macrophages adopt several functional phenotypes in response to the tissue microenvironment 
in vivo. They recognize pathogens to initiate and direct T-cell dependent immune responses 
[38]. The activated T cells release cytokines such as IFN and IL-4 to further activate 
macrophages [38]. In response to stimulation, macrophages can be polarized into classically 
activated macrophages (CAM, M1 macrophages) and alternatively activated macrophages 
(AAM, M2 macrophages) [2]. Macrophages are polarized toward CAM in the activation of 
IFN alone or in concert with TNF or LPS. Conversely, Th2 cytokines such as IL-4 and IL-13 
polarize macrophages toward to AAM phenotype [2]. CAMs and AAMs exhibit different 
functional phenotypes in terms of receptor expression, effector function and cytokine 
production as discussed later.  
 
1.2.5.1 Classically activated macrophages 
Upon activation, CAMs produce high levels of pro-inflammatory cytokines (TNF, IL-1β), 
chemokines, costimulatory molecules (CD80, CD86) and effector molecules (NO, ROS) [32]. 
IFN and LPS induce macrophages to express chemokines CXCL10, CXCL9 and CCL5 [2]. 
The expression of these chemokines is dependent on LPS through the activation of the 
transcriptional factor ‘signal transducer and activator of transcription 1’ (STAT1) [82]. In 
addition, the IFN and TLR signalling dependent expressions of CXCL10, CXCL9 and CCL5 
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are inhibited by IL-4 [82]. The suppression of transcriptional activation of IFN and LPS by 
IL-4 requires ‘signal transducer and activator of transcription’ (STAT6), which inhibits the 
activation of STAT1 and NF-B [83]. NK cell production of IFNγ is required for the 
maturation of Ly6Chi monocytes following L. monocytogenes infection [84]. The NK cell 
secreted IFN is transient and the maintaining CAM activation needs adaptive immune 
responses [84]. TNF only activates macrophages in the presence of IFN, and the activated 
macrophages produce TNF and the new synthesised TNF activates macrophages with IFNγ in 
an autocrine manner [32]. IFN or TNF deficient mice are susceptible to L. monocytogenes 
infection, suggesting the requirement of both IFN and TNF in response to bacterial infection 
[85]. LPS combines with IFNγ and induces CAMs through toll like receptor 4 (TLR4) 
signalling [32]. Gene expression profiles of IFNγ in combination with LPS are different with 
the treatment of IFNγ, LPS alone [86]. IFNγ and LPS produce high levels of TNF in 
macrophages, as  IFNγ enhances the transcription and mRNA stability of TNF [87]. These pro-
inflammatory factors activate T cells and orchestrate a fully-activated inflammatory response. 
 
Nitric oxide (NO) is an essential anti-microbial mediator produced by CAMs, which enables 
the capacity of macrophages to eliminate intracellular pathogens [69]. NO is a water soluble 
gas and it reacts with oxygen to exhibit microbial toxicity [88]. The enzyme of NO synthesis 
is NO synthase (NOS), which has three forms in mammals: NOS1, inducible NO synthase 
(iNOS or NOS2), and NOS3 [89]. NOS1 and NOS3 are constitutive forms and produce low 
amounts of NO in healthy hosts [90]. iNOS is the main enzyme involved in the production of 
NO under inflammatory conditions [90]. IFN, TNF, LPS induces the expression of iNOS in 
macrophages, often in a synergistic way [91]. L. major infected macrophages release TNF, 
which activates macrophage production of high levels of NO. This occurs in synergy with IFN 
via an autocrine mechanism [92]. The expression of iNOS in IFNγ/LPS activated macrophages 
requires TNF, as anti-TNF antibody blocks NO release upon IFNγ/LPS activation [93]. TNF 
induces the expression of iNOS through the activation of NF-B [94, 95]. iNOS is beneficial 
in the defence against L. monocytogenes infection, as iNOS deficient mice have increased 
susceptibility to this pathogen [96]. However, some evidence suggests that NO increases L. 
monocytogenes survival by delaying phagolysosomes fusion in LPS activated macrophages 
[97]. The mechanisms by which NO in macrophage eliminates L. monocytogenes remains to 
be identified.  
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1.2.5.2 Alternatively activated macrophages 
Th2 cytokines IL-4 and IL-13 induce macrophages into AAMs by binding the membrane 
receptor IL-4R and IL-13R1 respectively [98]. The transcription factor STAT6 is activated 
to regulate gene expression, including Arg1, CD206, Resistin-like molecule (Fizz1), and 
Chitinase 3-like 3 (Ym1) [99]. These genes are restricted to the mouse, since the human 
genome either lacks the homologs or they are dysfunctional [100]. Transglutaminase 2 (TGM2) 
exists in both the mouse and human genomes and it is recognized as the AAM marker in both 
species [20]. The high expression of mannose receptor CD206 in response to IL-4/IL-13 has 
been employed as a marker of AAMs. CD206 is widely expressed in tissue resident 
macrophages, lymphocytes and DCs [101]. IL-4/IL-13 induced AAMs have enhanced 
mannose-receptor-mediated phagocytosis [102], suggesting it is involved in macrophage 
phagocytosis of pathogen [101]. Fizz1 is highly induced by IL-13 and it is a secreted protein 
expressed by macrophages and eosinophils. Fizz1 deficiency in mice increases lung 
inflammation during Schistosoma mansoni infection [103]. Fizz1-/- AAMs promote the 
differentiation of antigen-specific Th2 cells [103]. The enzyme arginase-1(Arg1) is 
upregulated in AAMs and it is a competitor of iNOS in L-arginine metabolism. IL-4 induces 
the expression of Arg1 in the STAT-6 dependent manner [104]. TLR pathway is also reliant 
on the Arg1 production in the infection of intracellular pathogens such as Toxoplasma gondii 
[105]. iNOS converts L-arginine into nitric oxide and Arg1 converts L-arginine into urea and 
L-ornithine [69, 106]. The competition of iNOS and Arg1 in using limited L-arginine substrates 
shifts the metabolic pathway. The metabolism of L-arginine in macrophages is a key defining 
feature in CAMs and AAMs. NO is a key effector molecule in cell proliferation inhibition and 
microbicidal activity, whereas AAMs production of L-ornithine promotes tissue repair and cell 
proliferation [107]. Arg1 suppresses T cell proliferation by depleting arginine in the 
microenvironment [108], and promotes wound repair by converting arginase into collagens and 
increasing the availability of fibroblasts [109].  In addition to the phenotype markers, AAM 
have anti-inflammatory functions with high production of the cytokines IL-10 and TGF-β [110]. 
Macrophages produce IL-10 through the activation of TLR, C-type lectin and glucocorticoids 
[111]. IL-10 is essential in the regulation of several infections, as IL-10-/- mice have a lethal 
immunopathology following the infection of Toxoplasma gondii [112] and malaria [113]. IL-
10 inhibits the production of chemokines and prevents the recruitment of DCs during 
mycobacterial infection, thus leading to the failure of Th1 cell differentiation [114]. IL-10 
suppresses pro-inflammatory responses by inhibiting CD4+ T cell proliferation and the 
                                              
25 
inflammatory cytokine expression (IFN, TNF) [115]. TGF-β induces collagen synthesis in 
fibroblasts  and it is required in wound healing [116].   
 
1.2.5.3 Macrophage and cancer 
Macrophages play a key role in tumour cell migration, invasion and angiogenesis. High density 
of tumour-associated macrophages (TAMs) occurs in several human cancers, such as breast, 
bladder and prostate cancer [2]. This suggests that macrophage infiltration is essential in 
tumour progression [117]. The inflammatory cytokines (IFN, TNF) produced by macrophages 
sustain the chronic inflammation in the tumour initiation and invasion [118]. After tumour 
establishment, TAMs change their phenotype to promote tumour progression [2]. The invasion 
and proliferation ability of tumour cells are enhanced when culturing with macrophages as 
macrophage secreted substances (MMP-9, TNF, TGF-) stimulate tumour promotion [117]. 
They share the same characteristics with AAMs, with high expression of the surface markers 
(Arg1, Fizz1, Ym1) and release of the cytokines (IL-10, TGF-) [119]. Generation of new 
blood vessels in and around the tumour is required for tumour progression [2]. TAMs promote 
angiogenesis by producing angiogenesis-modulating enzymes such as MMP-9, MMP-2 and 
cyclo-oxygenase-2 (COX-2) [120]. In addition, tumour cells express high levels of integrin 
 
Figure 1.3: Properties of polarized macrophages. Classically activated macrophages (CAM) are 
activated by IFN and TNF, and LPS. Their phenotypes are characterized by the capacity for bacterial 
killing and production of pro-inflammatory mediators (TNF, IL-1, iNOS). Conversly, alternatively 
activated macrophages (AAM) are induced by IL-4/IL-13. They express high levels of surface 
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associated protein(CD47) to inhibit phagocytosis of TAMs [121]. Application of monoclonal 
antibody of CD47 enhances macrophage phagocytosis of bladder cancer cells in vitro [121]. 
Therefore, understanding the role of macrophages in tumour progression provides valuable 
ideas for anti-tumour therapy. 
 
1.2.6 Macrophage phagocytosis 
Phagocytosis is the main function of macrophages in defence against pathogens and contributes 
to innate and adaptive immune responses [122]. The process of phagocytosis includes receptor 
recognition, actin polymerization, phagosome maturation and degradation of pathogens [122]. 
Macrophages have ‘pattern recognition receptors’ (PRRs) to sense the ‘pathogen-associated 
molecular patterns’ (PAMPs) in microbial pathogens, including bacteria, parasites and virus 
[123]. Macrophage phagocytosis related PRRs include mannose receptor, complement 
receptors (CR) and the Fc family of receptors (FcR) [124], these mediate phagocytosis through 
binding non-opsonized targets or opsonic molecule coated targets [125].  
 
The mannose receptor binds and internalizes non-opsonized bacterial and fungal pathogens 
[119] by recognizing mannose-rich glycoconjugates [126]. The mannose receptor mediated 
non-opsonized phagocytosis is important in the early immune response before antibodies are 
synthesized [122]. Opsonized phagocytosis with antibody or complement is more efficient than 
non-opsonized phagocytosis in eliminating pathogens [127]. The mannose receptor mediated 
phagocytosis leads to the production of reactive oxygen intermediates and pro-inflammatory 
cytokines, including TNF [127], IL-6 and IL-1β [128]. The members of the complement 
receptor family (CR1, CR3, CR4) recognize complement coated microbes [129]. CR1 is 
mainly involved in binding C3b, C3bi and C4b, while CR3 and CR4 bind C3bi specifically 
[122]. Unlike the mannose receptor mediated phagocytosis, CR-mediated phagocytosis does 
not release the pro-inflammatory cytokines or reactive oxygen [130].  
 
FcRs recognize the Fc fragment of immunoglobulin- coated pathogens and they are classified 
into activating receptors (FcRI, FcRIIA, FcRIII) and inhibitory receptors (FcRIIB) [131].  
The activating FcRs have immunoreceptor tyrosine-based activation motifs (ITAMs) to 
activate downstream signal cascades. The inhibitory FcRs contain receptor tyrosine-based 
inhibition motifs (ITIMs) which dampen phagocytosis [131]. After initiation of phagocytosis, 
the tyrosine kinase Src phosphorylates ITAMs of FcγR to phosphorylate ITAMs. This recruits 
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and activates the tyrosine kinase Syk [132]. The impaired macrophage phagocytosis in Syk 
knockout mice indicates the essential role of Syk in phagocytosis [132]. The activation of Syk 
results in a series of downstream events such as rearrangement of actin and production of 
inflammatory mediators [122]. On the other hand, ITIMs mediate inhibition of phagocytosis 
which is important to avoid excessive phagocytosis. The phosphorylated ITIMs activate SH2 
domain-containing inositol 5’-phosphatase (SHIP) and then dampen subsequent signalling in 
phagocytosis inhibition [132]. Some downstream kinases are activated to stimulate the actin 
polymerization and induce phagosome formation. These kinases include PI-3 kinase, the rho 
family of GTPases, and protein kinase C (PKC) [122].  The PI-3 kinase inhibitor wortmannin 
or Ly294002 impairs Fc-receptor mediated phagocytosis by preventing the closure of 
phagosomes [133]. Members of Rho family of GTPases regulate Fc-receptor mediated 
phagocytosis by regulating cell spread, cell membrane ruffling and formation of stress fibres 
[134].  
 
After the recognition of FcRs, pathogens are formed into membrane wrapped phagosomes and 
phagocytosed by macrophages [125]. The phagosomes fuse with lysosomes to form the 
phagolysosome [125], which degrade the pathogens into small particles in the acidic 
environment [125]. The V-ATPase and GTPases (Rab5, Rab7) are associated with phagosome 
maturation [122]. V-ATPase establishes acidification by pumping protons to generate the 
acidification of phagolysosomes [135]. Rab5 induces membrane fusion of phagosome and 
endosomes in macrophages [136]. The overexpression of active Rab5 leads to increased killing 
ability of intracellular parasites [136]. Rab7 is required for late endosome formation as 
blocking of Rab7 leads to the impairment of phagolysosome formation and acidification [137]. 
The process of phagocytosis requires coordination of such events as receptor recognition, actin 
polarization, membrane trafficking, microbial killing and release of inflammatory cytokines, 
all of which regulate appropriate immune responses.  
 
1.2.7 The inflammasome  
In response to intracellular infection, the activation of inflammasome is the main inflammatory 
response to eliminate microbial invasion. Inflammasome is a group of protein platforms that 
sense intracellular stimulations  and release of pro-inflammatory cytokines IL-1β and IL-18 
[138]. The receptors related to inflammasome activation belong to  pattern recognition 
receptors include toll-like receptors (TLRs), node-like receptors (NLRs) and RIG- like 
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helicases [139]. TLRs have 10 members in humans and 13 members in mice [140]. TLR2 binds 
a variety of bacterial products such as lipopeptide and peptidoglycan. TLR3 recognizes double-
stranded RNA (dsRNA) and TLR4 recognizes the Gram-negative component LPS. The 
bacterial and viral CpG motifs are recognized by TLR9 [140]. NLRs have 23 members in 
human and over 34 members in mice [138]. They are composed of a N- terminal effector region 
caspase recruitment domain (CARD), C-terminal leucine-rich repeats (LRRs) and pyrin 
domain (PYD) acidic domain, a critical domain for sensing stimulus [141]. Some members of 
NLRs including NLRP1, NLRP3, NLRC4 are related to the formation of inflammasome, which 
is essential in host defense against infection [139].  
1.2.7.1 The NLRP3 inflammasome 
After phagocytosis, the lysosomal disruption with the release of lysosomal contents in the 
cytoplasm, might be a common pathway that results in the activation of NLRP3 inflammasome 
[142]. It is supported by the observation that the inhibition of  lysosomal disruption leads to 
the inhibition of inflammasome activation [142]. NLRP3 is a member of NLR proteins and it 
is the most fully characterized inflammasome. NLRP3 inflmmasome consists of NLRP3 
scaffold, ASC adaptor, and caspase-1. It is activated upon the infection of pathogens and self-
derived molecules. The pathogens include a range of microorganisms (bacteria, fungi), 
microbial stimuli (LPS, bacterial RNA, dsRNA analogy poly I:C [143]). Self-derived 
molecules include ATP from injury cells, elevated excellular glucose from metabolic stress, 
and monosodium urate (MSU) crystals from gout [141]. NLRP3 inflammasome is also 
activated by environmental irritants, such as UVB irradiation, silica, and asbestos [138].  
Two steps are required in NLRP3 inflammasome activation. The first step is primed by 
transcriptional activation of NLRP3 and pro-IL-1β through NF-B signalling activation [144]. 
After priming, the NLRP3 inflammasome is activated by ATP or bacterial toxins. Caspase-1 
is then activated and leads to IL-1β maturation and secretion by cleaving pro-IL-1β [138]. 
Caspase-1 is the active form of pro-caspase-1, and the caspase-1 deficient mice have impaired 
IL-1β release, suggesting the essential role in IL-1β maturation [145]. The activation of 
caspase-1 is related to a form of cell death termed pyroptosis, which has the features of both 
apoptosis and necrosis [146]. NLRP3 inflammasome activation involves K+ efflux, which is 
induced by pore formation in the cell membrane, reactive oxygen species (ROS) production 
and mitochondria damage [138]. ATP stimulation induced low intracellular K+ concentration 
is critical for NLRP3 inflammasome activation [147]. Moreover, incubation of the cells with 
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high extracellular K+ concentration abolishes NLRP3 inflammasome activation [147]. ATP 
induced ion channel purinergic ATP-gated P2X7 receptor (P2X7R) is required in NLRP3 
inflammasome activation [148]. The activation of P2X7R leads to the collapse of normal ionic 
gradients, allowing for the release of intracellular K+ [148]. Moreover, the production of ROS 
has been suggested to be related to NLRP3 inflammasome activation. Inhibitors of ROS 
generation leads to the impaired IL-1β production, suggesting the requirement of ROS in 
inflammasome activation [149]. Mitochondria, but not NADPH oxidase, is the essential source 
of ROS required for inflammasome activation [150]. The inhibition of mitochondrial ROS 
scavenger Mito-TEMPO inhibits the activation of NLRP3 inflammasome [150]. The ligand for 
NLPR3 inflammasome might be from ROS released from the mitochondria, but requires 
further study. NLRP3 inflammasome senses mitochondrial dysfunction and initiates immune 
responses in the cellular stress.  
 
1.2.7.2 The NLRC4 inflammasome 
NLRC4 is another member in NLR family involved in inflammasome [151]. NLRC4 
inflammasome is composed by NLRC4, ASC, caspase-1 and the BIR-domain-containing 
protein NAIP5 [152]. NLRC4 inflammasome recognizes flagellin from bacteria such as L. 
monocytogenes, Salmonella and Pseudomonas species [153]. Flagellin of bacteria binds 
NLRC4 and leads to the activation of NLRC4 inflammasome, thus results in the release of IL-
1β [151]. The activation of NLRC4 inflammasome is inhibited when macrophages are infected 
with flagellin deficient Salmonella strains [154].  NLRC4 and NAIP5 appear to bind a similar 
region of flagellin in bacteria [155]. NLRC4 is required in NAIP5 induced caspase-1 activation, 
but NAIP5 is independent in the activation of caspase-1 by NLRC4 [155]. Interestingly, the 
flagellate free bacteria Shigella flexneri also activates NLRC4 inflammasome [156]. The 
activation of NLRC4 inflammasome can also be blocked by bacteria, such as Mycobacterium 
tuberculosis [157]. These data suggest the other molecules beside flagellin also can be 
recognized by NLRC4 inflammasome, which remains to be uncovered.   
 
1.2.7.3 The AIM2 inflammasome  
The cytosolic double-stranded DNA from bacteria, virus and host are recognized by the absent 
in melanoma-2 (AIM2) inflammasome. AIM2 belongs to the HIN200 protein family which 
shares a repeat of 200 amino acids [158]. AIM2 inflammasome consists of AIM2, ASC, and 
caspase-1 [153]. AIM2 binds dsDNA via the C-terminal HIN200 domain and activates 
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caspase-1 by recruiting the adaptor ASC [159]. Similar to other inflammasome, the activation 
of caspase-1 results in the maturation and secretion of IL-1 [159]. Ligands activate AIM2 
inflammasome are cytosolic dsDNA from bacteria, virus or host. AIM2 inflammasome is the 
only inflammasome directly binds to the dsDNA that activates inflammasome formation [152]. 
As a sensor of cytoplasmic DNA, AIM2 inflammasome is an attractive target for treatment in 
dsDNA related autoimmune disease, including Systemic Lupus Erythematosis (SLE) [153]. 
AIM2 inflammasome triggers pyroptosis which is a caspase-1 dependent cell death [151]. 
Pyroptosis is often observed in cytosolic pathogen infection, and it is immunologically ‘silent’ 
[151].  In addition to the AIM2 inflammasome activation, the presence of cytosolic DNA is 
sensed by cGAS/STING [160]. Cyclic-GMP-AMP (cGAMP) synthase (cGAS) binds DNA 
and synthesizes cGAMP which subsequently binds and activates STING in endoplasmic 
reticulum membrane [161]. The activation of STING triggers the activation of transcription 
factor NF-B and IRF3 [160]. Cytosolic RNA is detected by RIG-I like receptors to produce 
cytokines such as IFN [161].   
 
1.2.7.4 Inflammasome and human disease 
IL-1β is a key pro-inflammatory cytokine and the elevated production of IL-1β is related to 
many diseases, including gout, type II diabetes (T2D) and Alzheimer’s disease [138]. The 
metabolic disturbances of gout is associated with elevated deposition of monosodium urate 
(MSU) crystals in joints [162]. MSU activates NLRP3 inflammasome activation in vitro and 
MSU-dependent neutrophils infiltration requires the activation of IL-1R, ASC and caspase-1 
in vivo [162]. Increased IL-1β secretion is involved in T2D development and it drives the 
pancreatic islets β cell destruction and glucose-induced insulin secretion [163]. High 
extracellular glucose also triggers NLRP3 inflammasome and IL-1β secretion [164]. Mutations 
of NLRP3 have been identified as the cause of some rare inflammatory diseases, including the 
familial cold auto inflammatory Muckle-Wells syndrome and neonatal onset multi-systemic 
inflammatory disease [142]. The NLRP3 mutation leads to consistent activation of NLRP3 
inflammasome with increased caspase-1 activation and IL-1β release. It has been reported that 
monocytes from the patients with NLRP3 mutations produce IL-1β spontaneously [165]. Anti-
IL-1β therapy using IL-1 receptor antagonist has been used to reverse clinical symptoms [166]. 
The Anakinra which is an antagonist of IL-1RA has been applied in clinical trials [167]. 
Additionally, the high affinity for IL-1, IL-1Trap, and IL-1β neutralized monoclonal antibodies 
are available to the clinical trials for a wider range of diseases [167]. The future research of 
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inflammasome associated mechanisms will provide new approaches to autoimmune disease 
treatments.  
 
1.3 The intracellular bacterium- Listeria monocytogenes 
Listeria monocytogenes (L. monocytogenes) was first identified in 1926, as is a gram-positive 
bacterium which causes lethal disease in a rabbit colony [168]. L. monocytogenes is found in 
water, soil and uncooked meat and cheeses [169]. L. monocytogenes can cause serious 
infections in immunocompromised individuals, neonates and pregnant women [169]. Pregnant 
women develop chorioamnionitis and septic abortion with the infection of L. monocytogenes 
[170]. Gastroenteritis can be caused by the exposure to L. monocytogenes by ingesting 
incompletely cooked meats and unpasteurized dairy products [170]. Therefore, L. 
monocytogenes is a permanent pathogen in caring for pregnant women, neonates, and 
immunocompromised individuals. As L. monocytogenes is one of the best characterized and 
easily manipulated bacterial pathogens. It has been widely used in the research of interface 
between the mammalian immune system and a pathogenic microorganism [169].  
 
1.3.1 Life cycle of L. monocytogenes in macrophages 
L. monocytogenes infects various cells including macrophages, epithelial cells [171], 
fibroblasts and neurons [172]. Macrophages are the main effector cells for clearing L. 
monocytogenes infection [173]. L. monocytogenes are phagocytosed by macrophages in 
membrane-coated phagosomes [174]. L. monocytogenes then escapes from the acidic 
environment of the phagosome into the cytoplasm by lysing the membrane of the phagosome. 
After escape, L. monocytogenes reproduces rapidly and rearranges the actin to move in the 
cytoplasm by forming pseudopods [174]. Neighbouring cells then engulf the pseudopods to 
form double membrane vacuoles with L. monocytogenes  and start the new cycle of infection 
[174]. The product of the hemolysin (hly) genes in L. monocytogenes, listeriolysin O (LLO), is 
essential for escape from the primary and secondary vacuoles [174]. LLO is a pore-forming 
toxin belonging to the cytolysin group that is commonly expressed by gram-positive bacteria 
[175]. The lytic activation of LLO is optimal in acidic pH and leads to L. monocytogenes escape 
from phagosomes [176]. The LLO-dependent vacuole fusion with lysosomes therefore inhibits 
L. monocytogenes degradation in the acidic environment. LLO-deficient L. monocytogenes 
escapes inefficiently compared with wild type L. monocytogenes [177].  
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After L. monocytogenes escape from the phagosome, the cell surface protein ActA is anchored 
to the membrane of mitochondria and modulates the movement of L. monocytogenes by 
rearranging the actin in the cytoplasm [178]. ActA is the product of gene actA and the actA 
mutant of L. monocytogenes leads to inhibition of intracellular movement [179]. ActA is a 
surface protein has 639 amino acids with a transmembrane motif at its carboxyl-terminal 
domain. The domain containing four proline-rich repeats triggers the Listeria actin-based 
motility [180]. The region of ActA (amino acids 31–263) is crucial in inducing bacterial 
movement, through activating Arp2/3, inducing actin polymerization and generating the array 
of actin filaments [181].  
 
1.3.2 Macrophage responses during L. monocytogenes infection 
Monocytes are essential phagocytes in host defence against L. monocytogenes infection. 
Ly6Chi monocytes, recruited from bone marrow, differentiate into TNFα and iNOS producing 
dendritic cells (TipDCs) [69]. The chemokine CCR2 is required for Ly6Chi monocyte 
recruitment into the infected sites [182]. CCR2 deficiency leads to reduced Ly6Chi monocyte 
infiltration to spleen and increased susceptibility to L. monocytogenes infection [182]. IFNγ 
produced by NK cells is important for maturation of Ly6Chi monocytes [84]. Ly6Clow 
monocytes are recruited in the early stages of L. monocytogenes infection. They transiently 
secrete TNF then display anti-inflammatory phenotypes with up-regulated expression of Fizz1 
 
Figure 1.4: Macrophage phagocytosis of L. monocytogenes. L. monocytogenes is phagocytosed by 
macrophages in membrane formed phagosome. L. monocytogenes then expresses LLO to lyse the 
membrane and escape from the vacuole. In the cytoplasm, L. monocytogenes reproduces rapidly and 
expresses ActA to rearrange the actin to move into the cytoplasm. Sequentially, the released L. 
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and CD206 [71]. The intracellular adaptive protein MyD88 is required for host defence against 
L. monocytogenes infection [183].  
 
L. monocytogenes has a range of TLR ligands such as flagellin and peptidogylcan which can 
be recognized by macrophages [173]. TLRs are required for inflammatory cytokine production 
and host response to L. monocytogenes infection [184]. For instance, L. monocytogenes 
infected macrophages produce high amounts of TNF and IL-12 through the activation of the 
TLRs. Mice deficient in the TLR adaptor molecule MyD88 are susceptible to L. 
monocytogenes infection and are unable to produce TNF and IL-12 in response to TLR 
engagement [184]. Macrophages also produce chemokines such as CCL-2, and CCL-7 to 
recruit inflammatory monocytes into the infected tissue [184]. Activated macrophages are 
essential for sensing and eliminating L. monocytogenes infection. The activated macrophages 
are stimulated by IFN in combination with LPS or TNF. The high levels of nitric oxide 
produced by activated macrophages are bactericidal and effective in killing L. monocytogenes  
as iNOS deficient mice are highly susceptible to L. monocytogenes infection [185]. However, 
the enhanced production of NO is a double-edged sword in L. monocytogenes elimination [186]. 
L. monocytogenes takes advantage of the high NO concentration to promote their spread during 
infection. The iNOS inhibitor W1400 significantly reduces L. monocytogenes spread in the 
hosts [186]. Activated macrophages inhibit phagosome escape of L. monocytogenes through 
reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI) [97]. The 
inhibitors of ROI and RNI block L. monocytogenes vacuolar escape in macrophages [97]. The 
production of ROI and RNI are co-localized with L. monocytogenes, suggesting the direct 
microbial activities in the individual phagosomes of macrophages.  
 
1.3.3 Inflammasome activation in L. monocytogenes infection 
L. monocytogenes infection is also sensed by inflammasomes which is crucial for macrophage 
responses to infection through the production of IL-1β and IL-18 [187]. L. monocytogenes 
activated inflammasomes include NLRP3, NLRC4 and AIM2 [187]. NLRP3 inflammasomes 
are activated following L. monocytogenes infection and NLRP3 deficiency in macrophages 
leads to impaired caspase-1 activation and IL-1β release in response to L. monocytogenes 
infection [188]. Furthermore, inflammasome activation depends on the cytosolic invasion of L. 
monocytogenes as IL-1β cannot be secreted by macrophages when infected with the LLO 
deficient L. monocytogenes [189], consistent with the essential role of cytosolic signaling in 
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host responses to L. monocytogenes infection. In addition to the IL-1β release, L. 
monocytogenes infection also leads to caspase-1 dependent cell death [189]. NLRC4 
inflammasome senses flagellin in L. monocytogenes and leads to caspase-1, IL-1β activation 
[190]. AIM2 inflammasome senses L. monocytogenes by recognizing DNA of L. 
monocytogenes in the cytosol [159]. The bacterial DNA is released after L. monocytogenes 
escape from phagolysosome [158]. Knockdown of AIM2 in macrophages leads to impaired 
caspase-1 activation, IL-1β release, and cell death after infection of L. monocytogenes [159].  
1.4 Devil facial tumour disease  
The Tasmanian devil (Sarcophilus harissii) is the largest marsupial carnivore in the world, 
since the extinction of Tasmanian tiger (Thylacinus cyanocephalus) in 1936 [191]. Devils are 
nocturnal scavengers that feed on carrion and sometimes hunt for birds and small mammals 
[192]. They are medium sized and weigh between 4.5 kg and 13.0 kg [191]. The jaws and teeth 
of devils are extremely powerful which enable them to devour their prey [192]. This species is 
threatened by the fatal disease, devil facial tumour disease (DFTD). DFTD was first recorded 
in 1996 and has been the main factor responsible for the decline of devil population [192]. 
Consequently, devils are listed as endangered as a result of the DFTD epidemic. The extinction 
of the Tasmanian devil would be crucial in the ecosystem. It is risky to feral cats and potentially 
foxes, which would be the disastrous consequences for native species [193].  
 
1.4.1 Pathology and origins of DFTD 
DFTD is transmitted as an allograft. DFTD cells are the infectious agent and transmitted 
between devils by biting [194]. The biting in Tasmanian devils is a common interaction in 
mating seasons and feeding [195], suggesting that biting is the key means of disease 
transmission. DFTD appears as firm, spherical nodules, or ulcerate tumours located on the face, 
neck and head [192]. The face and neck are the primary locations of DFTD and the tumours 
often show necrosis, bacterial contamination, and metastasis to other organs [196]. DFTD was 
derived from a female devil in the northeast Tasmania in 1996 [197]. Research shows that 
DFTD originated from a Schwann cell [198]. The Schwann cell myelin protein, periaxin (PRX) 
is expressed in primary DFTD tumours, and DFTD cultured cells, suggesting its utility as a 
marker for DFTD [198]. There are several other markers such as S100, nerve growth factor 
receptor and myelin basic protein that identify DFTD cells, albeit inconsistently [196]. The 
clonal origin of DFTD has been confirmed by sequencing of the multiple microsatellite loci of 
tumour and matched devil hosts. All the tumours were identical at MHC and multiple 
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microsatellite loci, and differed from their hosts [199]. In contrast with the female devil derived 
DFTD (DFT1), the second transmissible cancer, DFT2 was identified in 2015 [200]. DFT2 has 
distinct histological and genetic phenotypes from the DFT1. It carries a Y chromosome in 
comparison of the two X chromosomes, different alleles to its hosts at MHC loci and 
microsatellite [200]. As a transmissible allograft tumour, there are several possible 
explanations for the establishment of DFTD in the devil population: incompetent immune 
system of devils; low genetic especially at the MHC loci; or tumour escape from the host’s 
immune system. 
 
1.4.2 The devil’s immune system  
Tasmania devils are scavengers and are exposed to a wide range of bacteria and parasites due 
to their diet and biting behaviour. Little evidence shows that wild devils succumb to disease of 
bacteria and parasites. Similarly, research has demonstrated functional immune responses 
[201]. Thus, it is assumed that devils have a fully competent innate immune system which 
provides primary protection against these pathogens [196].  
Studies on basic histological and immunology function assay suggest that devils have a 
competent immune system [202]. Devil tissue architecture and distribution of the immune cells 
were analysed by using CD3, CD79b and MHCII antibodies [202]. The thymus, spleen and 
peripheral lymph nodes have similar structure to mammals and other marsupials. This study 
indicated that devils have the immune system competent required for immune responses [202]. 
Neutrophils isolated from peripheral blood of devils exhibit the ability to phagocytose E. coli 
[203]. The respiratory burst in neutrophils was identified by the nitro blue tetrazolium assay, 
suggesting the  active oxygen dependent pathway in phagocytosis of bacteria [203]. NK-like 
cells from devil peripheral blood exhibit rapid cytotoxic responses in the presence of antibody 
[204]. The peripheral blood mononuclear cells from Tasmanian devils proliferate in response 
to PHA, PMN and Con A stimulation [203]. In response to horse red blood cells (HRBC) 
injection, devils showed evidence of antibody production, suggesting the Tasmanian devils are 
capable of humoral immune responses [205]. Following immunization with xenogeneic human 
erythroleukemia line K562 cells, devils produced antibodies and cytotoxic responses [204].  
 
1.4.3 Low genetic diversity of devils 
Since devil facial tumours are allografts, the devil immune system should recognize the DFTD 
cells as foreign pathogens. Why do DFTD cells survive as an allograft? The low diversity of 
                                              
36 
MHC class I of the species was put forward as one explanation [199]. From a study in 1985, 
South African cheetah (Acinonyx jubatus) were shown to have extremely low genetic diversity 
including Major Histocompatibility Complex (MHC) [206]. The acceptance of skin grafts 
between unrelated cheetahs indicated the species vulnerability in the cheetah [206]. The lack 
of MHC class I diversity is the cause of the spread of contagious tumour in the Syrian hamster 
[207]. Similarly, the analysis of whole-genome sequence of Tasmanian devils indicated the 
moderate genetic diversity [208]. However, skin allografts were rejected 14 days after surgery 
with extensive T cell infiltration, the low genetic variety at MHC cannot explain the failure of 
devils to recognise DFTD cells. [209].   
DFTD cells in vivo and in vitro have been shown to have low expression of MHC class I, 
suggesting the depletion of antigen- processing pathway [199]. Analyses of MHC transcript 
show that DFTD cells have functional MHC genes. [199]. Treatment of DFTD cells with 
histone deacetylase inhibitor trichostatin A (TSA) restored the MHC class I expression [199]. 
This evidence showed that the absence of expression of MHC I on the cell surface is due to 
epigenetic modifications rather than structural mutations [199]. Some human tumours also 
have structural mutations of MHC I genes with decreased MHC I molecule expression which 
leads to escape from effective T cell responses [210]. Recombinant devil IFNγ treated DFTD 
cells with increased expression of MHC I, has been used in the anti-DFTD vaccine protocol. 
On the other hand, NK cells would be expected to be effector cells to DFTD cells in response 
to the lack of MHC I expression. However, the DFTD cells can’t be recognized by devil NK 
cells [211], further investigations are required to find the mechanism involved.  
1.4.4 Immunosuppressive Cytokines 
The immunosuppressive cytokine such TGF- and IL-10 are released from tumour cells in the 
micro-environment favouring tumour progression and host immune response suppression 
[196]. TGF- regulates immune responses by modulating T cell activation, differentiation and 
proliferation [212]. IL-10 inhibits T cells activation by inhibitory effects on macrophages and 
DCs [213]. In the analysis of TGF- and IL-10 transcriptome from DFTD biopsies, there was 
no significant upregulation in tumour tissues [214]. Detection of the expressions of TGF- and 
IL-10 at protein level would be valuable to quantify these cytokines. Understanding the 
mechanism of DFTD immune escape is important in development of vaccines to protect 
Tasmanian devils in the wild.   
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1.4.5 Macrophages and devils 
Macrophages play an important role in tumour development. Immunohistochemical analysis 
has shown macrophages in Devil spleen. These macrophages are in irregular shapes, with large 
phagosomes and numerous mitochondria in the cytoplasm [215]. The lack of devil-specific 
reagents such as devil derived M-CSF or GM-CSF has been the main obstacle in culturing 
devil macrophages in vitro. Devil specific antibodies for immunohistochemistry and flow 
cytometry are not available for the investigation of macrophage activity in DFTD.   
 
1.5 Final remarks 
TNF is an important pro-inflammatory cytokine in response to infection. TNF is mainly 
produced by macrophages and it activates macrophages with high efficiency in bacterial 
elimination. There is evidence of TNF in inhibition of AAM differentiation in parasitic 
infection [35] and tumour model [34]. In this study we investigate the common activity of TNF 
in macrophage differentiation in another infection model, L. monocytogenes. Splenic and 
peritoneal macrophages have been used to determine the role of TNF in AAM differentiation 
during L. monocytogenes infection. 
 
Phagocytosis is the main function in macrophage defence against pathogens. The effects of 
TNF in macrophage phagocytosis under different activation status of macrophages is unclear. 
Consequently, we investigated role of TNF in macrophage phagocytosis of tumour cells under 
different activation conditions. The tumour cells used in this study were Devil Facial Tumour 
Disease (DFTD) cells. These tumour cells were selected to determine if DFTD cells could be 
phagocytosed. The understanding of macrophage phagocytosis in DFTD cells will improve the 
knowledge of DFTD immune escape mechanisms.  
 
1.6 Aims of thesis 
The therapeutic modulation of TNF has been used widely to treat chronic inflammatory 
diseases. The TNF antagonists such as Infliximab® (Centocor), Etanercept® (Amgen/Wyeth), 
Certolizumab®, Golimumab® [216] have been showing good therapeutic effect in the 
treatment of Rheumatoid arthritis, Crohn’s disease, Ankylosing spondylitis and Psoriasis [217, 
218]. However, it has been implicated that anti-TNF treatment can cause the recrudescence of 
existing latent infections, such as tuberculosis [218] and leishmaniasis [219]. The roles and 
mechanisms of TNF in mediating protection or pathology during infection are still unclear in 
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some details and need to be investigated. Therefore, a comprehensive investigation of the role 
of TNF in innate immune responses to intracellular pathogens such as L. monocytogenes will 
provide a better understanding of potential consequences of using TNF antagonists to treat 
chronic inflammatory diseases.  
Macrophages are important innate immune cells in regulating immune response to pathogens. 
TNF is mainly produced by macrophages and activates macrophages with higher ability in 
elimination of pathogens. TNF activates macrophages into CAMs in concert with IFNγ.  
Additionally, TNF has been reported to inhibit AAMs polarization in the condition of tumour 
[34] and L. major infection [35]. Therefore, role of TNF in macrophage polarization during 
bacterial infection is worth to investigate. Macrophages release pro-inflammatory cytokine IL-
1 during bacterial infection by inflammasome activation. TNF in regulating macrophage 
releasing IL-1 during bacterial infection is interesting to investigate. Macrophage 
phagocytose pathogens and consequently eliminate them and regulate immune responses. TNF 
in regulating macrophage phagocytosis of bacteria and the other target such as DFTD cells is 
investigated.  
Thus, the aims of my thesis are as followed: 
 
Aim 1: To investigate the role of TNF in splenic monocyte differentiation  following L. 
monocytogenes infection 
 
Aim 2: To examine TNF regulation of peritoneal monocyte differentiation upon L. 
monocytogenes infection 
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Table 2.1 Commonly used reagents  
Reagent Supplier Catalogue number 
2-Mercaptotoethanol  Gibco 21985023 
Acetic acid glacial  BDH AnalaR Prod 10001 
Acetone Sigma-Aldrich 270725-2L 
Adenosine 5′-triphosphate (ATP) Sigma-Aldrich A2383-1G 
Bovine serum albumin (BSA) Sigma-Aldrich A7906-100G 
Brain Heart Infusion Broth (BHI)  BD bioscience 237500 
Cell count beads eBioscience 01-1234-42 
Collagenase IV Sigma-Aldrich  M9445 
DAPI Sigma-Aldrich D9542 
Ethanol  Sigma-Aldrich E7023-500ML 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich EDS-500G 
Fetal calf serum (FCS)  Gibco 10099-141 
Fluorescent mounting medium  Dako Cytomation S3023 
Gelatin Sigma-Aldrich G1890-100G 
Gentamicin Invitrogen 15750060  
Glycerol Sigma-Aldrich G6279-500ML 
Halt® protease inhibitor Thermo Fisher 78430 
HEPES Sigma-Aldrich H3375-100G 
Interferon γ (IFNγ) Peprotech 315-05 
Interleukin-4 (IL-4) Peprotech 214-14 
L-Glutamine                                                 Gibco 25030081 
Lipopolysaccharide (LPS 055:B5) Sigma-Aldrich L6529-1MG 






Non-essential amino acids  Gibco 11140050 
Penicillin/streptomycin  Gibco 15140122 
Phosphoric acid (H3PO4) Sigma-Aldrich 438081-500ML 
Potassium chloride (KCl) Sigma-Aldrich P3911-500G 
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Reagent Supplier Catalogue number 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich P9791-500G 
Proteinase k Sigma-Aldrich P6556-5MG 
Rat serum Sigma-Aldrich R9759-10ml 
RPMI 1640 medium Invitrogen 11875093 
Sodium azide (NaN3) Sigma-Aldrich S2002-100G 
Sodium chloride (NaCl) Sigma-Aldrich S5886-500G 
Sodium nitrite (NaNO2) Sigma-Aldrich 237213-500G 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich 30435-500G 
Sodium pyruvate  Gibco 11360070 
Sulfanilamide (H2NC6H4SO2NH2) Sigma-Aldrich S9251-100G 
Thioglycollate BD bioscience 211716 
TMB ThermoFisher N301 
Tris base Sigma-Aldrich T1378-1KG 





Table 2.2 Commonly used disposables 
Disposables Supplier Catalogue number 
1 mL Syringe  Terumo 20650240 
10 l Tips VWR LAC23584 
10 ml Syringe Terumo 20650240 
1000 l Tips VWR SORELAC1707 
15 ml Centrifuge tube Corning CLS430791-500EA 
200 l Tips VWR LAC1702 
22x 22 mm Coverslip  Deckglaser 22 x 22 mm 
40 m cell Strainers Falcon 21008-949 
50 ml Centrifuge tube Corning CLS430829-500EA 








Disposables Supplier Catalogue number 
CellTrace Violet Cell Proliferation 
Kit 
ThermoFisher C34557 
Elisa 96-well plate Sarstedt 82.1583.200 
Eppendorf tube  Eppendorf 80-1500 
Flat-bottomed 96-well microplate Corning NUN167008 
Fluorescent mounting medium DakoCytomation S3023 
FOXP3 fix/perm kit eBioscience 00-5523-00 




iScript gDNA Synthesis Kit Bio-Rad 172-5035 
Light microscope  Leica DM2500 




Microscope slide  Livingstone 7105-U 
Needle 21G Terumo 20650030 
Needle 26G  Terumo 20650050 
NucleoSpin® RNA XS kit Macherey-Nagel 740902.50 
NueleoSpin RNA XS kit Macherey Nagel 740902.50 
NuPAGETM gel Life technologies NP0322BOX 
Protein broad range standard Bio-Rad 161-0317 
ReliaPrep RNA Cell Miniprep 
System 
Promega Z6011 




Round-bottomed 96-well microplate Corning CLS3799-50EA 
SsoAdvanced Universal SYBR 
Green Mix 
Bio-Rad 172-5271 
Streptavidin HRP  BD 554066 




Table 2.3 Commonly used equipment 
 
Equipment   Supplier 
– 80 °C Freezer  Sanyo 
Autoclave Atherton 
Bench top centrifuge Beckman Coulter 
Bench top microcentrifuge Thermo scientific 
BX50 Fluorescent microscope  Olympus 
Canto II flow cytometer BD biosciences 
Class II biological safety cabinet Gelman Sciences 
Confocal microscope Nikon 
Cyan ADP flow cytometry Beckman Coulter 
iBlot™ 2 dry blotting system Invitrogen 
Incubator Sanyo 
Light microscope Olympus 
Lightcycler 480 qPCR instrument Roche 
Microplate reader Bio-Rad 
MoFlo Astrios cell sorter Beckman Coulter 
pH meter  inoLab  
Platform mixer Ratek Instruments 





2.4.1 0.5 M EDTA stock  
EDTA       46.53 g   
EDTA was dissolved in 200 ml Milli-Q® water, the pH was adjusted to 8.0 with NaOH, and 
the volume was adjusted to 250 ml with Milli-Q® water.  
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2.4.2 0.5% Gelatine 
Gelatine      0.5 g 
Gelatine was dissolved in 100 ml PBS and stored at 4 C after autoclave. 
 
2.4.3. 50% Glycerol stock 
Glycerol      20 ml 
PBS       20 ml 
Under sterile condition, glycerol was mixed with PBS. The solution was stored at 4 ºC. 
 
2.4.4. 10x Phosphate buffered saline (PBS) 
NaCl       80.0 g 
KCl       2.0 g 
Na2HPO4      14.4 g 
KH2PO4      2.4 g 
Milli-Q® water     1000 ml 
Using a magnetic stirrer, the reagents were dissolved in Milli-Q® water. The volume was 
adjusted to 1000 ml. The solution was diluted in 10 times before use. 
 
2.4.5. 3x Western blot sample buffer (For 500 ml) 
187.5 mM Tris–HCl (pH 6.8)    178 ml 0.5-M Tris–HCl pH 6.8 stock  
6% SDS      150 ml 20% SDS stock solution 
0.03% Phenol Red     150 mg 
30% Glycerol      172 ml 87% Glycerol stock solution 
The reagents were dissolved in Milli-Q® water and stored at 4 ºC. The solution was diluted in 
3 times with Milli-Q® water before use. 500 M DTT was added before freezing samples. 
 
2.4.6. BHI broth media 
BHI       3.7 g 
BHI powder was dissolved in 100 ml dH2O. The medium was kept at 4 ºC after autoclave. 
 
2.4.7. DFTD complete culture medium 
RPMI 1640 medium     500 ml 
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Heat inactivated FCS     50 ml 
L-glutamine      5 ml  
Penicillin/streptomycin    5 ml 
Under sterile condition, the RPMI-1640 medium was supplemented with the above solution 
and mixed by inversion. The solution was stored at 4 ºC. 
 
2.4.8. ELISA coating buffer 
NaHCO3      4.2 g 
Na2CO3      1.8 g 
The reagents were dissolved in 500 ml dH2O and pH was adjusted to 9.5. The solution was 
stored at room temperature.  
 
2.4.9. FACS buffer 
PBS       1.5 l 
BSA       3 g 
10% AZ buffer     3 ml 
The reagents were mixed by inversion, and stored at 4 C.  
 
2.4.10. Freeze L. monocytogenes 
50% Glycerol      100 l   
PBS       400 l   
L. monocytogenes to be frozen was centrifuged at 5,000 rpm for 5 min and the supernatant was 
discarded. The tube containing L. monocytogenes pellet was added in 100 l 50% Glycerol. 
The solution was mixed and stocked at -80 ºC.  
 
2.4.11. Freezing medium 
Complete DFTD culture medium   20 ml 
DMSO       20 ml 
FCS       60 ml 
The reagents were mixed by inversion, and stored at 4 ºC. 
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2.4.12. Griess assay reagent I 
1% Sulphanilamide     0.5 g 
2.5% H3PO4      1.25 ml 
The reagents were dissolved in 50 ml Milli-Q® water. The solution was stored at room 
temperature and protected from light.   
 
2.4.13. Griess assay reagent II 
NH2CH2CH2NH2. 2HCl    0.05 g 
The reagent was dissolved in 50 ml Milli-Q® water, stored at room temperature and protected 
from light.   
 
2.4.14. Heat inactivated fetal calf serum (FCS) 
FCS was thawed at room temperature and heated for 1 h at 57 C. Aliquots were stored into 
sterile 10 ml tubes at -20 ºC. 
 
2.4.15. Immunofluorescence blocking buffer 
BSA 1% (10% BSA stock)    10 ml 
Sodium Azide                                                             100 mg  
Glycine      2.25 g  
The reagents were dissolved in 100 ml PBS and the solution was kept at 4 ºC. 
 
2.4.16. Macrophage complete medium 
RPMI 1640       500 ml 
Heat inactivated fatal bovine serum    50 ml 
 L929 hybridoma supernatant    50 ml  
Heat inactivated horse serum    25 ml 
L-Glutamine (100x)      5 ml 
Non-essential amino acids (100x)    5 ml 
Penicillin/streptomycin (100x)   5 ml 
Sodium pyruvate (100x)    5 ml 
2-Mercaptotoethanol      500 l 
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Under sterile condition, the RPMI 1640 medium was supplemented with the above solution 
and mixed by inversion. The medium was stored at 4 ºC. 
 
2.4.17. Mice tail lysis buffer 
1 M Tris pH 8      10 ml 
2 M NaCl      10 ml 
0.5 M EDTA pH 8     1 ml 
10% SDS      2 ml 
The reagents were dissolved in 100 ml dH2O, stored at room temperature. The solution was 
diluted with Proteinase k (10 mg/ml) at 50:1 before use. 
 
2.4.18. Macrophage harvesting media 
PBS       500 ml 
BSA       5 ml 10% stock 
2 mM EDTA      2 ml 500 mM stock 
Under sterile condition, the solution was mixed and kept at 4 ºC. 
 
2.4.19. Ponceau staining solution (For 500 ml) 
0.05% Ponceau S     250 mg 
3% Trichloroacetic acid    15 g 
The reagents were dissolved in 500 ml dH2O, and kept at room temperature.  
 
2.4.20. Red blood cells lysis buffer  
0.17 M Ammonium chloride    9.0933 g/l 
0.02 M HEPES     4.766 g/l 
The reagents were dissolved in 1000 ml dH2O and stored at room temperature.  
 
2.4.21. Spleen lysis buffer 
PBS       2.445 ml 
1mM EDTA      5 l 500 mM stock 
0.05% TritonX 100     25 l 5% TritonX 100  
Halt®  Protease inhibitor    25 l (100x dilute) 
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Set up 2.5ml spleen lysis buffer and freeze at -20 ºC.  
 
2.5 Methods 
2.5.1 Animals   
The gene-targeted C57BL/6 (B6.TNF-/-) mouse strains deficient for TNF were generated on a 
genetically pure C57BL/6 (B6.WT) background as described [220]. The screening procedure 
followed the protocols described previously [220]. All animals were housed in pathogen-free 
conditions. Mice aged 8-16 weeks were used in all experiments following approval of the 
Animal Ethics Committee of University of Tasmania (UTAS) under the ethics number A13933, 
A13934 and A13936. 
 
2.5.2 Cell culture 
2.5.2.1 Bone marrow derived macrophages (BMDMs) culture 
BMDMs from B6.WT and B6.TNF-/- mice were generated from pelvic and femoral bones. 
BMDMs were cultured in macrophage complete medium for 7-9 days.  
For the experiment of inflammasome, BMDMs were harvested and were activated with LPS 
at 100 ng/ml in 96 well plates for 3 hours. After washing with PBS twice, BMDMs were co-
cultured with L. monocytogenes at Multiplicity of infection (MOI) 5, 10, 20, 40 for 40 min. 
ATP was added for positive control and KCl was for negative control as described previously 
[221]. BMDMs were incubated with 10 g/ml gentamicin to kill extracellular bacteria. Cell 
culture supernatants were collected after 6 hours’ incubation and analysed with ELISA and 
western blot. Cells were lysed using western blot buffer and kept at -80 C.  
For the experiment of phagocytosis assay, BMDMs were treated with the following substances: 
20 ng/ml IFNγ, 100 ng/ml LPS or a combination of IFNγ and LPS for 24 h or 5 ng/ml IL-4 for 
48 h. Control macrophages were cultured in medium alone. The macrophages were identified 
as CD11b+F4/80+ and the purity of macrophages obtained was always at least 90%.  
 
2.5.2.2 Thioglycollate-elicited peritoneal macrophages collection 
Thioglycollate-elicited peritoneal macrophages were prepared from the peritoneal cavity of 
B6.WT or B6.TNF-/- mice. After 3 days after i.p injection of 3% Brewer’s thioglycollate broth 
at dose of 10 l/g of mice weight. Cells were then adhered to the bottom of petri dish for 2 h 
and the adherent cells were harvested. The purity of macrophages was analysed using flow 
cytometry by staining for CD11b and F4/80. Macrophages were cultured in 24 well-plates with 
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0.2% gelatine coated 12 mm coverslips at 5x104 macrophages/well. The macrophages were 
subsequently incubated in fresh medium supplemented with 10% FCS or stimulated with 20 
ng/ml IFNγ and 100 ng/ml LPS for 24 h or 5 ng/ml IL-4 for 48 h, and infected with L. 
monocytogenes as indicated.   
 
2.5.2.3 Devil Facial Tumour Disease cell culture 
The Devil Facial Tumour Disease cell line, C5065, was established from primary tumour 
samples [222]. Cells were grown in DFTD complete culture medium and maintained in a 
humidified 5% CO2 incubator at 35 C. Phagocytosis assays required co-culturing of mouse 
macrophages with DFTD cells were maintained at 37 C. 
 
2.5.3 L. monocytogenes culture 
L. monocytogenes strain EGD was grown overnight in brain heart infusion (BHI) broth at 37 °C 
with shaking. Bacterial suspension was diluted at 1:50 in fresh BHI broth and shaken at 37 °C 
for 2 h to obtain an OD600 of 0.10. 1 ml bacterial culture has 2x108 L. monocytogenes. Bacteria 
were washed by pelleting and washed with PBS for two times. L. monocytogenes were 
suspended in PBS for infection in vitro or in vivo.  
 
2.5.4 Cell collection from L. monocytogenes infected mice 
2.5.4.1 Splenocytes and bone marrow cells dissociation 
Spleens were dissociated with collagenase V in PBS for 10 min at room temperature. Red blood 
cells were lysed using ACK lysis buffer. Splenocytes were filtered through 40 m cell strainers 
to remove cell debris. Cell pellets were suspended in 10 ml FACS buffer for cell counting. 
Bone marrow cells were collected by flushing from femurs with ice-cold PBS. Red blood cells 
were lysed using red blood cells lysis buffer and centrifuged at 500 g for 5 min. Cell pellets 
were suspended in 10 ml FACS buffer for cell counting. 
 
2.5.4.2 Isolation of peritoneal cavity cells 
The peritoneal lavage fluid was collected after the infection of L. monocytogenes. Mice were 
injected with 5 ml ice-cold PBS and the mouse abdomen was massaged gently to allow cells 
to suspend in the lavage fluid. The lavage fluid was extracted gently and slowly using a 21-G 
needle. The collected peritoneal fluid was transferred to a 15 ml tube and kept on ice, the 
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volume of fluid was recorded. Peritoneal cells were centrifuged at 500 g for 5 min and 
suspended in FACS buffer for cell counting.  
 
2.5.5 CFUs assay 
Spleen and liver were removed from animals and homogenized in 5ml lysis buffer (PBS with 
0.05% Triton X-100). Serial 10-fold dilutions of homogenate were made in 96 well plates. 
Twenty µl undiluted homogenate was added into 180 µl lysis buffer and mixed thoroughly 
before starting any dilution. Fifty µl homogenate was spread in BHI agar plate and cultured at 
37°C overnight. Colony forming units (CFUs) between 20 and 200 were counted and recorded 
as CFU/organ. Alternatively, to determine the bacterial load in cells, cells were isolated by 
flow cytometry and 5000 cells were lysed in 50µl buffer. The homogenate was plated in BHI 
agar plates and CFU were recorded as CFU/5000 cells. 
 
2.5.6 Quantitative real-time PCR 
The qPCR primers were designed using Primer-BLAST in PubMed. DNA template was 
entered, to avoid amplification of contaminating genomic DNA, the option ‘Primer must span 
an exon-exon junction’ was selected. Primers with GC content of around 50-60% and primer-
dimer were needed to be avoided. A standard curve was used to determine qPCR efficiency. 
Fivefold dilution series of cDNA were run in duplicate. The slope of a graph where log (dilution 
factor) is on the x-axis and Ct on the y-axis. Efficiency was calculated using the formula: 
efficiency = 10^ (-1/slope). The efficiency from 90-110% was preferred.  
RNA was extracted using ReliaPrepTM RNA Cell Miniprep System or NucleoSpin® RNA XS 
kit according to the manufacturer’s instructions. The iScript™ gDNA Clear cDNA Synthesis 
Kit was used to reverse-transcribe total RNA. Quantitative real-time PCR was carried out on 
the Lightcycler 480 qPCR instrument with 10 μl reactions using the SsoAdvanced™ Universal 
SYBR® Green and the primers are listed in Table 3.2. Reactions were performed in duplicate 
and gene expression levels were normalized to the housekeeping gene GAPDH.  Relative gene 
expression was calculated by the comparative CT (threshold cycle) normalized to GAPDH 
message; ΔCT values were determined by subtracting CT (target) from CT (GAPDH). 




















2.5.7 Flow cytometric analysis of splenic monocytes and cell sorting 
1 million splenocytes were stained with anti-CCR2 antibody for 30 min on ice. After the 
application of secondary antibody, the cells were washed and blocked with 10% rat serum for 
10 min. 1 million cells were stained for other surface markers on ice for 30 min. 20 µl DAPI 
(100 ng/ml) was added just prior to flow cytometry analysis for excluding dead cells. For 
intracellular staining, cells were fixed according to the manufacturer’s instruction with FOXP3 
fix/perm kit. Live/dead fixable Aqua dead cell stain kit was used for dead cell exclusion. Data 
were acquired using CyAn ADP. Fluorescence minus one control was used for gate strategy to 
identify interest cells. Neutrophils were identified as Ly6G+, DCs were identified as CD11c+, 
and monocytes were gated with the expression of Ly6C and CCR2. Splenic monocytes were 
sorted by Beckman Coulter MoFlo Astrios cell sorter. Ly6Chi and Ly6Clow monocytes or Ly6C+ 
monocytes were sorted by the same gate strategy. The purity of sorted cells were detected and 







Table 2.4: Primers used for quantitative PCR characterizing monocytes 
Primers Forward 5’-3’ Reverse 5’-3’ Product 
length 
Arg1 GTG AAG AAC CCA CGG 
TCT GT 
CTG GTT GTC AGG GGA GTG 
TT 
209bp 
CD206 TGC AAA GCT ATA GGT 
GGA GAGC 
ACG GGA GAA CCA TCA CTCC 164bp 
Fizz1  TCC CTC CAC TGT AAC 
GAA GAC 
AGG CAG TTG CAA GTA TCT 
CCA 
153bp 
GAPDH GTG AAG GTC GGT GTG 
AAC GG 
ATG TTA GTG GGG TCT CGC 
TCC 
245bp 
IL-10  TTG AAT TCC CTG GGT 
GAG AAG 




IL-6 AGT TGC CTT CTT GGG 
ACT GA 
TCC ACG ATT TCC CAG AGA 
AC 
159bp 
iNOS  GGA ATC TTG GAG CGA 
GTT GT 




TGM2 CGA ATC CTC TAC GAG 
AAG TAC AGC 
CAG TTT GCG GTT TTG CTT GG 177bp 
 
















Table 2.5: Antibodies used for splenic monocytes in flow cytometry 
Host Mouse 
immunogen 
Fluorochrome Clone Supplier 
Rat CCR2  - MC-21 M. Mack, Regensburg 
Mouse CD11b  PE-Cy7 M1/70 eBiosciences 
Rat CD11b  PerCP-Cy5.5 M1/70 BD Pharmingen 
Rat CD11c  PE-Cy7 HL3 BD Pharmingen 
Rat CD11c  Biotinylated HL3 BD Pharmingen 
Rat CD80 FITC 16-10A1 BD Pharmingen 
Rat CD86 PE GL1 BD Pharmingen 
Mouse Gr1 PerCP-Cy5.5 RB6-8C5 BD Pharmingen 
Rabbit iNOS - Polyclonal BD Biosciences 
Rat Ly6C  FITC AL-21 BD Pharmingen 
Rat Ly-6G  PE IA8 BD Pharmingen 
Rat Ly-6G  BV421 IA8 Biolegend 
Mouse MHC class II Biotinylated I-Ab, AF6-120.1 BD Pharmingen 
 
Table 2.6: Secondary labelling for splenic monocytes in flow cytometry 
Host Reactivity Fluor chrome Supplier 
Donkey Rat IgG AF 647 Jackson ImmunoResearch 
Laboratories 
Goat Rabbit IgG Pacific Blue Molecular probes 
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2.5.8 Flow cytometric analysis of peritoneal macrophages and cell sorting 
 
 
One million peritoneal cells were stained with anti-CCR2 antibody for 30 min on ice. After 
the application of secondary antibody, the cells were washed and blocked with 10% rat 
serum for 10 min. Cells were stained for surface markers on ice for 30 min. DAPI was added 
just prior to flow cytometric analysis for exclusion of dead cells. Data were acquired using 
CyAn ADP. Fluorescence minus one control was used for gate strategy. Neutrophils were 
identified as Ly6G+, B cells were identified as CD19+, eosinophils were excluded from 
macrophages by the high side scatter (SSC) as previously described [3]. Peritoneal 
monocytes and macrophages were gated with the expression of Ly6C and CCR2 and sorted 
by MoFlo Astrios cell sorter. The sorted cells were collected in 1 ml FACS buffer and spun 
down at 500 g for 5 min. Cells were lysed in RNA isolation buffer and frozen at -80C. The 
purity of sorted cells was determined and the obtained purity was always > 95%. 
Table 2.7: Primary antibodies used for peritoneal macrophages in flow cytometry 
Host Mouse 
immunogen 
Fluorochrome Clone Supplier 
Rat CCR2  - MC21 M. Mack, Regensburg 
Mouse CD11b PEcy7 M1/70 eBioscience 
Rat CD19 APCy7 ID3 BD Pharmingen 
Rat CD19 FITC ID3 BD Pharmingen 
Rat F4/80 Pecpcy5.5 BM4 Biolegend 
Rat Ly6C  FITC AL-21 BD Pharmingen 
Mouse Ly6C APC HK1.4 BD Pharmingen 
Rat Ly6G  PE IA8 BD Pharmingen 
Rat Ly6G  BV421 IA8 Biolegend 
Mouse MHC class II biotinylated I-Ab, AF6-120.1 BD Pharmingen 
 
Table 2.8: Secondary labelling for peritoneal macrophages in flow cytometry 
Host Reactivity Fluorochrome Supplier 
- - 
(MHC II) 





AF 647 Jackson ImmunoResearch 
Laboratories 
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2.5.9 Intracellular staining of peritoneal cavity cells  
For intracellular flow cytometry analysis, 1 million cells were stained for cell surface marker 
staining. Then cells were fixed and permeabilized according to the manufacturer’s instruction 
with FOXP3 fix/perm kit. Live/dead fixable Aqua dead cell stain kit was used for dead cell 
exclusion. Data were acquired using a CyAn ADP flow cytometer. 
 
 
2.5.10 Spleen lysate for ELISA analysis 
Spleen cut was weighed and smashed using the lid of Ependorff tube. The spleen lysis buffer 
was added at volume of 1ml per 1g spleen cut. Cells were lysed for 10 min on ice and cell 
debris were spin down. Supernatant was collected and froze at -80 C.  
 
2.5.11 IL-1 ELISA 
BMDMs were cultured in 96 well plate at concentration of 2x105 and primed with 200 ng/ml 
LPS for 3 h. Cells were then infected with L. monocytogenes at MOI 5, 10, 20, 40 for 45 min. 
Extracellular L. monocytogenes were killed by adding medium with 10 µg/ml Gentamicin. Cell 
culture supernatant was collected and froze at -80 C.  
Table 2.9: Antibodies used in intracellular flow cytometry 
Host Mouse 
immunogen 
Fluorochrome Clone Supplier 
Sheep Arg1 PE polyclonal R&D 
Mouse CD11b PEcy7 M1/70 eBioscience 
Armenian Hamster CD11c FITC HL3 BD Pharmingen 
Rat CD19  APCy7 ID3 BD Pharmingen 
Rat F4/80 Pecpcy5.5 BM4 Biolegend 
Rabbit iNOS  - polyclonal BD Biosciences 
Mouse Ly6C APC HK1.4 BD Pharmingen 
Rat Ly6G  PE IA8 BD Pharmingen 
Rat Ly6G  BV421 IA8 Biolegend 
Rabbit Ki67 - polyclonal Abcam 
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96-well ELISA plates were coated with goat anti-mouse-IL-1 monoclonal antibody (diluted 
1:400) overnight at 4 C (coating buffer 50 l/well). After washing in PBS/0.05% tween three 
times, the plate was blocked with PBS/1% BSA at room temperature (200 l/well) for 2 h. The 
plate was washed in PBS/0.05% tween three times and the samples for IL-1 analysis were 
added in duplicate and incubated at 4 oC overnight. The plate was washed in PBS/0.05% tween 
three times, then biotinylated hamster anti-mouse-IL-1 polyclonal antibody (diluted 1:500) 
was added with 50 l per well and kept at room temperature for 2 h. The plate was washed in 
PBS/0.05% tween three times before streptavidin HRP (diluted 1:5000) was added and 
incubated at room temperature for 30 min. TMB substrate was added to all wells at 50 l, 3M 
sulfuric acid was added at 50 l to stop the reaction. Optical density was read on plate reader 
at 450 nm. Recombinant IL-1 protein range from 2500 pg/ml to 31 pg/ml was used for 
standard curve.  
 
2.5.12 Western blot 
Cell culture supernatant and cell lysates were subjected to NuPAGE™ gel and subsequently 
transferred to nitrocellulose membranes by iBlot™ 2 dry blotting system. The membranes were 
shipped to University of Queensland and were immunoblotted with anti-IL-1, anti-caspase-1, 
anti-NLRP3 antibodies. The anti-IL-1β antibody (clone P028) was used to detect both pro- and 















Table 2.10: Antibodies for ELISA and Western blot analysis 
Host Mouse immunogen Catalogue number Clone Supplier 
Mouse Caspase-1 
p20(mono) 
AF-20B-0042-C100 P006 Sapphire 
Bioscience 
Goat IL-1 (polyclonal) AF-401-NA P028 R&D 
Biosystems 
Mouse NLRP3 (Cryo-2) 
(mono) 








Rabbit IL-1 biotinylated 
antibody 
13-7112-81 polyclonal eBioscience 
Mouse Mouse IL-1 
Recombinant Protein  
14-8012-62 - eBioscience 
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2.5.13 L. monocytogenes CFSE labelling 
L. monocytogenes were labelled with 5 mM of the dye carboxyfluorescein diacetate 
succinimidyl ester (CFSE) for 40 min. After wash with PBS for two times, bacteria were 
resuspended in PBS and used for macrophage infection. 
 
2.5.14 L. monocytogenes phagocytosis assay 
Macrophages were infected with CFSE labelled L. monocytogenes at MOI of 10. After 40 min 
of infection, cells were washed twice with PBS, the cells were then incubated with medium 
supplemented with 10 g/ml gentamicin for 1 h to kill extracellular bacteria. Cells were fixed 
with acetone and macrophages were labelled with anti-CD11b biotin antibody and Streptavidin 
Alexa Fluor 546. Cells were washed twice with PBS, and counterstained with DAPI. 
Coverslips were mounted on slides using fluorescent mounting medium. Pictures were taken 
with Olympus BX50 microscopy. Percentage of phagocytosis = (bacteria inside macrophages/ 
total number of bacteria counted) x100.  
 
2.5.15 L. monocytogenes phagosomal escape assay 
Following L. monocytogenes infection, cells were harvested after incubation for 3 h. Cell were 
washed, fixed with ice-cold acetone, and washed with PBS. Then cells were permeabilized 
with 0.25% Triton X-100 for 10 min at room temperature. After permeabilization, cells were 
washed and blocked in blocking buffer for 20 min. Actin filaments were labelled with 
phalloidin conjugated Alexa Fluor 594 antibody and counterstained with DAPI. The cells were 
washed three times in PBS and mounted using fluorescent mounting medium. Confocal 
microscopy was performed using spinning disk and z-stacks were taken in slices of 1 µm. 
Twenty macrophages per slide were examined for the presence of bacteria co-localizing with 
phalloidin. Phagosome escape was expressed as the percentage of phalloidin positive bacteria.  
 
Tabel 2.11: Antibodies used in immunofluorescence  
Host Reactivity Fluor chrome Supplier 
Rabbit mouse Anti-LAMP1 antibody (1D4B) BD Pharmingen 
- - Phalloidin conjugated Alexa Fluor 594 Thermo Fisher  
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Tabel 2.12: Secondary antibodies used in immunofluorescence 
Host Reactivity Fluor chrome Supplier 
Goat rabbit Alexa Fluor 594 Molecular probes  
- - Streptavidin Alexa Fluor 546 BD Pharmingen 
  
 
2.5.16 DFTD cells phagocytosis assay  
BMDMs (effector cells) were labelled with CellTrace™ Violet (CTV). DFTD cells (target cells) 
were labelled with 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) according 
to the manufacturer’s instruction. BMDMs were suspended in cell culture medium at 106/ml. 
A 100 l doubling dilution of BMDMs was performed to obtain effector to target ratios of 10:1, 
5:1 with 104 target DFTD cells. The phagocytosis assays were performed using duplicates or 
triplicates and incubated for 4 and 24 h at 37 °C and for 4 h at 4 °C for the negative control. 
The plates were analysed on a BD Canto II flow cytometer. To calculate phagocytosis, three 
regions were identified. R1, total CFSE+ tumour cells = total tumour cells. R2, CFSE+/CTV+ 
cells = tumour cells phagocytosed by macrophages. R3, CFSE+/CTV- cells = free tumour cells. 
The formula used for calculating phagocytosis was: percentage of phagocytosis= (R2/R1) x 
100%.  
For the 24 h incubation, in order to avoid complication of tumour cell division or been 
phagocytosed by macrophages, bead assay was used in enumerating tumour cells and 
macrophages in each treatment. For the bead count method, 5,000 beads were added in wells 
before the analysis of flow cytometry. The number of cells and beads were recorded together 
and the number of cells were calculated according to the ratio of collected beads to 5,000. The 
number of DFTD cells remaining = (5000/number of beads collected) x R3 cells. Flow 
cytometry was conducted at least three times in duplicate or triplicate wells. 
 
2.5.17 Cell staining and confocal microscopy 
CTV labelled BMDMs were grown in 24 well plates on 0.2% gelatine coated 12 mm coverslips. 
CFSE labelled DFTD cells were added when the coverslip was almost confluent with BMDMs. 
After 4 and 24 h incubation, cells were gently washed with PBS. Cells were permeabilized 
with 0.25% Triton X-100 for 20 min and blocked with a 1% BSA for 20 min. Antibody staining 
was conducted for 30 min with a rabbit anti-mouse-LAMP1 antibody. The goat anti rabbit 
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Alexa Fluor 594 secondary antibody was applied for 30 min. The cells were washed three times 
in PBS and mounted using Dako mounting medium. Confocal microscopy was performed 
using spinning disk and z-stacks were taken in slices of 1 µm.  
 
2.5.18 Griess assay for detection of nitrite 
The contents of nitrate and nitrite in the cell culture media were determined by the Griess assay 
as described previously [223]. 50 l cell culture medium was mixed with 50 l 1% 
sulphanilamide in 2.5% H3PO4, then 50 l Griess reagent (0.1% napthylenediamide 
dihydrochloride) and incubated at room temperature for 10 min. The absorbance at 540 nm 
was measured by a microplate reader and compared to a standard nitrite curve using sodium 
nitrite.  
 
2.5.19 Software/ Programmes 
Data analysis of flow cytometry was performed using FlowJo V10.1. 
Immunofluorescence assay was analysed by Image J. 
Statistical analyses were performed in Graphpad Prism5. 
 
2.5.20 Statistical analysis  
Statistical significance was determined by Mann-Whitney test in Chapter 3 and 4. Student’s 
unpaired t-test was used in Chapter 5. Each experimental group was compared to B6.WT 
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Chapter 3: Lack of TNF leads to alternative activation in splenic macrophages during 
L. monocytogenes infection 
 
3.1 Introduction 
TNFα (TNF) is a cytokine that plays an important role in inflammatory responses. TNF is 
mainly produced by macrophages and T cells during infection [5]. Macrophages are plastic in 
their differentiation as they can become either classically activated macrophages (CAMs) or 
alternatively activated macrophages (AAMs) in response to the environment in the tissues [41]. 
As a pro-inflammatory cytokine, it has been documented that TNF inhibits AAMs 
differentiation in both Leishmania major infections [35] and tumour models [34]. The role of 
TNF in macrophage differentiation during bacterial infection such as L. monocytogenes is 
unknown. 
 
The spleen is the major target tissue of systemic L. monocytogenes infection. Ly6ChiCD11b+ 
monocytes are recruited into spleen and differentiate into macrophages or dendritic cells during 
L. monocytogenes infection [69]. CCR2 is required for recruitment of monocytes, thus CCR2-
/- mice are susceptible to L. monocytogenes infection due to the lack of Ly6ChiCD11b+ 
monocyte infiltration to spleen [69]. The recruited Ly6ChiCD11b+ monocytes produce high 
levels of NO and TNF, which are required to eliminate the bacterial infection [69]. Neutrophils 
are essential during the early control phase of L. monocytogenes infection via phagocytosis 
[224]. Neutrophils release reactive nitrogen and oxygen intermediates to kill L. monocytogenes 
directly and modulate tissue damage with overproduction of these mediators [224]. It has been 
shown that the depletion of neutrophils using an anti-Gr-1 (RB6-8C5) monoclonal antibody 
results in a severe bacterial burden following infection with L. monocytogenes [225].  
 
We hypothesised that TNF inhibits splenic macrophages differentiation into AAMs during 
infection with L. monocytogenes. We compared the innate immune responses in spleen, 
including monocyte differentiation, neutrophil composition, cytokine IL-1 release, between 
TNF deficient mice and wild-type controls with L. monocytogenes infection. Our study showed 
that splenic macrophages from TNF deficient mice were biased toward AAM phenotype 
following L. monocytogenes infection, demonstrating the key role of TNF and CAMs in control 
of intracellular bacterial infection. Moreover, splenic neutrophil numbers and IL-1 production 
were enhanced in response to the impaired bacterial clearance in TNF deficient mice. 
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3.2 Results 
3.2.1 B6.TNF-/- mice are susceptible to L. monocytogenes infection. 
The bacterial burden in spleen and liver was examined at the indicated days post infection to 
investigate the role of TNF in anti- L. monocytogenes responses. As shown in Figure 3.2.1A, 
3.2.1B, bacterial loads in B6.WT and B6.TNF-/- mice were similar in spleen and liver at day 1 
post infection. It suggested that these two strains had the similar initiation of infection. 
Compared with WT controls, B6.TNF-/- mice displayed increased bacterial burden in spleen 
but not in liver at day 2 of infection (Fig 3.2.1A, 3.2.1B). B6.TNF-/- mice showed aggressive 
infection in spleen and liver at 3 days and 4 days after infection (Fig 3.2.1A, 3.2.1B), suggesting 
the high susceptibility in B6.TNF-/- mice with L. monocytogenes infection.  
 
3.2.2. Splenic neutrophil, DC, monocyte subpopulation kinetics in B6.WT and B6.TNF-/- 
mice after L. monocytogenes infection.  
To understand the protective effects of TNF in response to L. monocytogenes infection, we 
analysed the composition of innate immune cells, including neutrophils, DCs and monocytes. 
Under steady-state conditions (e.g. day 0), total numbers of neutrophil and DC were 
comparable in B6.WT and B6.TNF-/- mice (Fig 3.2.2A, 3.2.2B), suggesting that the 
development of neutrophils and dendritic cells were not affected by TNF deficiency. Upon L. 
 
Figure 3.2.1: B6.TNF-/- mice had increased bacterial loads in spleen and liver after infection 
with L. monocytogenes intraperitoneally. B6.WT and B6.TNF-/- mice were i.p injected with L. 
monocytogenes. At the indicated days after infection, CFUs were assayed by culturing organ 
homogenates on brain heart infusion (BHI) plates overnight. Bacterial loads in spleen (A) and liver 
(B) from B6.WT and B6.TNF-/- mice infected with L. monocytogenes at indicated days. n= 4-6 mice 
from two independent experiments, error bars indicate SEM, * p< 0.05. 
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monocytogenes infection at day 1 and day 2, no significant differences in the numbers of 
neutrophil and DC were identified. At day 3 and day 4 post infection, the total numbers of 
neutrophil in B6.TNF-/- mice were higher than WT controls (Fig 3.2.2A), but no difference was 
identified in the number of DCs (Fig 3.2.2B). It indicated that TNF signalling is involved in 
neutrophil accumulation but not DCs kinetics in response to L. monocytogenes infection.  
Monocytes were identified by the expression of Ly6C antigen. As shown in Figure 2C, 
CCR2+Ly6C+ monocytes were grouped into Ly6ChiR1 and Ly6ClowR2 monocytes according 
to the expression of Ly6C. The numbers of CCR2+Ly6C+ monocytes were similar in B6.WT 
and B6.TNF-/- mice (Fig 3.2.2D), suggesting TNF does not affect the recruitment of 
CCR2+Ly6C+ monocytes. Ly6ChiR1 monocytes are the most abundant subset of CCR2+Ly6C+ 
monocytes. The numbers of Ly6ChiR1 monocytes were similar between two strains of mice 
(Fig 3.2.2E). The numbers of Ly6ClowR2 monocyte were reduced in B6.TNF-/- mice after day 
3 and day 4 infection, compared with WT controls (Fig 3.2.2F). It indicated that TNF was 
involved in balancing the monocyte subsets in response to L. monocytogenes infection.  
 




Figure 3.2.2: Kinetics of neutrophil, DC and monocyte subsets following L. monocytogenes 
infection. The analysis of splenic cell subsets from B6.WT and B6.TNF-/- mice at indicated day post 
infection with 1,000 L. monocytogenes. Total numbers of splenic neutrophil, DC and monocyte were 
analysed by flow cytometry. The numbers of neutrophil (A) and DC (B) following L. monocytogenes 
infection were quantified. (C) Representative flow plots of CCR2+Ly6C+ monocytes from B6.WT 
and B6.TNF-/- mice. CCR2+Ly6C+ monocytes were gated into Ly6ChiR1 and Ly6ClowR2 monocytes. 
Quantification of total numbers of CCR2+ monocyte (D), Ly6ChiR1 (E) and Ly6ClowR2 (F) 
monocyte from uninfected or L. monocytogenes infected B6.WT and B6.TNF-/- mice. Each time 
point represents 6-12 mice from two of three independent experiments (error bars indicate SEM), * 
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3.2.3. TNF deficiency does not alter iNOS expression in Ly6ChiR1 and Ly6ClowR2 
monocytes.  
As demonstrated before [69], iNOS is the important effector molecule produced by Ly6Chi 
inflammatory monocytes with L. monocytogenes infection. We next investigated the role of 
TNF in iNOS expression in Ly6ChiR1 and Ly6ClowR2 monocytes during L. monocytogenes 
infection. The expression of iNOS was examined by intracellular flow cytometry. Ly6ChiR1 
monocytes in B6.TNF-/- mice expressed similar level of iNOS with B6.WT mice (Fig 3.2.3), 
indicating the intact capacity in iNOS production in the deficient of TNF. In the comparison of 
iNOS expression in Ly6ChiR1 and Ly6ClowR2 monocytes within the same genotype of mice, 
Ly6ChiR1 monocytes expressed increased amount of iNOS compared to Ly6ClowR2 monocytes 
in both two genotypes. It indicated that Ly6ChiR1 monocytes were the main producers in iNOS 
synthesis and iNOS expression was independent of TNF following L. monocytogenes infection.  
 
3.2.4. AAM differentiation from B6.TNF-/- mice following L. monocytogenes infection.  
Our results showed that iNOS synthesis is independent of TNF during L. monocytogenes 
infection. We then compared CAM and AAM differentiation using qPCR profiling of subset 
specific gene expression. The Ly6ChiR1 monocyte and Ly6ClowR2 monocytes from B6.WT 
 
Figure 3.2.3: iNOS expression in Ly6ChiR1 and Ly6ClowR2 monocytes after day 3 infection. 
B6.WT and B6.TNF-/- mice infected with L. monocytogenes for 3 days, the expression of iNOS in 
iNOS from Ly6Chi R1 and Ly6Clow R2 monocytes were detected by intracellular flow cytometry. MFI 
of iNOS in Ly6Chi R1 and Ly6ClowR2 monocytes in B6.WT and B6.TNF-/- mice. n=8 mice from two 
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and B6.TNF-/- mice were sorted at 3 days post infection with L. monocytogenes. The expression 
of CAM markers iNOS, IL-6 and AAM markers Arg1, CD206, TGM2, Fizz1, IL-10 were 
detected by qPCR. The iNOS expressions in Ly6ChiR1 and Ly6ClowR2 monocytes were similar 
between B6.WT and B6.TNF-/- group, which is consistent with the flow cytometry results (Fig 
3.2.3). Compared with WT controls, the expression of Arg1, TGM2 in Ly6ChiR1 monocytes 
were increased in B6.TNF-/- mice (Fig 3.2.4B, 3.2.4E). Whereas the expression of mannose 
receptor CD206 was decreased in Ly6ChiR1 monocytes in B6.TNF-/- mice (Fig 3.2.4D). These 
results indicated that TNF deficiency altered AAM differentiation of Ly6ChiR1 monocytes in 
response to L. monocytogenes infection.  
 
For the analysis of gene expression between Ly6ChiR1 monocytes and Ly6ClowR2 monocytes 
within the same genotype of mice, the expression of AAM markers (CD206, TGM2, Fizz1, IL-
10) were upregulated in Ly6ClowR2 monocytes (Fig 3.2.4D-G). It suggested that Ly6ClowR2 
monocytes were AAMs, which were required for tissue modelling and repair from infection 
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Figure 3.2.4: Expression of activation markers by Ly6ChiR1 and Ly6ClowR2 monocytes in the 
spleen at 3 days post infection. Ly6Chi R1 and Ly6Clow R2 monocytes were sorted from spleen of 
B6.WT and B6.TNF-/- mice infected with L. monocytogenes for 3 days. Gene expression of 
Ly6ChiR1 and Ly6ClowR2 monocytes was analysed by qPCR. Representative plots of R1 and R2 
monocytes for cell sorting (A). The relative mRNA expression of Arg1, iNOS, CD206, TGM2, 
Fizz1, IL-10, IL-6 (B-H) in Ly6ChiR1 and Ly6ClowR2 monocytes. n= 3-8 mice for each group, 
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Our result showed the increased expression of Arg1 in Ly6ChiR1 monocytes in the deficiency 
of TNF. Due to the low yield of rare cells (Ly6Chi and Ly6Clow monocytes), we isolated Ly6C+ 
( combined Ly6Chi and Ly6Clow monocytes) monocytes. We then investigated the bacterial 
load, Arg1 and iNOS expression in Ly6C+ monocytes. The bacterial loads in TNF deficient 
Ly6C+ monocytes were increased than WT controls (Fig 3.2.5A), suggesting the impairment 
of L. monocytogenes elimination of Ly6C+ monocytes in the deficiency of TNF. The 
expressions of Arg1 and iNOS in Ly6C+ monocytes from TNF deficient mice were enhanced, 
though did not reach significant difference (Fig 3.2.5B, 3.2.5C).  
 
 
3.2.6. TNF deficiency leads to reduced neutrophil composition in the bone marrow 
during L. monocytogenes infection. 
Neutrophils are generated and matured in the bone marrow, then rapidly recruited into tissues 
in response to inflammatory stimulus [226]. Increased neutrophil numbers were observed in 
B6.TNF-/- spleen during L. monocytogenes infection (Fig 3.2.2A), we next examined whether 
it is due to the increased recruitment form bone marrow in B6.TNF-/- mice. Naïve B6.WT, 
B6.TNF-/- mice had similar total number and percentage of neutrophils in the bone marrow 
 
Figure 3.2.5: Bacterial loads and expression of Arg1 and iNOS in Ly6C+ monocytes at 3 days 
post infection. Ly6C+ monocytes were sorted from spleen of B6.WT and B6.TNF-/- mice infected 
with L. monocytogenes for 3 days. Bacterial load in Ly6C+ monocytes from B6.WT and B6.TNF-/- 
mice after BHI agar plates culturing for 24 hours (A). The relative mRNA expression of Arg1 (B) 
and iNOS (C) in Ly6C+ monocytes was determined and normalized to the housekeeping gene 
GAPDH. n = 3-5 mice/ genotype; * p < 0.05, NS not significant difference.  
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(Fig 3.2.6A, 3.2.6B). Following L. monocytogenes infection for 3 and 4 days, B6.TNF-/- mice 
had both reduced number and percentage of neutrophils compared to B6.WT littermates (Fig 
3.2.6A, 3.2.6B). The reduced neutrophil numbers in the bone marrow were consistent with the 




3.2.7. TNF deficiency results in enhanced IL-1β release during L. monocytogenes 
infection in vivo.   
The increased neutrophils in spleen in B6.TNF-/- mice suggested an enhanced inflammatory 
response to L. monocytogenes infection compared to WT controls. To investigate further, 
expression of the inflammatory cytokine IL-1β was determined following L. monocytogenes 
infection. In order to investigate the role of TNF in IL-1β release during L. monocytogenes 
infection, we measured IL-1β production in spleen lysate (method referred to section 2.4.21) 
and peritoneal fluids from L. monocytogenes infected B6.WT and B6.TNF-/- mice at indicated 
days. IL-1β production in spleen lysate from B6.TNF-/- mice was increased at day 3 infection 
(Fig 3.2.7A). Peritoneal lavage from B6.TNF-/- mice had increased IL-1β level at day 2 and 
day 3 of infection compared to WT controls (Fig 3.2.7B).  
 
Figure 3.2.6: TNF deficiency results in reduced neutrophils composition in the bone 
marrow after L. monocytogenes infection. The bone marrow cells were harvested from femurs 
of B6.WT, B6.TNF-/- mice under naïve or L. monocytogenes infected conditions. Total number 
of neutrophils in the bone marrow (A) and frequency of neutrophils in the bone marrow (B) 
were analysed by flow cytometry. n= 6-8 mice from two independent experiments, error bars 
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3.2.8. TNF deficiency results in enhanced pro-IL-1β production during L. 
monocytogenes infection in vitro.   
In order to confirm the results in vivo, we next examined the role of TNF in IL-1β releasing 
during L. monocytogenes infection in vitro. IL-1β production is regulated by inflammasomes 
which are multiple protein platforms termed NLRP3, ASC, and pro-caspase-1 [138]. The 
components of inflammasome such as NLRP3, caspase-1, pro-caspase-1 were examined to 
investigate the role of TNF in IL-1β release. BMDMs from B6.WT and B6.TNF-/- mice were 
primed with LPS for 3 h and infected with L. monocytogenes at MOI 5, 10, 20, 40. The IL-1β 
concentrations in cell culture supernatants were measured with ELISA. Following L. 
monocytogenes infection at MOI 10, MOI 20 and MOI 40 (Fig 3.2.8A), macrophages from 
B6.TNF-/- mice released enhanced levels of IL-1β compared to WT controls. These results were 
consistent with the increased production of IL-1β in B6.TNF-/- mice with L. monocytogenes 
infection in vivo.  
We next performed western blot of cell culture supernatants and cell lysates to further examine 
the IL-1β release. Due to some unexpected problems, the western blot was only performed 
once and further experimentation would be required. The level of IL-1β in cell culture 
supernatants from B6.TNF-/- BMDMs was higher after L. monocytogenes infection (Fig 
3.2.8B), which is cautiously consistent with the ELISA results. In the cell lysates, increased 
levels of pro-IL-1β from TNF deficient BMDMs were identified (Fig 3.2.8B), which is 
 
Figure 3.2.7: Deficient of TNF results in enhanced IL-1β production in response to L. 
monocytogenes infection in vivo. B6.WT and B6.TNF-/- mice were infected with L. monocytogenes 
for indicated days, spleen lysate and peritoneal fluids were collected at indicated days. The 
concentration of IL-1β in spleen lysate (A) and peritoneal fluids (B) was measured using ELISA. n= 
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cautiously consistent with the increased IL-1β levels during L. monocytogenes infection. The 
levels of inflammasome components such as NLRP3, caspase-1, pro-caspase-1 were similar in 
BMDMs from B6.WT and B6.TNF-/- mice, may indicate that TNF is independent in NLRP3 
inflammasome activation during L. monocytogenes infection.   
 
Figure 3.2.8: TNF absence results in enhanced IL-1β production during L. monocytogenes 
infection in vitro. BMDMs from B6.WT and B6.TNF-/- mice were primed with LPS for 3 h, then 
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medium with 10ug/ml Gentamycin for 6 hours, the concentrations of IL-1β in cell culture supernatants 
were examined by ELISA (A). The expressions of pro-caspase-1, pro- IL-1β, NLRP3 and GAPDH in 
cell lysates and caspase-1, IL-1β in cell culture supernatants were examined by western blot (B). n= 4 
from two independent experiments, error bars were SEM, * p < 0.05. Note: figure B came from the 
antibody staining from Kate Schroder’s group. 
 
3.3 Discussion 
The importance of TNF in the elimination of microbial infection has been evidenced in the 
study of TNFR1 deficient mice during L. monocytogenes infection [31]. This chapter showed 
that TNF deficiency in splenic Ly6Chi monocytes results in AAM bias, which leads to the 
impaired killing ability of L. monocytogenes. It is consistent with the role of TNF in AAM 
differentiation during parasitic infections [35] and in tumour models [34]. This indicates the 
essential role of TNF in protection from infection by regulation of macrophage function.  
 
Ly6Chi monocytes that produce large amounts of iNOS and TNF have been shown to be 
essential in defence against L. monocytogenes infection [69]. In combination with IFN, TNF 
promotes macrophage differentiate into classically activated macrophages (CAMs) [111]. In 
addition, parasite and tumour models have indicated that TNF is a negative regulator of AAM 
differentiation. TNF deficiency leads to highly expressed Arg1 in macrophages [34, 35]. 
Results in this chapter indicate that Arg1 was highly expressed in Ly6Chi monocytes of 
B6.TNF-/- mice following the infection of L. monocytogenes (Fig 3.2.6B). This is consistent 
with the role of TNF in dampening Arg1 expression in parasitic infection and tumour models 
[34, 35]. TNF inhibits Arg1 expression by  suppressing histone acetylation at the Arg1 
promoter and enhancer elements [35]. The hyper expressed Arg1 impairs NO release, which 
leads to parasite proliferation following L. major infection [35]. We found that TNF deficiency 
did not alter the expression of iNOS (Fig 3.2.5, 3.2.6C), but showed impaired L. 
monocytogenes elimination in monocytes (Fig 3.2.6C). The relationship between high 
expression of Arg1 and reduced NO production needs to be investigated further. Moreover, the 
mechanism of TNF inhibition of Arg1 expression in macrophages during L. monocytogenes 
infection needs to be investigated. In addition to the enhanced expression of Arg1 in the 
deficiency of TNF, TGM2 expression is also increased. It is possible that TNF downregulates 
transcriptional level of Arg1 and TGM2 during L. monocytogenes infection. Thus protein levels 
of Arg1 and TGM2 in TNF deficient splenic macrophages are needed to be investigated in the 
future. The other AAM markers Fizz1 and IL-10 were unchanged and CD206 was decreased. 
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In the deficiency of TNF, these Ly6Chi monocytes may not ‘typical AAMs’ which have high 
expression of AAM markers. The changes in expression of Arg1, TGM2 and CD206 might 
lead to functional changes in Ly6Chi monocytes in response to infection of L. monocytogenes 
(see more in discussion of chapter 4). 
 
Ly6Clow monocytes are termed resident monocytes and patrol along vascular endothelium and 
surrounding tissues to combat infection [43, 68]. These monocytes are characterized by high 
expression of chemokine receptor CX3CR1 and lack expression of CCR2 [68]. Ly6Clow 
monocytes are proposed to be AAMs involved in wound healing at late stage of ischemic 
myocardium, by expressing vascular-endothelial growth factor (VEGF) [227]. It has been 
suggested that Ly6Clow monocytes initiate a transcriptional program of AAMs in the early stage 
of L. monocytogenes infection, which is consistent with tissue repair [71]. Our results showed 
the AAM phenotypes of Ly6Clow monocytes with high expression of AAM markers (TGM2, 
CD206, Fizz1 and IL-10) (Fig 3.2.6D-G), which is in line with other models. However, the 
Ly6Clow monocytes in our study expressed CCR2 (Fig 3.2.2C), which has not been shown in 
other studies. The CCR2 expression suggests that these Ly6Clow monocytes are derived from 
the bone marrow. It has been suggested that Ly6Chi monocytes become Ly6Clow monocytes by 
down regulating Ly6C expression in the blood and bone marrow [228]. In the sterile wound 
healing model, Ly6Chi monocytes mature into Ly6Clow monocytes as ‘repair’ macrophages 
[229]. Thus, it appeared that Ly6Clow monocytes were generated from Ly6Chi monocytes and 
that TNF was required when Ly6Chi monocytes matured into Ly6Clow monocytes. We found 
an increased bacterial load in TNF deficient Ly6C+ monocytes (Fig 3.2.6A), which might 
correlate to a reduced transition from Ly6Chi to Ly6Clow monocytes. It is not certain whether it 
is the TNF or the uncontrolled bacterial infection that promotes Ly6Chi monocyte maturation 
into Ly6Clow monocytes.   
  
It has been suggested that TNF induces the expression of CXCL1 (KC) and CXCL2 (MIP-2) 
[230], which facilitates the homing of neutrophils into infected tissues. The chemokines 
CXCL1 (KC) and CXCL2 (MIP-2) are required for neutrophil infiltration into infected tissue 
[231]. The high expression of CXCL1 was reported in the liver from TNF deficient mice with 
L. monocytogenes infection, suggesting CXCL1 may be the chemokine responsible for 
infiltration of neutrophils in TNF deficiency [232]. The enhanced infiltration of neutrophils in 
TNF deficient mice in our study might result from the chemokines such as CXCL1 and CXCL2. 
Neutrophils kill L. monocytogenes by phagocytosis and ROS production [233]. The production 
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of ROS in neutrophil such as O2- and H2O2 are regulated by the formylpeptide peptides binding 
to the receptor (FPR1) and calcium entry [234]. The overproduction of ROS in neutrophils can 
also cause tissue damage, as inhibition of ROS production from phagocytes prevents host tissue 
damage and it is necessary for the resolution of an inflammatory response [235]. The 
neutrophils lead to tissue damage following L. monocytogenes by killing endothelial cells in 
liver [236]. Thus, the aggressive infiltration of neutrophil in B6.TNF-/- mice might lead to tissue 
damage, and finally cause high susceptibility during L. monocytogenes infection. 
Our results showed an increased IL-1 production in B6.TNF-/- mice following L. 
monocytogenes infection, which contradicts previous reports [237].The secretion of IL-1 
requires two steps: the first is the synthesis of pro-IL-1 in the cells; the second is activation 
of caspase-1, which cleaves pro-IL-1 into activated IL-1 [142]. It has been indicated that 
exogenous TNF induces IL-1 release through NF-B activation, as the drugs that inhibit NF-
B activation result in impaired pro-IL-1 production [237]. In addition, TNF upregulates ROS, 
which triggers the activation of caspase-1, thus inducing IL-1 release in response to TNF 
stimulation [237]. The macrophages we used were differentiated by M-CSF, whereas other 
studies used cell lines or macrophages derived by GM-CSF [237]. This chapter shows the 
similar expression of elements in NLRP3 inflammasome (caspase-1, NLRP3). However, the 
increased expression of pro-IL-1 in macrophages from TNF deficient mice suggests the high 
priming efficiency of LPS.  
 
In summary, TNF deficiency results in alternative activation of splenic macrophages following 
L. monocytogenes infection. The inhibition of TNF in AAM differentiation might explain the 
essential role of TNF in defense against bacterial infection, and it ensures appropriate pro-
inflammatory response to infection. The AAM differentiation in the absence of TNF leads to 
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Chapter 4: Role of TNF in alternative activation of peritoneal macrophages following 
L. monocytogenes infection 
 
4.1 Introduction  
TNF is an important inflammatory cytokine that is essential in regulating immune responses to 
bacterial infection. Macrophages are the main cell population that kill L. monocytogenes in the 
early stages of infection [238]. Macrophages reside in almost every tissue such as spleen, liver, 
and peritoneum [38]. They are the essential innate immune cells in phagocytosis of bacteria, 
production of cytokines, and activation of T cells [38]. Following inflammation with infections 
such as L. monocytogenes, bone marrow derived monocytes migrate into infected tissue and 
differentiate into TNF and inducible nitric oxide synthase (iNOS) producing dendritic cells 
(TipDCs) [69]. These cells are essential in mediating immune responses to L. monocytogenes. 
TNF combines with IFN, which activates macrophages into classically activated macrophages 
(CAM) [110]. Conversely, in response to a different microenvironment, macrophages activated 
by IL-4 or IL-13 differentiate into alternatively activated macrophages (AAMs) [110]. AAMs 
are anti-inflammatory therefore important for tissue repair and wound healing by producing 
anti-inflammatory cytokines (TGF-, IL-10) [110]. The surface markers CD206, TGM2 and 
Fizz1 are upregulated in AAMs [98]. In addition, the enzyme Arginase 1(Arg1) is upregulated 
and essential for AAM metabolism [98]. Arg1 and iNOS competitively use the same L-arginine 
substrate. Arg1 converts L-arginine into L-ornithine whereas iNOS uses L-arginine to produce 
nitric oxide [239]. As an important pro-inflammatory cytokine, it has been suggested that TNF 
inhibits macrophage differentiate into AAMs in tumours [34] and in the parasite Leishmania 
major model [35]. We therefore hypothesised that TNF also inhibits AAM differentiation 
during infection with L. monocytogenes.  
 
Peritoneal macrophages reside in the peritoneal cavity which also includes B cells, T cells, NK 
cells, eosinophils and dendritic cells [1]. There are two subsets of peritoneal macrophages, 
large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs) [1]. LPMs 
are F4/80highCD11b+ and SPMs are characterized as F4/80lowCD11b+ [49]. CD11b is expressed 
on macrophages, eosinophils, T cells, B cells and it is required for adhesion with other immune 
cells [51]. F4/80 has been used as a marker for macrophages. It is expressed by peritoneal 
macrophages but exhibits at low levels in splenic macrophages [1]. Under steady state 
conditions, LPMs are the most abundant of the peritoneal macrophages [49]. After 
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inflammatory stimuli, peritoneal cell subsets are dramatically altered, including inflammatory 
monocytes which have migrated en masse from bone marrow. This results in increased SPMs, 
but LPMs disappear which is referred as ‘macrophage disappearance reaction’ [1]. SPMs and 
LPMs display distinct phagocytic abilities and levels of NO production in response to 
stimulation [49]. In response to LPS stimulation in vitro, SPMs produce enhanced levels of NO 
and TNF [240]. Under inflammatory conditions SPMs are differentiated from bone marrow 
derived monocytes, whereas LPMs renew by self-proliferation [1]. The proliferation of LPM 
correlates with tissue repair after inflammation [57],  and Ki67 has been used as a marker of 
peritoneal macrophage proliferation [241].  
 
The role of TNF in the alternative activation of peritoneal macrophage is unknown. In this 
study, we compared peritoneal macrophage and monocyte subsets in B6.WT and B6.TNF-/- 
mice during L. monocytogenes infection. The expression of CAM and AAM markers were 
studied in the investigation of TNF activity in peritoneal macrophage differentiation. We 
showed that TNF deficient peritoneal macrophages express high levels of Arg1 following L. 
monocytogenes infection, suggesting an AAM bias in the absence of TNF.    
 
4.2 Results 
4.2.1  TNF deficiency alters the peritoneal cellular composition during L. 
monocytogenes infection.  
In order to investigate the role of TNF in peritoneal macrophage differentiation with L. 
monocytogenes infection, we first examined the TNF effects on peritoneal cellular composition 
after infection. The cell subsets in peritoneum during L. monocytogenes infection were 
compared between B6.WT and B6.TNF-/- mice. The total numbers of peritoneal cells in B6.WT 
and B6.TNF-/- mice were similar, though slightly higher in B6.TNF-/- mice (Fig 4.2.1A). 
Neutrophils migrate into infection sites rapidly following L. monocytogenes infection, which 
is essential in the early control of bacterial infection [242]. At day 1 post infection, the 
abundance of neutrophils increased in the peritoneum in both strains of mice, indicating the 
initiation of infection. At day 3 and day 4, neutrophil abundance had returned to the basal levels 
in B6.WT mice, but remained elevated in B6.TNF-/- group (Fig 4.2.1B).  
 
During inflammation in the peritoneum, the resident macrophage numbers are reduced, which 
has been referred to as the ‘macrophage disappearance reaction’ [54]. Following the infection 
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of L. monocytogenes, total peritoneal macrophages from B6.WT and B6.TNF-/- mice were 
decreased (Fig 4.2.1C). B6.TNF-/- mice harbored fewer peritoneal macrophages than wild-type 
controls at day 3 and day 4 post infection (Fig 4.2.1C). The number of monocytes increased at 
day 1 with L. monocytogenes infection in both strains of mice (Fig 4.2.1D). Peritoneal 
monocyte numbers in B6.TNF-/- mice were slightly higher than wild-type controls and were 
significantly higher at day 4 post infection (Fig 4.2.1D). 
 
4.2.2 SPM and LPM in B6.WT and B6.TNF-/- mice showed different kinetics following 
L. monocytogenes infection.  
We have shown that peritoneal macrophages in B6.TNF-/- mice decreased at day 3 and day 4 
post infection compared to B6.WT mice. We then investigated the kinetics of SPM and LPM 
during L. monocytogenes infection. LPMs (F4/80highCD11b+) were the more abundant subset 
under naïve and L. monocytogenes infected conditions in both strains of mice (Fig 4.2.2A). The 
numbers of SPM (F4/80lowCD11b+) in B6.WT and B6.TNF-/- mice were elevated at day 1 post 
infection. SPM numbers were increased in B6.WT whereas reduced in B6.TNF-/- mice at day 
 
Figure 4.2.1: The subsets of peritoneal neutrophil, macrophage, monocyte with L. monocytogenes 
infection. B6.WT mice and B6.TNF-/- mice were infected with 1,000 L. monocytogenes 
intraperitoneally. The total number of peritoneal cells after infection at indicated days was analysed 
with flow cytometry. Total number of peritoneal cells (A), neutrophils (B), macrophages (C) and 
monocytes (D) from non-infected and L. monocytogenes infected B6.WT and B6.TNF-/- mice. n = 4-8 
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2 post infection, then SPMs were disappeared in both strains at day 3 and day 4 post infection 
(Fig 4.2.2B). The difference reached significance after infection for 4 days. In addition, LPM 
numbers in B6.TNF-/- mice were significantly reduced at day 3 and day 4 after infection, 
compared with wild-type controls (Fig 4.2.2C). 
  
4.2.3 Phenotypes of peritoneal macrophage and monocyte following L. monocytogenes 
infection. 
The expression of CCR2 and MHC-II are important phenotypes of peritoneal macrophage and 
monocyte. We therefore investigated the levels of CCR2 and MHC-II expression in SPMs, 
LPMs and monocytes by flow cytometry. Monocytes and SPMs expressed higher levels of 
CCR2 in both strains of mice, suggesting the bone marrow derivation of monocytes and SPMs 
following L. monocytogenes infection (Fig 4.2.3A-C). There was no significant difference in 
the expression of CCR2 in SPMs and monocytes between B6.WT and B6.TNF-/- mice (Fig 
4.2.3A, 4.2.3C). LPMs from B6.TNF-/- mice expressed increased levels of CCR2 than wild-
 
Figure 4.2.2: The kinetics of SPM and LPM subset in peritoneal macrophages. B6.WT and 
B6.TNF-/- mice were infected with 1,000 L. monocytogenes intraperitoneally.  SPMs and LPMs were 
analysed using flow cytometry. Representative plots of peritoneal macrophages were identified as 
SPMs and LPMs according to the expressions of F4/80 and CD11b (A). The numbers of SPM (B) and 
LPM (C) were analysed. n = 4-8 mice from two independent experiments, error bars represent SEM, 
*p < 0.05.   
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type controls at day 3 and day 4 post infection (Fig 4.2.3B). It has been described that SPMs 
express higher level of MHC-II than LPMs [49]. We showed higher expression of MHC-II in 
SPMs than LPMs in both strains of mice (Fig 4.2.3D-F). However, no significant differences 
were shown in the expression of MHC-II in SPMs, LPMs and monocytes (Fig 4.2.3E-F) 
between B6.WT and B6.TNF-/- mice. 
 
4.2.4 qPCR analysis in peritoneal macrophages and monocytes during L. monocytogenes 
infection for 3 days.  
Our results showed that TNF effects the kinetics of peritoneal macrophages and monocytes 
during L. monocytogenes infection (Fig 4.2.2). To gain a deeper insight, we sorted peritoneal 
macrophages, monocytes at day 3 post infection with L. monocytogenes. The expression of 
CAM and AAM markers such as iNOS, Arg1, CD206, Fizz1, IL-10, and IL-6 was analysed by 
qPCR. TNF deficiency did not alter the expression of Arg1, iNOS in peritoneal macrophages 
and monocytes (Fig 4.2.4B, 4.2.4C). B6.TNF-/- peritoneal macrophages expressed increased 
levels of TGM2 and decreased CD206, unchanged levels of Fizz1, IL-10 and IL-6 (Fig 4.2.4D-
 
Figure 4.2.3: Expression of CCR2 and MHC-II in SPM, LPM and monocyte. B6.WT and 
B6.TNF-/- mice were intraperitoneally infected with 1,000 L. monocytogenes. Peritoneal cells were 
collected and the mean of fluorescence intensities (MFIs) of CCR2 and MHC-II in the SPMs, LPMs 
and monocytes were analysed by flow cytometry. n= 4-8 mice from two independent experiments, 
error bar represents SEM, *p < 0.05, ***p < 0.001.  
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G). It suggested that TNF deficiency altered the TGM2 and CD206 expression in peritoneal 
macrophages. We compared gene expressions between peritoneal macrophage and monocyte. 
There was no significant difference in the expression of Arg1 in peritoneal macrophages and 
monocytes (Fig 4.2.4B). B6.TNF-/- peritoneal macrophages expressed higher level of iNOS 
than monocytes, but not in B6.WT controls (Fig 4.2.4C). The levels of CD206, TGM2, Fizz1, 
IL-10, and IL-6 in peritoneal macrophages were enhanced in monocytes in both strains of mice 
(except TGM2 in B6.WT mice). This suggested the AAM bias in peritoneal macrophages after 
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Figure 4.2.4: Gene expression of macrophages and monocytes in the peritoneum at day 3 post 
infection. B6.WT and B6.TNF-/- mice were infected with L. monocytogenes for 3 days. Peritoneal 
macrophages and monocytes were sorted using flow cytometry, gene expression was analysed by qPCR. 
Representative plots of peritoneal macrophages and monocytes for cell sorting (A). The expression of 
relative mRNA of Arg1, iNOS, CD206, TGM2, Fizz1, IL-10, and IL-6 in peritoneal macrophages and 
monocytes (B-H). n = 3-8 mice for each group, error bars were SEM, *p < 0.05, **p < 0.01, ***p < 
0.001.  
 
4.2.5 Intact iNOS expression in peritoneal macrophages and monocytes from B6.TNF-/- 
mice after L. monocytogenes infection for 3 days.  
Since iNOS is a key marker of CAM, we investigated the expression of iNOS in peritoneal 
macrophages and monocytes from B6.WT and B6.TNF-/- mice. The mean fluorescence 
intensity (MFI) of iNOS in SPMs, LPMs and monocytes was analysed using intracellular flow 
cytometry (Fig 4.2.5A). The iNOS expressions in SPM, LPM and peritoneal monocyte were 
similar in TNF deficient mice, compared with wild type controls (Fig 4.2.5B). LPMs, but not 
SPMs or monocytes, are the major iNOS producer in B6.WT and B6.TNF-/- mice (Fig 4.2.5B).  
Total numbers of iNOS+ subsets (SPMs, LPMs and monocytes) were not significantly different 
(data not shown), iNOS+ SPMs and LPMs were pooled into macrophages. The total numbers 
of iNOS producing peritoneal macrophages and monocytes were decreased in B6.TNF-/- mice, 
though did not reach significant difference (Fig 4.2.5C). 
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Figure 4.2.5: iNOS expressions in peritoneal macrophage and monocyte after infection with L. 
monocytogenes for 3 days. B6.WT and B6.TNF-/- mice were infected with 1,000 L. monocytogenes for 
3 days. Expressions of iNOS in peritoneal macrophage and peritoneal monocyte were assessed using 
flow cytometry. Representative plots of iNOS expression in peritoneal macrophages, monocytes from 
B6.WT mice (A). MFI of iNOS in LPMs, SPMs and peritoneal monocytes (B). Total numbers of iNOS+ 
peritoneal macrophages and monocytes in peritoneum cavity (C). n = 8 mice from two independent 
experiments, error bars indicate SEM, *p < 0.05.   
 
 
4.2.6 Increased expression of Arg1 in LPMs from B6.TNF-/- mice during L. 
monocytogenes infection.   
The high expression of Arg1 is an indicative phenotypic marker of AAM, so we investigated 
the Arg1 expression in SPMs, LPMs and monocytes by intracellular flow cytometry (Fig 
4.2.6A). In both strains of mice, LPM was the more abundant subset expressing Arg1 with L. 
monocytogenes infection, displaying higher level of Arg1 than SPMs and monocytes (Fig 
4.2.6B). In addition, total numbers of Arg1+ subsets (SPMs, LPMs and monocytes) were not 
significantly different (data not shown), so SPMs and LPMs were pooled into macrophages. 
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4.2.6B). The total number of Arg1+ peritoneal macrophages was higher in B6.WT mice (Fig 
4.2.6C). 
 
4.2.7 Normal cell proliferation in peritoneal macrophages in B6.TNF-/- mice with L. 
monocytogenes infection.  
The high expression of Arg1 in LPMs from B6.TNF-/- mice suggests tissue repair after infection 
with L. monocytogenes for 3 days. We then investigated local proliferation in peritoneal 
macrophages, which is a characteristic of tissue repair. Ki67 has been used as a marker of cell 
proliferation and can be assessed using intracellular flow cytometry (Fig 4.2.7A). The levels 
of Ki67 in SPMs, LPMs and peritoneal monocytes were similar in B6.WT and B6.TNF-/- mice, 
 
Figure 4.2.6: Arg1 expression in the peritoneal macrophages and monocytes after infection with 
L. monocytogenes for 3 days. B6.WT and B6.TNF-/- mice were infected with 1,000 L. monocytogenes 
for 3 days. Expression of Arg1 in peritoneal macrophages and monocytes was examined with 
intracellular flow cytometry. Representative plots of Arg1 expression in the peritoneal macrophages 
and monocytes in B6.WT mice (A). MFI of Arg1 in SPMs, LPMs and monocytes (B). Total numbers 
of Arg1+ peritoneal macrophages and monocytes in peritoneum were shown (C). n = 8 mice from two 
















































































                                              
88 
suggesting the peritoneal macrophage proliferation is independent of TNF (Fig 4.2.7B). The 
expression of Ki67 in LPMs were slightly higher than SPMs and significantly higher than 
monocytes (Fig 4.2.7B). Total numbers of Ki67+ subsets (SPMs, LPMs and monocytes) were 
not significantly different (data not shown), so SPMs and LPMs were pooled into macrophages. 
The total numbers of Ki67+ peritoneal macrophages were decreased in B6.TNF-/- mice, 
compared with wild-type controls (Fig 4.2.7C). 
4.3 Discussion  
TNF is an important cytokine in defence against bacterial infection as TNFR1 deficient mice 
are susceptible to L. monocytogenes infection [31]. This chapter showed that in the absence of 
TNF, infection with L. monocytogenes caused peritoneal macrophages to differentiate into 
AAMs. The high expression of Arg1 in AAM impairs NO release, which would account for an 
increased susceptibility to infection. A similar situation has been demonstrated with L. major 
 
Figure 4.2.7: Ki67 expression in peritoneal macrophages and monocytes following L. 
monocytogenes infection for 3 days. B6.WT and B6.TNF-/- mice were infected with 1,000 L. 
monocytogenes for 3 days. Ki67 expression was assessed using intracellular flow cytometry. 
Representative plots of Ki67 expression in peritoneal macrophages and monocytes in B6.WT mice 
(A). MFI of Ki67 in SPMs, LPMs and peritoneal monocytes (B). Total numbers of Ki67+ peritoneal 
macrophage and monocyte were analysed (C). n = 8 mice from two independent experiments, error 
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infection [35]. Furthermore, the inhibition of TNF in AAM differentiation has also been 
demonstrated in tumour models [34]. Given this consistency, TNF appears essential in 
regulating macrophage function during infection.  
 
Infections cause peritoneal inflammation result in a depletion of macrophages, which is 
referred as ‘macrophage disappearance reaction’ [54]. This was also observed in both B6.WT 
and B6.TNF-/- mice with L. monocytogenes infection. In the absence of TNF the reduction of 
macrophages was increased. This is correlated to a larger infiltration of monocytes into the 
peritoneum, thus TNF may have a role in attempting to maintain homeostasis of macrophages, 
but under severe inflammatory conditions it is overwhelmed by the infection. In addition, 
monocyte migration to infected tissue during infection requires the chemokine receptor CCR2 
[182]. Results in this chapter showed that CCR2 expression in LPMs is increased in the absence 
of TNF. This is consistent with research showing that exogenous TNF reduces the expression 
of CCR2 [243]. The increased expression of CCR2 appears to lead to B6.TNF-/- LPMs 
migration out of the peritoneal cavity. LPMs have been indicated to migrate from peritoneum 
to omentum after intraperitoneal injection of black carbon particles [55]. The extensive 
migration of B6.TNF-/- LPMs might explain the reduced number of LPMs following L. 
monocytogenes infection.  
 
Following the infection with L. monocytogenes, TNF absence leads to change of the peritoneal 
macrophage phenotype. qPCR analysis in the expression of Arg1 in peritoneal macrophages 
did not show significant difference between B6.WT and B6.TNF-/- groups. However, the higher 
expression of Arg1 in LPMs was found in B6.TNF-/- mice using flow cytometry. In order to 
investigate the expression of Arg1 at transcriptional level, LPMs will have to be isolated in 
future experiments. LPMs might be the subset of peritoneal macrophages which display 
distinct phenotypes in the absence of TNF. As an essential murine marker of CAM, iNOS 
showed a similar expression in B6.WT and B6.TNF-/- peritoneal macrophages. The intact iNOS 
expression in B6.TNF-/- mice has also been demonstrated in the L. major infection model [35]. 
In addition, our data showed that TNF-deficient peritoneal macrophages have increased Arg1, 
TGM2 and decreased CD206 expression, but unchanged Fizz1 and IL-10 expression. 
Schleicher et.al had reported the upregulated expression of Arg1, CD206 and similar 
expression of Fizz1 in draining lymph nodes macrophages from TNF-/- mice during L. major 
infection [35]. IL-10 expression is regulated by transcription factor- cAMP- responsive element 
binding protein (CREB), our data may suggest that TNF signalling is not required in the 
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activation of CREB during L. monocytogenes infection [244]. The distinct phenotype of 
‘AAMs’ from TNF-/- mice may occur during bacterial and parasite infection. The mechanism 
under the role of TNF in AAM phenotypes with L. monocytogenes infection needs to be further 
understood. During the infection of L. monocytogenes, the ‘AAMs’ with increased expression 
of Arg1, TGM2 and decreased CD206 might not ‘typical AAMs’. The expression of Arg1 and 
CD206 is regulated by transcription factor STAT6 [245], TNF in enhancing CD206 expression 
during L. monocytogenes infection is required to be investigated further. Additionally, it has 
been indicated that high expression of Arg1 impairs NO release in the site of infection, which 
causes non-healing infection with L. major [35]. The high level of Arg1 in ‘untypical AAMs’ 
in B6.TNF-/- mice might responsible to high susceptibility to L. monocytogenes infection.  
 
Following infection, monocytes are recruited from bone marrow to the infected site (e.g. 
peritoneal cavity). SPM is the peritoneal macrophage subset differentiated from bone marrow 
derived monocytes. LPMs are considered to be resident macrophages that are maintained by 
self-proliferation. The higher expression of CCR2 in SPM, but not in LPMs suggests the bone 
marrow origin of SPM. 
 Ki67 is the marker of the cell cycle and it is absent in resting cells (G0 phase) but present in 
the active phases of cell cycle [246]. Macrophage proliferation is a phenotype of IL-4 induced 
Th2 inflammation [57]. L. monocytogenes induced macrophage proliferation correlates with 
the AAM phenotype in macrophages [247]. It allows the liver to return to homeostasis after 
bacterial infection. The zinc finger transcription factor GATA-binding protein 6 (GATA6) 
appears to be involved in proliferation related gene profile of peritoneal macrophages [67]. 
However, loss of TNF signalling did not alter the proliferation of LPM during L. 
monocytogenes infection as a similar level of Ki67 was found in B6.TNF-/- mice. It may suggest 
that TNF is not required in GATA6 regulated proliferation in peritoneal macrophages. In 
response to the infection of L. monocytogenes, a higher level of Ki67 was found in LPM but 
not in SPM. It could suggest that proliferation of LPM occurs during L. monocytogenes 
infection as has been indicated a high Ki67 expression in liver resident macrophages following 
the infection of L. monocytogenes [247].  
 
Neutrophils are the essential immune cells in killing L. monocytogenes. The absence of TNF 
leads to elevated neutrophil numbers in the peritoneal cavity after day 3 infection. TNF has 
been indicated to induce the expression of CXCL1 (KC) and CXCL2 (MIP-2) [230], which 
facilitates the homing of neutrophils into infected tissues. The high expression of CXCL1 was 
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reported in the liver from TNF deficiency mice with L. monocytogenes infection, suggesting 
CXCL1 may be the chemokine responsible for infiltration of neutrophils in TNF deficiency 
[232]. Chemokines CXCL1 (KC) and CXCL2 (MIP-2) might mediate the TNF related 
neutrophil recruitment with L. monocytogenes infection. In addition, higher neutrophil number 
in the peritoneal cavity might lead to over inflammation in B6.TNF-/- mice. On the other hand, 
after the infection of L. monocytogenes for 3 days, peritoneal macrophages are characterized 
with AAM phenotypes. They displayed high levels of CD206, TGM2, Fizz1 and IL-10 in 
peritoneal macrophages in both B6.WT and B6.TNF-/- mice. The peritoneal macrophages with 
AAM phenotype are essential in mediating tissue repair and remodel. A decreased number of 
peritoneal macrophages in B6.TNF-/- mice appears to lead to ongoing inflammation during 
bacterial infection. It is in line with the increased neutrophil number in B6.TNF-/- mice, which 
might lead to tissue damage.  
 
The inhibition of TNF in AAM differentiation is essential in TNF mediated pro-inflammatory 
responses. Appropriate control of TNF drives the appropriated response to infections, such as 
L. monocytogenes. Since anti-TNF therapy has been widely used in the treatment of 
inflammatory diseases, the high risk of bacterial infection needs to be considered in the 
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Macrophages are a heterogeneous population of innate immune cells with the important role 
of protection against pathogens. Macrophage phagocytosis involves receptor recognition, 
cytoskeleton rearrangement and phagosome maturation [122]. During the process of 
phagocytosis pathogens are endocytosed and become engulfed as membrane coated 
phagosomes [248]. The phagosomes then fuse with lysosomes to form an acidic environment 
to degrade the pathogens [122]. Actin polymerization is required for pathogen uptake and 
reactive oxygen and nitrogen species contribute to the degradation of the pathogen [122]. TNF 
appears to inhibit the clearance of apoptotic cells from the lung by reducing phagocytic 
efficiency [249]. In a murine model of otitis media TNF was shown to have an important role 
in clearing bacteria during a middle ear infection. TNF deficient macrophages were found to 
have a reduced ability to endocytose nontypeable Haemophilus influenza [250]. Furthermore, 
TNF appears to enhance IFNγ primed macrophage phagocytosis of apoptotic cells in a nitric 
oxide (NO) dependent manner [251]. Therefore, the roles of TNF in macrophage phagocytosis 
under different activation states and with different target cells are unclear.  
 
L. monocytogenes and Devil Facial Tumour Disease (DFTD) provide useful targets to 
investigate role of TNF in macrophage phagocytosis. L. monocytogenes provide a target for 
phagocytosis of bacteria. After being recognized by macrophages, L. monocytogenes are 
phagocytosed within a phagosome and escape into cytoplasm by disrupting the phagosome 
membrane [4]. Then, L. monocytogenes replicate in the cytoplasm and infect the neighbouring 
cells through actin-based motility [252]. Listeriolysin O (LLO) of L. monocytogenes is required 
in bacterial escape from the phagosome by disrupting the phagosome membrane [253]. 
Moreover, actin assembly-inducing protein (ActA) of L. monocytogenes plays a central role in 
listerial intracellular motility through promoting actin recruitment and polymerization [254].  
 
Devil Facial Tumour Disease (DFTD) cells provide an example of cancer cells. They were 
selected for two main reasons. Firstly, to determine if DFTD cells could be phagocytosed and 
secondly to investigate the role of TNF in phagocytosis of tumour cells. DFTD was first 
recorded in 1996 and is responsible for the catastrophic decline of the Tasmanian devil 
(Sarcophilus harrisii) population [255]. The cancer is transmitted as an allograft by biting and 
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is characterized by tumours located on the face and neck of infected devils [191]. Histological 
and immunohistochemical analyses of lymphoid organs have shown that Tasmanian devils 
possess the components required for a competent immune system [202]. Changes in histone 
deacetylation results in an absence of MHC-I expression on the DFTD cell surface, thereby 
causing the cancer cells to escape CD8+ T cell recognition [199]. Devil NK cells appears to 
have the capacity for cytotoxicity against DFTD cells in an antibody dependent manner [204]. 
It is unknown whether devil macrophage can phagocytosis DFTD cells, hence the selection of 
these cells for this study. 
 
Macrophages from wild type and B6.TNF-/- mice were isolated and the phagocytosis of L. 
monocytogenes and DFTD cells were investigated. This chapter showed that DFTD cells can 
be phagocytosed by murine macrophages. After activation by IFNγ/LPS or LPS alone, TNF 
was found to reduce the efficiency of macrophage phagocytosis.  
 
5.2 Results 
5.2.1 Role of TNF in thioglycollate- elicited peritoneal macrophage phagocytosis of L. 
monocytogenes. 
Thioglycollate-elicited peritoneal macrophages from B6.WT and B6.TNF-/- mice were used to 
investigate the role of TNF in macrophage phagocytosis of L. monocytogenes. Macrophages 
were infected with L. monocytogenes (MOI 10) and the phagocytic ability was analysed using 
fluorescence microscopy (Fig 5.2.1A). As shown in Fig 5.2.1B, in untreated or IFNγ/LPS 
activated macrophages, the number of L. monocytogenes in infected macrophages was similar 
for the B6.WT and B6.TNF-/- group. Following activation with IL-4, macrophages from 
B6.TNF-/- mice phagocytosed less L. monocytogenes than wild type controls (Fig 5.2.1B). But 
IL-4 activation did not show difference in percentage of infected macrophages in B6.WT and 
B6.TNF-/- group (Fig 5.2.1C). A smaller number of L. monocytogenes was detected in 
macrophages but the percentage of infection was unchanged in B6.TNF-/- macrophages, 
suggesting the alteration of phagocytosis ability due to the lack of TNF. It suggests that TNF 
might be required in enhanced phagocytosis of L. monocytogenes during the activation by IL-
4. The percentage of infected macrophages was enhanced by IFNγ/LPS treatment. But the 
IFNγ/LPS treatment did not alter the percentage of infected macrophages from B6.WT and 
B6.TNF-/- mice (Fig 5.2.1C).  
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5.2.2 TNF is not involved in L. monocytogenes phagosomal escape in thioglycollate-
elicited peritoneal macrophages.  
After phagocytosis by macrophages, L. monocytogenes escape into cytosol to avoid 
degradation in phagosome [252]. The escaped L. monocytogenes move in the cytoplasm by 
actin polymerization [252], which is essential for L. monocytogenes intracellular survival. So, 
 
Figure 5.2.1: Similar phagocytosis of L. monocytogenes in thioglycollate-elicited peritoneal 
macrophages from B6.WT and B6.TNF-/- mice. Thioglycollate-elicited peritoneal macrophages 
from B6.WT and B6.TNF-/- mice were collected at day 3 after thioglycollate injection. Macrophages 
were activated with IFNγ and LPS or IL-4 as indicated in methods. Macrophages were infected with 
CFSE labelled L. monocytogenes at MOI 10 and phagocytosis capacity was analysed by fluorescence 
microscopy. (A) After infection with L. monocytogenes, cells were stained with anti-CD11b antibody 
and DAPI (Blue= DAPI; Red= macrophages; Green= L. monocytogenes). The number of L. 
monocytogenes in infected macrophages (B) and the percentage of phagocytosed macrophages was 
analysed (C) by fluorescence microscope. Data were from 4-6 mice from two or three independent 
experiments, error bars indicate SEM, * p < 0.05.  
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we investigated the role of TNF in phagosomal escape from macrophages. The co-localization 
of phalloidin with L. monocytogenes represented L. monocytogenes that had escaped into the 
cytoplasm (Fig 5.2.2A). The phagosomal escape of L. monocytogenes in macrophages from 
B6.WT and B6.TNF-/- mice was analysed using confocal microscopy. Macrophages from 
B6.WT and B6.TNF-/- mice had similar percentages of phagosomal escape, in untreated, 
IFNγ/LPS or IL-4 activated macrophages (Fig 5.2.2B). Therefore, in the absence of TNF there 
is no increase in escape of L. monocytogenes into the cytoplasm. However, the percentage of 
L. monocytogenes that had escaped from the phagosome in macrophages from B6.WT and 
B6.TNF-/- mice was significantly less in IFNγ/LPS activated macrophages than control 
macrophages. Hence IFNγ/LPS activation may prevent escape into the cytoplasm. But no 






Figure 5.2.2: TNF is not ionvolved in L. monocytogenes phagosomal escape in thioglycollate-
elicited peritoneal macrophages. B6.WT and B6.TNF-/- thioglycollate-elicited peritoneal 
macrophages were infected with CFSE-labelled L. monocytogenes. Phagosomal escape was 
analysed with confocal microscopy. (A) After infection of L. monocytogenes, cells were stained with 
phalloidin and DAPI (Blue=DAPI; Red=phalloidin; Green=L. monocytogenes). (B) Percentage of 
phalloidin positive CFSE-L. monocytogenes. Data were from 3-6 mice of two or three independent 
experiments, error bars indicate SEM, * p < 0.05. 
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5.2.3 DFTD cells can be phagocytosed by B6.WT and B6.TNF-/- BMDMs.  
DFTD cells were used as cellular targets in the investigation of the role of TNF in macrophage 
phagocytosis of tumour cells. Due to the low yield of the thioglycollate-elicited peritoneal 
macrophages, we used BMDMs in the following experiments. To determine if DFTD cells can 
be phagocytosed, BMDMs from B6.WT and B6.TNF-/- mice (CTV-labelled; blue) were co-
incubated with DFTD C5065 cells (CFSE-labelled; green). After 4 and 24 h culture, 
phagocytosis was analysed by confocal microscopy (Fig 5.2.3). Green DFTD cells could be 
identified within the blue macrophages from both B6.WT and B6.TNF-/- mice. When z-stacks 
were analysed the green fragments were identified inside the macrophages, suggesting the 
tumour cells had been engulfed (Fig 5.2.3). The degradation of phagocytosed cellular material 
involves the process of phagosome maturation through homotypic and heterotypic fusion of 
early endosomes, late endosomes and lysosomes [191]. The presence of lysosomal-associated 
membrane protein 1 (LAMP1) was used to discriminate a late phase of phagocytosis, after 
phagosome/lysosome fusion [256]. LAMP1 and engulfed tumour fragments were co-localized, 
confirming phagocytosis (Fig 5.2.3). As BMDMs from B6.WT and B6.TNF-/- mice can 
phagocytose DFTD cells, it suggests that TNF is not required for phagocytosis and that DFTD 
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5.2.4 TNF deficiency results in enhanced phagocytosis capacity in IFNγ/LPS treated 
macrophages. 
Confocal microscopy showed that DFTD cells are phagocytosed by BMDMs from B6.WT and 
B6.TNF-/- mice, but to determine phagocytic efficiency flow cytometry was used. BMDMs 
were labelled with CTV and DFTD cells were labelled with CFSE, then incubated at ratios of 
10:1 and 5:1 BMDMs: DFTD cells at 37 C or 4 C for 4 h. Phagocytosed DFTD cells were 
recognized as CFSE and CTV double positive cells. In the absence of stimulation (control) the 
phagocytic efficiencies of BMDMs from B6.WT and B6.TNF-/- mice were similar at both 10:1 
(Fig 5.2.4A) and 5:1 (Fig 5.2.4B) ratios. It suggests that TNF is not required for macrophage 
phagocytosis of DFTD cells under steady-state conditions.  
 
In order to determine TNF involvement in phagocytosis following macrophage activation, 
BMDMs were stimulated with IFNγ and LPS, IFNγ alone, LPS alone or IL-4 alone. Following 
IFNγ/LPS activation, BMDMs from B6.TNF-/- mice displayed enhanced phagocytosis 
efficiency at both 10:1 (Fig5.2.4A) and 5:1 (Fig 5.2.4B) ratios, compared with BMDMs from 
B6.WT mice. However, BMDMs from B6.TNF-/- mice stimulated with IFNγ, LPS or IL-4 alone 
 
    
Figure 5.2.3: Confocal microscope analysis of macrophage phagocytosis of DFTD cells. CTV 
labelled BMDMs (blue) were incubated with CFSE labelled DFTD cells (green) for 4 h and 24 h, cells 
were fixed and permeabilized, then labelled with anti-LAMP1 antibody (red) (A). Phagocytosis was 
analysed by confocal microscopy. The z-stack demonstrated that tumour cells were inside B6.WT and 
B6.TNF-/- macrophages after 4 h and 24 h incubation. Arrows represent DFTD cells inside BMDMs 
(B). 
B A 
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did not show a significant difference in phagocytic efficiency, compared with BMDMs from 
B6.WT mice (Fig 5.2.4A, 5.2.4B). To confirm that the CFSE and CTV double positive cells 
represented phagocytosis rather than cell binding, DFTD cells and macrophages were co-
incubated at 4 C for 4 h (Fig 5.2.4C, 5.2.4D). The proportion of double positive cells was 
substantially reduced providing support for phagocytosis at 37 C rather than just binding to 




Figure 5.2.4: IFNγ/LPS treated B6.TNF-/- BMDMs exhibited enhanced phagocytic efficiency of 
DFTD cells compared to B6.WT BMDMs. BMDMs from B6.WT and B6.TNF-/- mice were treated 
with IFNγ/LPS, IFNγ alone, LPS alone, or IL-4 alone. BMDMs were labelled with CTV and DFTD 
cells were labelled with CFSE. After labelling, BMDMs were co-incubated with DFTD cells for 4 hours. 
The percentage of phagocytosed DFTD cells in the incubation of 37 C (A, B) and 4 C (C, D) was 
investigated by flow cytometry. Data were from 3-7 mice of two or three independent experiments, error 
bars indicate SEM, ΔP< 0.05 versus WT control, #P< 0.05 versus B6.TNF-/- control, *P< 0.05 versus 
WT versus B6.TNF-/-, NS not significantly. 
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5.2.5 IFNγ/LPS, LPS activated BMDM from B6.TNF-/- mice phagocytose and kill DFTD 
cells more effectively than BMDM from B6.WT mice following 24 h incubation. 
Macrophage phagocytosis and killing of DFTD cells was analysed with flow cytometry by 
enumerating the number of viable DFTD cells remaining. The absolute number of free DFTD 
cells was calculated using cell count beads. IFNγ/LPS and LPS alone activated BMDMs from 
B6.TNF-/- mice cultured with DFTD cells for 24 h resulted in fewer DFTD cells remaining 
compared to BMDMs from B6.WT mice at 10:1 and 5:1 ratios (Fig 5.2.5A, 5.2.5B). However, 
IFNγ or IL-4 activated BMDMs from B6.TNF-/- mice had similar number of DFTD cells with 
wild-type controls at 10:1 and 5:1 ratios (Fig 5.2.5A, 5.2.5B). These results indicate that LPS 
and potentially IFNγ/LPS activated macrophages from B6.TNF-/- mice phagocytosed more 
DFTD cells the macrophages from the B6.WT control mice. Thus, although phagocytosis by 
activated BMDMs was observed in the presence of TNF, the absence of TNF appeared to 
increase the phagocytic activity. 
 
 
Figure 5.2.5:  IFNγ/LPS activated B6.TNF-/- macrophages remain less DFTD cells after 
24 hours incubation.  After co-incubation with macrophages and DFTD cells for 24 hours, 
number of DFTD cells at (A) (E: T) 10:1, (B) (E: T) 5:1 were determined by flow cytometry 
by collecting all cells in each treatment. The numbers of DFTD cells were calculated as 
describing in materials and methods chapter. Data were from 3-5 mice of two or three 
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5.2.6 Less nitric oxide is released from IFNγ/LPS, LPS activated B6.TNF-/- BMDMs 
after incubation with DFTD cells for 24 h. 
Nitric oxide (NO) is an essential effector molecule in macrophages and is cytotoxic to tumour 
cells [91]. As TNF regulates the production of NO in macrophages [95], we investigated 
whether NO was reduced in the absence of TNF during phagocytosis of DFTD cells by 
IFNγ/LPS activated BMDMs. IFNγ/LPS, IFNγ alone, LPS alone treated BMDMs from B6.WT, 
B6.TNF-/- mice were incubated with DFTD cells for 24 h and the NO contents in the cell culture 
supernatant were measured. As shown in Figure 5.2.6, untreated BMDMs released 
undetectable NO and were similar in both genotypes. Compared with the B6.WT controls, less 
NO was released from IFNγ/LPS treated B6.TNF-/- BMDMs after incubation with DFTD cells 
for 24 h (Fig 5.2.6A, 5.2.6B). Similarly, less NO was released in LPS activated BMDMs from 
B6.TNF-/- mice than wild-type controls (Fig 5.2.6A, 5.2.6B). IFNγ treatment did not alter NO 
production of B6.WT, B6.TNF-/- BMDMs after incubation with DFTD cells for 24 h (Fig 
5.2.6A, 5.2.6B).   
 
5.2.7 iNOS inhibitor cannot reverse enhanced phagocytic activity of IFNγ/LPS activated 
B6.TNF-/- macrophages. 
To determine whether NO is required for phagocytosis in the presence of TNF, NO release was 
 
Figure 5.2.6: Reduced NO production from IFNγ/LPS, LPS activated B6.TNF-/- BMDMs 
phagocytosis of DFTD cells. B6.WT and B6.TNF-/- BMDMs were stimulated with IFNγ/LPS, IFNγ 
alone, or LPS alone. BMDMs and DFTD cells were co-incubated at E: T 10:1 (A) and 5:1 (B) for 24 
h, the concentration of NO in the cell culture supernatant was analysed by Griess assay. Data were 
from 3 mice, error bars indicate SEM, * P<0.05, ** p < 0.01. 
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blocked by the inhibitor of nitric oxide synthesis, L-N6- (1-Iminoethyl) lysine 
dihydrochlorideinducible (L-NIL). After incubation with IFNγ/LPS or IFNγ/LPS and L-NIL 
for 24 h, BMDM from B6.WT and B6.TNF-/- mice were co-incubated with DFTD cells for 24 
h. The numbers of DFTD cells were measured by flow cytometry and cell counting beads. As 
shown in Figure 5.2.7, L-NIL did not alter phagocytosis following stimulation with IFNγ/LPS 
of BMDMs from B6.WT mice or B6.TNF-/- mice. In B6.WT mice, L-NIL treatment in 
IFNγ/LPS activated BMDMs showed similar phagocytosis with IFNγ/LPS activated BMDMs 
(Figure 5.2.7). It suggests that nitric oxide was unrelated to the TNF inhibition of macrophage 




Macrophage phagocytosis is essential in defence against pathogens. This chapter investigated 
TNF activity in macrophage phagocytosis using L. monocytogenes and DFTD cells as models 
of bacteria and tumour cells. In the study of phagocytosis with L. monocytogenes, IFNγ/LPS 
treatment of macrophages resulted in an increased phagocytosis efficiency and reduced 
phagosomal escape. It has been reported that IFNγ/LPS activation enhances macrophage 
 
Figure 5.2.7: NO is unrelated to TNF involved macrophage phagocytosis of DFTD cells. B6.WT 
and B6.TNF-/- BMDMs were treated with IFNγ/LPS or IFNγ/LPS with L-NIL overnight. After 
incubation with BMDMs and DFTD cells for 24 hours, the numbers of DFTD cells at E: T 10:1 (A), 5:1 
(B) ratios were analysed by flow cytometry and cell counting beads. The numbers of DFTD cells were 
calculated as methods described. Data were from 3-5 mice of two or three independent experiments, 
error bars indicate SEM, * P< 0.05, NS not significantly. 
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phagocytosis with L. monocytogenes and retains L. monocytogenes in phagosomes [257], 
which is in line with results in this thesis. TNF did not appear to have a role in macrophage 
phagocytosis or preventing phagosomal escape of L. monocytogenes. But treatment with 
IFNγ/LPS or LPS alone, TNF reduced macrophage phagocytosis of DFTD cells.  
 
L. monocytogenes and DFTD cells had been used to investigate the role of TNF in macrophage 
phagocytosis. In response to the activation of IFNγ/LPS, TNF deficiency leads to higher 
efficiency in phagocytosis of DFTD cells, but not L. monocytogenes. There are two potential 
reasons for the different role of TNF in macrophage phagocytosis of L. monocytogenes and 
DFTD cells. Firstly, the role of TNF in macrophage phagocytosis is distinct in different 
phagocytosis targets. Macrophages appear to have distinct mechanisms in the phagocytosis of 
bacteria and tumour cells. Secondly, thioglycollate-elicited peritoneal macrophages were used 
in the investigation of TNF effects in macrophage phagocytosis of L. monocytogenes. The 
eliciting agent Brewer’s thioglycollate broth has been used to increase the yield of 
macrophages from peritoneal cavity [258]. However, thioglycollate injection causes 
inflammation in the peritoneal cavity and monocytes are recruited from bone marrow and 
differentiate into small peritoneal macrophages (SPM) [49]. Therefore, the studies of 
thioglycollate-elicited peritoneal macrophage reflect the function of resident SPMs and 
monocyte derived SPMs [49]. The problem is directly comparing phagocytosis when two 
different macrophage sources were used. In addition, macrophages might change their 
physiology function in response to thioglycollate injection, as they have defective intracellular 
killing of microorganism [259]. Due to the limitation of thioglycollate-elicited peritoneal 
macrophages, macrophages derived bone marrow were used in the study of TNF effects in 
macrophage phagocytosis of DFTD cells. Therefore, the different sources of macrophages 
might result in distinct function of TNF in phagocytosis. 
  
The absence of MHC-I expression on DFT1 cells prevents the activation CD8+ T cell adaptive 
immune response [199]. This would prevent an adaptive cell mediated immune response. An 
enhancement of innate immune response to DFTD such as macrophage phagocytosis may 
provide a mechanism to promote anti-DFTD immune responses. This could be either natural, 
in the wild, or artificial, through vaccination. The evidence that immunised devils [260, 261] 
and some wild devils [200] can produce antibodies against DFT1 cells is in line with antibody 
mediated opsonisation of DFT1 cells and subsequent phagocytosis. For this to occur, DFT1 
cells would need the capacity to be phagocytosed. Tumour cells can avoid phagocytosis by 
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expressing inhibitory molecules such as the ‘don't eat me signal’, which is part of the immune 
checkpoint inhibitory pathway, preventing phagocytosis [262]. RNA transcriptome analysis 
identified CD47 from devil mononuclear cells, which aligned closely with other species [263]. 
Hence there is the potential for DFT1 cells to express this molecule to avoid phagocytosis.  
There are some difficulties in collecting devil macrophages for the analysis of DFTD 
phagocytosis. In the absence of monoclonal antibodies to identify such molecules and the 
unavailability of devil macrophages, we conducted phagocytosis of DFT1 cells using bone 
marrow derived mouse macrophages. The interpretation of DFTD phagocytosis by murine 
macrophages might provide evidence that DFTD cells can be phagocytosed by macrophages. 
If mouse derived macrophages could phagocytose DFT1 cells, then devil macrophages should 
also have this ability. But some of the usual ligand interactions may not operate across species. 
The CD47 ‘don’t eat me’ signal may not work from devil to mouse macrophages, but may 
work devil-devil preventing phagocytosis. We showed the phagocytosis of DFTD cells by 
mouse macrophages by two independent mechanisms, flow cytometry and confocal 
microscopy. The confocal microscopy, provided the additional evidence of destruction of the 
DFT1 tumour cells. The susceptibility of DFT1 cells to phagocytosis has at least two important 
implications. Firstly, wild devils that have the capacity to make antibodies against DFT1 cells 
could promote phagocytosis of antibody opsonised DFT1 cells [200]. Secondly, devil 
immunised with DFT1 cells that produce antibody [260] could also opsonise the DFT1 cells 
and target them for phagocytosis. In both situations, promotion of a specific immune response 
could follow due to the interaction of the macrophages and cytokines produced during 
phagocytosis. This could result in cytokines upregulating MHC-I [199] and the DFT1 cells 
becoming targets for CD8 T cells, as shown with immunotherapy [261]. 
 
TNF reduced macrophage phagocytosis of DFTD cells following activation with IFN/LPS or 
LPS. This is consistent with previous finding that exogenous TNF inhibits macrophage 
phagocytosis of  apoptotic cells [264]. Furthermore, LPS induced TNF production has been 
shown to reduce macrophage phagocytosis of apoptotic neutrophils in an autocrine way [265, 
266]. In contrast, inhibition by TNF in macrophage phagocytosis was not observed with human 
IgG-opsonized erythrocytes [266]. Nor has TNF been reported to be essential in the 
enhancement of macrophage phagocytosis of apoptotic cells [251]. Consequently the role of 
TNF in macrophage phagocytosis of tumour cells is not fully understood. Results in this thesis 
showing enhanced phagocytosis by B6.TNF-/- macrophages indicates that TNF is not required 
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for uptake of DFTD cells. As macrophages can produce TNF either by LPS or IFNγ/LPS 
activation, endogenous TNF production could increase TNF to inhibitory levels [94, 267]. 
IFNγ could activate macrophages to produce TNF only in the present of  LPS [268].  Although 
from a different source, TNF production from IFNγ primed macrophages has been 
demonstrated [251, 269]. IFNγ/LPS treatment induces higher level of TNF production than 
LPS alone [267]. Unlike IFNγ/LPS treatment, LPS activated B6.TNF-/- BMDMs display 
enhanced phagocytic ability at 24 h incubation but not 4 h incubation. The high production of 
TNF from IFNγ/LPS activated macrophages may inhibit phagocytosis of DFTD cells. The 
production of TNF from LPS, IFNγ and IFNγ/LPS treated macrophages needs to be further 
evaluated.   
 
Phagocytosis of pathogens by macrophages requires NO and TNF dependent NO production 
is required for the enhanced phagocytosis of apoptotic cells by IFNγ activated macrophages 
[251]. However, NO can impair phagocytosis of fluorescent particles by affecting cytoskeletal 
assembly and pseudopod formation [270]. TNF is definitely involved in NO production as it 
induces iNOS expression via NF-B [94, 95]. Furthermore, the expression of iNOS in 
IFNγ/LPS activation macrophages requires TNF [93]. TNF dependent NO production is 
required for the enhanced phagocytosis of apoptotic cells by IFNγ activated macrophages [251]. 
We blocked NO release by using L-NIL, but inhibition of NO did not alter phagocytosis 
efficiency in IFNγ/LPS treated macrophages. It suggests the NO is independent of TNF related 
IFNγ/LPS treated macrophages. Moreover, actin polymerization is an essential event in the 
process of macrophage phagocytosis. It has been suggested that exogenous TNF decreases 
actin reorganization in J774 macrophages [271]. The involvement of actin and TNF inhibition 
of phagocytosis activity in IFNγ/LPS activated macrophages needs to be further investigated.  
 
Macrophage phagocytosis plays an essential role in defence against tumour. Tumour cells 
express high levels of programmed cell death protein 1 (PD-1) to inhibit macrophage 
phagocytosis of tumour cells [272]. Monoclonal antibodies blocking PD-1 has been a notable 
therapy in patients with melanoma and colorectal cancer [272]. Similarly, the inhibition of TNF 
in macrophage phagocytosis of tumour cells appears to be essential in host’s response to 
tumour. Understanding the mechanisms of TNF in macrophage phagocytosis of tumour cells 
may thus be a target for the therapy of cancer.  
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Chapter 6 Final discussion 
Roles of TNF in regulating immune system are complex and diverse. As a pro-inflammatory 
cytokine, TNF is implicated in the pathogenesis of  chronic inflammatory diseases, such as 
rheumatoid arthritis, Crohn’s disease, and psoriasis [273]. It has indicated that increased release 
of TNF at inflammatory sites drives disease pathology [11]. Consequently, pharmacological 
interventions of TNF by using TNF antagonists have been the standard care in several chronic 
inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease [273]. 
However, despite the widely use of anti-TNF therapy, the increased recrudescence of latent 
infections including leishmaniasis and tuberculosis occurs in clinical application [8]. Some 
cases were reported in induction of psoriasis with anti-TNF agents in inflammatory bowel 
disease patients [274]. Therefore, further understanding the mechanisms and biology of TNF 
acts on immune response may provide insight into anti-TNF therapy in inflammatory diseases 
and provide basis for avoiding undesired latent or re-infection with pathogens.  
 
TNF can be produced by many types of cells but is mainly produced by macrophages and T 
cells during infections [5]. TNF has both beneficial and detrimental effects after microbial 
exposure. Secretion of TNF is essential in resolution of various infection of pathogens. TNFR1 
deficient mice are high susceptible to L. monocytogenes infection [31]. TNF deficiency leads 
to progressive cutaneous and visceral disease with the infection of  L. major (FEBNI strain) in 
C57BL/J mice [223]. TNF-/- mice succumbed to respiratory failure after infection by replicable 
mycobacteria and TNF acts as a negative regulator of type 1 immune response during bacterial 
infection [275]. Excessive production of TNF is related to increased organ injury and mortality 
rate in the condition of endotoxemia, bacterial infection and abdominal sepsis [276]. These 
disconcordant outcomes failed to answer the question about the role of TNF in mediating 
immune protection and immune mediated pathology. In this thesis, I investigated the role of 
TNF in the context of experimental L. monocytogenes infection and revealed roles of TNF in 
regulating macrophage mediated immune responses to defence against this intracellular 
infection. During L. monocytogenes infection, I found the bias of alternative activation in 
macrophages in the absence of TNF (chapter 3, 4), and TNF is required in macrophages restrict 
the release of IL-1 (chapter 3). Additionally, I showed that TNF is potentially involved in 
downregulating activated macrophages phagocytosis of tumour cells (chapter 5).  
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6.1 TNF in dampening AAM differentiation following L. monocytogenes infection 
Classically activated macrophages (CAM) and alternatively activated macrophages (AAM) are 
the two main macrophage phenotypes that develop in response to different stimuli which 
promote pathogen clearance and tissue repair respectively [41]. It has been reported that TNF 
inhibits AAM differentiation in experimental cutaneous leishmaniasis [35] and in tumour 
models [34]. The common activity of TNF in AAM differentiation in experimental L. 
monocytogenes infection is examined in this thesis. In spleen, it has been indicated that bone 
marrow derived monocytes differentiate into dendritic cells with high ability in producing 
iNOS and TNF (TipDCs) [69]. These TipDCs are Ly6Chi and share the similar characterization 
of CAMs [41]. The chemokine receptor CCR2 is required in monocyte recruitment as the 
monocyte recruitment is inhibited in CCR2 deficient mice during L. monocytogenes infection 
[182]. Therefore, the splenic inflammatory monocytes in this thesis were characterized with 
Ly6ChiCCR2+. In the context of L. monocytogenes infection, Ly6ChiCCR2+ monocytes from 
B6.TNF-/- mice displayed the phenotype of AAMs with upregulated Arg1, TGM2 expression 
(Figure 3.2.4). Similar to the results of splenic monocytes, alternative differentiation was found 
in peritoneal macrophages from B6.TNF-/- mice during L. monocytogenes infection. Large 
peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs) are two subsets of 
peritoneal macrophages with distinct expression levels of F4/80 [1]. The level of Arg1 in LPMs 
from B6.TNF-/- mice was higher than in wild type controls, which may suggest that TNF 
dampens AAM bias in peritoneal macrophages during L. monocytogenes infection (Figure 
4.2.6).  
 
The AAM differentiation in the absence of TNF is consistent with the studies in L. major [35] 
and with tumour models [34]. AAMs can be identified as producing Arg1, whereas CAMs 
produce iNOS [277]. Both enzymes are essential for the metabolism of L-arginine, and 
compete for its use [277]. TNF has been shown to inhibit AAM gene expression by 
downregulating the expression of genes triggered by IL-4 such as Arg1 and CD206 [35]. The 
inhibition by TNF of IL-4 induced AAM gene expression involves the suppression of the 
transcriptional factor STAT6 [35]. Arg1 expression in IL-4 triggered macrophages is 
dependent on H3 acetylation at the Arg1 promoter [35]. The downregulation of TNF reduces 
Arg1 expression through inhibition of H3 acetylation [35]. During infection with L. 
monocytogenes, the results showed lack of TNF affects on Arg1 and TGM2, but not CD206, 
expression (Figure 3.2.4). The role of TNF in modulating CD206 expression during the L. 
monocytogenes infection needs to be further characterised. The inhibition of TNF AAM 
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differentiation appears to coincide with the high susceptibility to L. monocytogenes infection. 
TNF did not alter the levels of iNOS in splenic and peritoneal macrophages during L. 
monocytogenes infection (Figure 3.2.4-5, Figure 4.2.5). Despite the normal activity of iNOS, 
excessive expression of Arg1 appears to inhibit NO production during infection with L. major, 
presumably by competing for the same substrate, resulting in failure to control infection in 
B6.TNF-/- mice [35]. Additionally, splenic AAMs with high level of Arg1 harboured more L. 
monocytogenes in B6.TNF-/- mice (Figure 3.2.5). The involvement of Arg1 in regulating NO 
production during experimental L. monocytogenes infection is worthy of further investigation.  
 
In addition, the splenic Ly6Clow monocytes were found to be AAMs during L. monocytogenes 
infection for 3 days. The two subsets of splenic monocytes (Ly6Chi and Ly6Clow monocytes) 
exhibit distinct function with Ly6Chi monocytes being pro-inflammatory and Ly6Clow 
monocytes having anti-inflammatory activities [37]. In response to L. monocytogenes infection, 
Ly6Chi monocytes migrate rapidly from bone marrow and produce high levels of TNF and 
iNOS, which are essential in killing bacteria and activating other immune cells [69]. The 
Ly6Clow monocytes are normally characterized by the low expression of CCR2 [68]. They 
patrol blood vessels to scavenge dead cells, oxidize lipids and pathogens [71]. This thesis 
compared gene expression between Ly6Clow and Ly6Chi monocytes during L. monocytogenes 
infection (Figure 3.2.4). The expression levels of Arg1, TGM2 and Fizz1 in Ly6Clow 
monocytes were greater relative to Ly6Chi monocytes, this suggests an AAM phenotype in the 
Ly6Clow monocytes following infection with L. monocytogenes (Figure 3.2.4). The AAM 
phenotype of Ly6Clow monocytes is consistent with these studies as they indicated a wound 
healing function of Ly6Clow monocytes by producing Arg1 and IL-10 [72]. Ly6Clow monocytes 
were gated as CCR2+ in this thesis, it is different from the ‘classical’ Ly6Clow monocytes which 
do not express CCR2 [40]. The high expression of CCR2 in Ly6Clow monocytes suggests bone 
marrow origin. Previous studies have shown that Ly6Chi monocytes are progenitors of Ly6Clow 
monocytes, and decrease expression of Ly6C as their transition [73]. After the resolution of 
the bacterial infection, Ly6Chi monocytes differentiate into Ly6Clow monocytes by 
downregulating Ly6C expression [40]. It is interesting to find that TNF signalling is required 
in Ly6Chi monocytes maturation into Ly6Clow monocytes (Figure 3.2.2).  
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Figure 6.1 TNF in orchestrate splenic innate immune subsets following the infection of L. 
monocytogenes. In response to L. monocytogenes infection, TNF absence leads to high 
expression of Arg1 and normal expression of iNOS in CCR2+Ly6Chi monocytes. Increased 
expression of Arg1 results in high bacterial survival and higher number of neutrophils. The 
release of IL-1 is also enhanced in B6.TNF-/- mice. Draw by XL.  
 
 
TNF is essential in mediating proper immune responses by maintaining homeostasis during 
infection. The ‘macrophage disappearance reaction’, a phenomenon where LPM’s migrate 
from peritoneal cavity to the omentum was apparent in mice after the intraperitoneal 
inoculation with L. monocytogenes (Reviewed in [1]). The reduction of peritoneal macrophage 
numbers was greater in B6.TNF-/- mice than in wild type controls, which is primarily with the 
LPM population (Figure 4.2.2). TNF may therefore play a role in maintaining macrophage 
homeostasis in the context of infection. As LPMs in B6.TNF-/- mice expressed higher levels of 
CCR2, the reduced numbers of LPMs appears due to the aggressive migration out of the 
peritoneum cavity. TNF is also required in maintain neutrophil homeostasis and lack of TNF 
resulted in excessive recruited of neutrophil into infection sites, such as spleen and peritoneum. 
The bias of AAM differentiation in the lack of TNF results in uncontrolled bacterial infection, 
hosts have to recruit neutrophils to resolve infection, which may cause tissue damage.  
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Figure 6.2 TNF in regulating peritoneal innate immune subsets after L. monocytogenes 
infection. TNF deficiency results in fewer number of peritoneal macrophages retaining in 
peritoneum following L. monocytogenes infection. LPMs express enhanced level of Arg1 in 
response to TNF absence. Increased number of neutrophils, monocytes were recruited and 
increased level of IL-1 was released in B6.TNF-/- mice after L. monocytogenes infection. 
Draw by XL.  
  
6.2 Role of TNF in inflammasome activation during L. monocytogenes infection 
In response to an intracellular stimulus, such as L. monocytogenes, macrophage release high 
levels of IL-1β by the activation of the inflammasome [138]. TNF signalling appears to inhibit 
macrophage release IL-1β during L. monocytogenes infection (Figure 3.2.8). This is 
controversial to the implication that TNF induces IL-1β production in macrophages [237]. 
Exogenous TNF triggers macrophage to release more IL-1 via NF-B activation, whereas the 
inhibition of NF-B leads to impaired IL-1β release [237]. The results showed a similar 
expression of inflammasome elements (caspase-1, pro-caspase-1, NLRP3). The level of pro-
IL-1β is upregulated in macrophages from B6.TNF-/- mice. It might result from the higher pro-
IL-1β production in the absence of TNF in the stimulation of LPS. Macrophages produce TNF 
in response to LPS, then TNF stimulates negative feedback in macrophages to restrict the 
production of IL-1β. The presence of TNF ensures the appropriate production of IL-1β in 
response to L. monocytogenes infection. In the condition of losing TNF, hosts have to release 
the pro-inflammatory cytokine IL-1 to resolve infection. On the other hand, the high 
production of IL-1β in the absence of TNF may contribute to the ongoing inflammation during 
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L. monocytogenes infection. The high concentration of IL-1β in sera of patients undergoing 
anti-TNF therapy might be a diagnose marker for bacterial infections.  
 
6.3 Role of TNF in macrophage phagocytosis of tumour cells 
Macrophage phagocytosis is a critical function in defence against pathogens. The role of TNF 
in macrophage phagocytosis was investigated with the tumour cells causing Devil Facial 
Tumour Disease (DFTD). TNF has no effect on phagocytosis of DFTD cells in the absence of 
stimulation. Following activation with IFNγ/LPS or LPS (but not IFNγ alone) however, the 
ability of phagocytosis was enhanced in the absence of TNF (Figure 5.2.4). Although TNF is 
regarded as a master regulator of inflammatory cytokine release (reviewed in [6]), there are 
reports that TNF can also inhibit macrophage phagocytic activity. Exogenous TNF has been 
shown to reduce capacity of macrophages to ingest apoptotic cells [278]. This inhibition 
appears to be specific for apoptotic cells as it is not observed with beads or antibody-opsonized 
cells [278]. It is proposed that within the inflammatory environment, the reduced phagocytic 
ability may ‘contribute to the local intensity of the inflammatory response’. Macrophages 
stimulated with LPS produce TNF which would inhibit macrophage phagocytosis of apoptotic 
cells in an autocrine manner [265]. TNF is also produced by IFNγ/LPS activated macrophages 
[94, 267]. IFNγ on its own is unable to activate macrophages to produce TNF, but can do so in 
the presence of LPS [268]. The situation can be somewhat murky as some studies showed IFNγ 
primed macrophages can produce TNF [251, 269]. Furthermore, IFNγ appears to restore an 
impaired ability of macrophages to phagocytose apoptotic cells, which is in a nitric oxide-
dependent manner and requires TNF production [251, 269]. However, these conflict results 
might be due to the macrophages coming from different sources and at different stages of 
maturation. For example, although TNF has no effect on phagocytosis by immature 
macrophages, it reduces phagocytosis by mature macrophages [278]. In response to the pro-
inflammatory signals of IFNγ/LPS or LPS, the inhibition of TNF in macrophage phagocytosis 
of tumour cells appears to be ‘anti-inflammatory’. This inhibition might be essential in 
response to pathogens properly to avoid effects of overreaction.  
 
In summary, roles of TNF in macrophage are complex and diverse. Firstly, TNF inhibits the 
AAM differentiation during L. monocytogenes infection, which may leads to the high 
susceptibility in B6.TNF-/- mice. The high expression of Arg1 in AAMs in B6.TNF-/- mice 
might lead to impaired elimination of L. monocytogenes infection by reducing iNOS activity. 
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The mechanisms mediated by TNF to inhibit AAM differentiation need to be further elucidated. 
The inhibition of AAM differentiation of TNF might promote CAM activation in response to 
bacterial infection. Following infection, the appropriate CAM activation is required in the 
efficient bacterial elimination. The imbalance of AAM and CAM activation might contribute 
to the pathology of inflammatory diseases. Secondly, TNF is shown to be an inhibitor of IL-1β 
release during infection with L. monocytogenes. Thirdly, TNF inhibits macrophage 
phagocytosis of tumour cells after activation with IFNγ/LPS or LPS alone. These findings 
showed the importance and requirement of TNF in inflammatory responses. As the protective 
role of TNF in defence against bacterial infection by inhibiting AAM differentiation, bacterial 
infection should be avoided in the treatment of chronic inflammatory diseases by using anti-
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During an immune response inflammatory macrophages with their wide variety of 
effector mechanisms including the expression of inducible nitric oxide synthase play an 
important part in the defense against invading pathogens. The inflammatory phenotype 
requires the presence of TNF which suppresses alternative activation. In the bacterial 
Listeria monocytogenes infection model inflammatory macrophages are crucial for 
protection. After infection, TNF-deficient hosts have a similar number of splenic 
macrophages but die rapidly. A more detailed analysis of these cells showed that while 
inducible nitric oxide synthase is expressed at a comparable level TNF-deficient 
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1. Introduction 
Failure to resolve inflammation is intrinsic in many 
human pathologies. Mechanisms that influence and 
modulate the inflammatory response are therefore, 
of general interest for our understanding of the 
underlying disease processes. One of the classical 
protagonists of inflammation is the 
proinflammatory cytokine tumor necrosis factor 
(TNF). This cytokine is present in high 
concentrations in inflammatory sites and has a 
variety of functions, such as activating cells and 
inducing the expression of functional cell surface 
molecules (Sedgwick et al., 2000). TNF is 
expressed by macrophages and T cells early after an 
immunological challenge and has been identified as 
a target for therapeutic intervention in a variety of 
chronic and autoimmune inflammatory diseases, 
including rheumatoid arthritis (RA) and 
inflammatory bowel disease (IBD) (Efimov et al., 
2009; Udalova et al., 2016a). Anti TNF-therapy that 
blocks TNF activity using antagonists based on 
antibodies or TNFR fusion proteins is now a proven 
method of treatment for these pathologies (Udalova 
et al., 2016b). However, TNF has also been 
identified to be essential in the establishment of 
protective immunity to infection. Experiments that 
block TNF and the use of gene-deficient animals 
have resulted in a list of bacterial and parasitic 
pathogens that are controlled by a functioning 
TNFR1-TNF signaling axis (Pfeffer et al., 1993; 
Rothe et al., 1993; Wilhelm et al., 2001). The 
implicit mechanisms that contribute to the 
protective role of TNF have been difficult to define 
due to the ubiquitous expression of this pleiotropic 
cytokine. In the murine model of experimental 
cutaneous leishmaniasis, TNF-deficiency induced a 
progressive visceral infection and was ultimately 
fatal in the normally resistant mouse strain 
C57BL/6 (Wilhelm et al., 2001). The underlying 
cause of this lack of protection proved to be elusive 
since both innate and adaptive immune responses 
seem largely unchanged. However, it has recently 
been shown that TNF is essential for the 
suppression of Arginase 1 (Arg1) and other genes 
of the pro-homeostatic alternatively activated 
macrophage signature due to a restriction of 
accessibility of their promoters and enhancers 
(Schleicher et al., 2016). Thus, TNF was deemed 
irreplaceable for an effective differentiation of 
monocytes to classically activated macrophages 
(Schleicher et al., 2016). Indeed, a large percentage 
of skin and lymph node-resident macrophages and 
inflammatory dendritic cells (DC) from Leishmania 
(L.) major infected B6.TNF−/− mice co-expressed 
classically and alternatively activated macrophage 
signature molecules such as Arg1 and iNOS, 
respectively (Schleicher et al., 2016). This co-
expression resulted in a lack of the central effector 
molecule nitric oxide (NO) in the lesion and the 
draining lymph node in infected tissues presumably 
due to a depletion of L-arginine, the substrate of 
both enzymes. This biological function of TNF to 
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restrict alternative macrophage differentiation 
during the inflammatory response to L. major has 
also been demonstrated in tumor models and we 
hypothesized that it would be applicable generally. 
Therefore, we used Listeria (L.) monocytogenes 
infection as a bacterial model with a well-established 
history of myeloid differentiation to analyze the 
consequences of TNF-deficiency in more detail 
(Serbina et al., 2003). The TNF-deficient mouse 
strain (B6.TNF−/−) was highly susceptible to the 
pathogen. Inflammatory splenic macrophages from 
B6. TNF−/− mice could be identified using Ly6 C and 
CD11b. These cells exhibited a high bacterial burden, 
normal iNOS and an elevated Arg1 and TGM2 
expression. 
2. Material and methods 
2.1. Animals and infection 
Eight to 16-week-old C57BL/6 (B6. WT) and 
B6.TNF−/− mice were used in all experiments. All 
mice were housed and bred in a certified SPF 
environment. To infect the mice we cultured a single 
colony of L. monocytogenes (obtained from Prof. 
Dirk Busch, Institute for Microbiology, Technical 
University Munich, Germany) in brain-heart 
infusion broth (BD Biosciences, North Ryde, 
Australia) overnight at 37 °C with shaking. The 
overnight culture was added to fresh medium at 
volume ratio 1: 50 and cultured for 1 h with shaking 
until an OD600 of 0.1 was reached. In a volume of 
100 ul PBS 1000 L. monocytogenes were injected 
intraperitoneally. All animal procedures were 
approved by the Animal Ethics Committee of the 
University of Tasmania (permit number A13933). 
2.2. Flow cytometry analysis 
Spleens were dissociated with collagenase V 
(Sigma-Aldrich, Castle Hill, Australia) and red blood 
cells lysed using a Hepes-buffered ammonium 
chloride lysis buffer. Splenocytes were filtered 
through cell strainers (40 μm; BD Biosciences) to 
remove cell debris. Cells were stained with rat anti-
mouse mAbs against Ly6 C (AL-21, FITC, BD 
Biosciences), CD11b (M1/70, PerCP-Cy5.5, BD 
Biosciences), CD11c (HL3, PE-Cy7, BD 
Biosciences), Ly-6G (IA8, PE, BD Biosciences), Ly-
6G (IA8, BV421, Biolegend, San Diego, USA), The 
rat anti-mouse CCR2 mAb (MC21) has been 
described (Mack et al., 2001) and was provided by 
Prof. Matthias Mack (Universitaetsklinikum 
Regensburg, Regensburg, Germany). The CCR2 
antibody was used unlabeled and before addition of 
donkey anti-rat AF647 (Jackson ImmunoResearch 
Laboratories, West Grove, USA) as secondary 
antibody cells were blocked with 10% rat serum 
(Sigma-Aldrich) for 10 min on ice. 
Dead cells were excluded by DAPI (Sigma-Aldrich). 
Data were acquired using CyAn ADP (Beckman 
Coulter, Gladesville, Australia) and data analysis 
was performed using FlowJo V10.1 (Tree Star, USA). 
Gating controls were determined by fluorescence 
minus one (FMO) controls. For flow cytometric cell 
sorting we used a MoFlo Astrios cell sorter 
(Beckman Coulter). The purity obtained was > 95%. 
2.3. CFUs assay 
Spleen and liver were removed from animals and 
homogenized in PBS containing 0.05% Triton X-
100 (Sigma-Aldrich). Alternatively, Ly6 C+ 
macrophages were isolated by flow cytometry and 
5000 cells were lysed in the same buffer. Serial 
dilutions were plated onto brainheart infusion agar 
plates and colony forming units (CFUs) counted 
after overnight culture at 37 °C. CFU were recorded 
as CFU/organ or CFU/5000 cells. 
2.4. Quantitative real-time PCR 
Splenic Ly6 C+ monocytes were sorted as described. 
RNA was extracted using ReliaPrep™ RNA Cell 
Miniprep System (Promega, Sydney, Australia) 
according to the manufacturer's instructions. The 
iScript™ gDNA Clear cDNA Synthesis Kit (Bio-
Rad, Gladesville, Australia) was used to reverse-
transcribe total RNA. Quantitative real- 
Table 1 qPCR 
primers used in 
this study. 















































time PCR (qPCR) was carried out on a Roche 
Lightcycler 480 qPCR instrument (Roche, North 
Ryde, Australia) with 10 μl reactions using the 
SsoAdvanced™ Universal SYBR® Green Mix (Bio-
Rad). Primers are listed in Table 1. Reactions were 
performed in duplicate and gene expression levels 
were normalized to the housekeeping gene GAPDH. 
2.5. Statistical analysis 
Statistical analyses were performed using GraphPad 
Prism 5 software. Statistical significance was 
determined by Mann–Whitney U test. Data were 
shown as the mean ± SEM. P values of smaller than 
0.05 were considered statistically significant. 
3. Results 
The experimental infection of mice with L. 
monocytogenes is a wellvalidated model for a 
bacterial infection that relies on macrophages as 
predominant host cells. Spleen and liver are the two 
major target organs of systemic L. monocytogenes 
infection. In B6.WT mice the infection reached a 
peak of 104 bacteria per organ at day 3 post-infection 
(p.i.) and started to subside thereafter (Fig. 1A and 
B). At the same time post infection, in spleens and 
livers of immunocompromised B6.TNF−/− mice the 
number of L. monocytogenes exceeded 106 and 105, 
respectively, and continued to increase at a dramatic 
rate (Day4: > 107 in spleen and liver). 
Based on a Ly6G− CD11b+ CD11c+ phenotype, two 
major populations of myeloid cells (Ly6G− 
CD11bhigh CD11clow (R1) and Ly6G− CD11blow 
CD11chigh (R2)) could be readily identified in the 
spleens of B6.WT and B6.TNF−/− mice three days 
after infection. Further analysis showed that the 
Ly6G− CD11bhigh CD11clow cells displayed an 
inflammatory phenotype with a strong expression of 
CCR2 and Ly6 C, Fig. 1C) while cells of the 
population R2 were predominately negative for 
CCR2 and Ly6 C (Fig. 1C). Subsequently, the 
development of the population of Ly6G− CD11bhigh 
CD11clow CCR2+ Ly6 C+ macrophages was analyzed 
in a time course. After infection, the proportion of 
inflammatory cells increased rapidly reaching an 
observed peak at day 4 after infection (Fig. 1D). 
Because of the susceptibility of the B6.TNF−/− mice 
to the pathogen the experiment had to be stopped at 
this stage. Interestingly, the total number while also 
significantly increasing from 1 × 106 (day 0 p.i.) to 
2.6 × 106 (day 2 p.i.) did not differ significantly 
between the genotypes (Fig. 1E). 
An analysis of inflammatory macrophages sorted 
from B6.WT and B6.TNF−/− mice at day 3 post 
infection showed a significant presence of bacteria in 
B6.TNF−/− macrophages while B6.WT were virtually 
free of pathogens indicating a lack of intrinsic 
defense mechanisms in the TNF knockout strain (Fig. 
2A). Therefore, we investigated the expression of the 
classically activated macrophage marker iNOS at 
this point in the infection and in parallel, Arg1 and 
TGM2 as marker molecules for alternative activation. 
Despite the absence of TNF, iNOS expression was 
unchanged in both genotypes pointing to a lack of 
TNF-dependent regulation of this enzyme (Fig. 2B). 
In contrast, the alternative activation marker 
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molecules Arg1 and TGM2 were significantly 
upregulated in B6.TNF−/− macrophages (Fig. 2C, D). 
These observations 
are in agreement with earlier findings in the model of 
experimental leishmaniasis (Schleicher et al., 2016; 
Fromm et al., 2012). Other marker molecules such as 
Fizz1 were not affected by TNF-deficiency and were 
equally expressed in both genotypes (data not 
shown). 
4. Discussion 
A deficiency in the TNF-TNFR1 signaling pathway 
causes a significant aggravation of the pathology of 
C57BL/6 mice infected with L. monocytogenes 
(Grivennikov et al., 2005; Pfeffer et al., 1993; Rothe 
et al., 1993). Investigations using a tissue-specific 
TNF-deficiency have been able to localize the source 
of the protective production of TNF in macrophages 
(Grivennikov et al., 2005). The TNF-deficient strain 
B6.TNF−/− displayed a rapid increase of the bacterial 
burden in spleen and liver within 4 d after 
intraperitoneal infection with 1000 CFU while B6. 
WT mice were able to control the infection. 
Interestingly, an analysis of the expression of the 
enzymes iNOS, Arg1 and TGM2, marker molecules 
for classically and alternatively activated 
macrophages respectively, by splenic macrophages 
showed a significant presence of the enzymes Arg1 
and TGM2 which are considered to be marker for 
alternative activation. 
This is an important finding since a recent detailed 
analysis of the innate immune response to the 
parasite L. major has demonstrated a skewed 
development of macrophages to an alternative 
activation-like phenotype in the absence of TNF 
(Schleicher et al., 2016). This newly described pro-
inflammatory function of the TNF-TNFR1 axis has 
been supported by observations in two tumor models 
(Kratochvill et al., 2015). In the absence of TNFR1 
an emergence of alternatively activated macrophages 
was reported. For the first time, our investigation of 
the listeriosis model now extends these findings to 
bacterial infection. This confirms the biological 
relevance of the initial reports. Our findings are 
highly significant because the ubiquitous presence 
and the high density of TLR-ligands in bacterial 
infection could have been instrumental in overriding 
the necessity for the pro-inflammatory role of TNF 
which suppresses Arg1 expression. Our data clearly 
indicate that TNF negatively regulates Arg1 
expression irrespective of the inflammatory 
environment in the host. 
A second important aspect of our observation is the 
increasing evidence for a general mechanism 
underlying the general susceptibility to intracellular 
pathogens of mice deficient for the TNF-TNFR1-
signaling pathway. In the analysis of the L. major 
infection model a competitive co-expression of 
iNOS and Arg1 could be demonstrated that caused a 
significant decrease of NO. This effector molecule is 
central in macrophage defense against intracellular 
infection (Bogdan et al., 2000) and a co-expression 
of both enzymes could deplete the pool of the 
substrate L-arginine and cause a lack of NO 
(Schleicher et al., 2016). This mechanistic aspect 
needs further investigation. 
Taken together, we have demonstrated a role for 
TNF in the development of classically activated 
macrophages in listeriosis. Without TNF, we 
demonstrated an increased production of Arg1, a 
hallmark of alternative activation in mice (Murray et 
al., 2014). Further research will be necessary to 
identify the pathways impacted by the lack of TNF 
and for proof of the involvement of L-arginine 
depletion for the augmented susceptibility to L. 
monocytogenes. 
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Fig. 1. TNF deficiency causes susceptibility to L. monocytogenes infection but does not change 
splenic Ly6 Chi monocyte recruitment. B6.WT and B6.TNF−/− mice were infected with 1000 L. 
monocytogenes intraperitoneally. Bacterial load and number of splenic monocytes were 
analyzed. (A,B) Bacterial load in spleen and liver of B6. WT and B6.TNF−/− mice was 
determined by culturing organ homogenates on BHI plates overnight (n = 4–6 mice in two 
independent experiments). The results are shown as mean ± SEM, *p < 0.05. (C) 
Representative FACS plots using Ly6G (granulozytes), CD11b and c, and CCR2 and Ly6 C. 
(D) Representative FACS plots of splenic CD11b+CCR2+Ly6 C+ monocytes from control 
                                              
138   
 
(uninfected) or L. monocytogenes-infected B6.WT and B6.TNF−/− mice over a period of 4 d 
after infection. (E) Quantification of total numbers of CD11b+CCR2+ Ly6 C+ monocyte from 
uninfected or L. monocytogenes infected B6.WT and B6.TNF−/− mice (n = 6–12 mice from two 
or three independent experiments). The results are shown as mean ± SEM. 
 
Fig. 2. Lack of TNF impairs anti- L. monocytogenes function and leads to the M2 phenotype 
of Ly6 C+ monocytes during L. monocytogenes infection. B6.WT and B6.TNF−/− mice were 
infected with 1000 L. monocytogenes intraperitoneally. Ly6 C+ monocytes were sorted from 
B6.WT and B6.TNF−/− mice infected with L. monocytogenes for 3 d. (A) Bacterial loads in 
5000 Ly6 C+ monocytes were measured using BHI agar plates (n = 6 from two independent 
experiments). (B–D) The expression of iNOS, Arg1 and TGM2 mRNA in Ly6 C+ R1 
monocytes from B6.WT and B6.TNF−/− mice were assessed by qPCR (primer see Table 1) (n 
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Abstract  
Macrophage phagocytosis of pathogens and tumour cells is an important early event in 
protection against infectious disease and cancer. As tumour necrosis factor α (TNF) is an 
important cytokine in macrophage activation, we investigated the involvement of TNF in 
macrophage phagocytosis of tumour cells. We used Devil Facial Tumour Disease (DFTD) 
cancer cells as the target tumour cells. The Tasmanian devil (Sarcophilus harrisii) population 
is threatened by the transmissible DFTD. By using DFTD cells provided the opportunity to 
determine if these cells can be phagocytosed and investigate requirement for TNF. If DFTD 
cells are unable to be phagocytosed, this might be another immune escape mechanism. As 
effector cells, bone marrow derived macrophages (BMDMs), generated from C57BL/6 wild 
type (B6.WT) and C57BL/6 TNF-/- (B6.TNF-/-) mice were used. Phagocytosis of DFTD cells 
was investigated by confocal microscopy and flow cytometry. DFTD cells were effectively 
phagocytosed by B6.WT and B6.TNF-/- BMDMs with similar efficiency. Consequently the 
DFTD cells are not resistant to phagocytosis. Following activation by exposure to IFNγ and 
LPS or LPS alone, B6.TNF-/- BMDMs had higher phagocytic efficiency and lower nitric oxide 
production compared to wild-type controls. In addition, nitric oxide (NO) inhibition failed to 
alter phagocytosis efficiency in IFNγ and LPS activated B6.TNF-/- macrophages. Our results 
indicate that TNF is not required for IFNγ and LPS or LPS alone activation of macrophage 
phagocytosis. TNF may negatively regulate macrophage phagocytosis of tumour cells.  
Introduction  
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Tumour necrosis factor α (TNF) is a member of the tumour necrosis factor family including 
TNF, TNFβ and lymphotoxin (LT) [245]. TNF receptor 1 (TNFR1) and TNFR2 are receptors 
for TNF [1]. Under steady-state conditions TNF is synthesised at low levels, but following 
infection macrophages increase the production of TNF [1]. Macrophages are a heterogeneous 
population of innate immune cells with the important role of protection against pathogens. 
Macrophage phagocytosis involves receptor recognition, cytoskeleton rearrangement and 
phagosome maturation [2]. During the process of phagocytosis pathogens are endocytosed 
and become engulfed as membrane coated phagosomes [3]. The phagosomes then fuse with 
lysosome to form an acidic environment to degrade the pathogens [2]. Actin polymerization 
is required for pathogen uptake and reactive oxygen and nitrogen species contribute to the 
degradation of the pathogen [2].   
In response to different stimuli, macrophages differentiate into “classically activated 
macrophages (M1)” or “alternatively activated macrophages (M2)” [4]. M1 macrophages 
require exposure to the pro-inflammatory cytokines interferon gamma (IFNγ) either alone or 
in combination with TNF or LPS. M2 macrophages require exposure to IL-4 and/or IL-13 [4]. 
M1 macrophages promote inflammation whereas M2 macrophages are anti-inflammatory [5]. 
Furthermore, M1 and M2 macrophages display different levels of phagocytosis [5]. IFNγ 
activation of M1 macrophages enhances phagocytosis of apoptotic cells [6]. In contrast, IL-4 
induced M2 macrophages exhibit impaired bacterial phagocytosis due to reduced phagosome 
formation [7]. TNF appears to inhibit macrophage phagocytosis of apoptotic cells in a time 
and dose dependent manner [8]. TNF deficient macrophages have a reduced ability to 
endocytose nontypeable Haemophilus influenza [9]. However, TNF appears to enhance IFNγ 
primed macrophage phagocytosis of apoptotic cells in a NO dependent manner [6]. Therefore, 
the effects of TNF in macrophage phagocytosis under different activation states of 
macrophages are unclear. Consequently, we investigated role of TNF in macrophage 
phagocytosis of tumour cells under different activation conditions. The tumour cells used in 
this study were Devil Facial Tumour Disease (DFTD) cells. These tumour cells were selected 
to determine if DFTD cells could be phagocytosed.  
  
The first case of Devil Facial Tumour Disease was recorded in 1996 and is primarily 
responsible for the catastrophic decline of the Tasmanian devil (Sarcophilus harrisii) 
population. In 2014 a second and independent DFTD was discovered (Pye) and has been 
called DFT2 to distinguish it from the first DFTD, now identified as DFT1. DFTD is a 
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transmissible cancer transmitted as an allograft by biting and is characterized by tumours 
located on face and neck of diseased devils [10]. Functional and histological analyses 
performed to date indicate that the devil has a competent adaptive immune system [11]. Thus, 
generalised immunosuppression does not explain why the DFTD cancer cells are not 
immunologically rejected. The most likely explanation why DFTD escapes immune 
recognition is because the DFTD cancer cells do not express surface MHC-I [12]. This avoids 
activation of the specific immune system. It is unknown whether DFTD cells can be 
phagocytosed, hence the selection of these cells for this study.  
We firstly determined if DFTD cells could be phagocytosed then examined different 
activation status of macrophages and the effect of TNF on their ability to phagocytose DFTD 
cells. We used bone marrow derived macrophages (BMDMs) isolated from wild type and 
B6.TNF-/- mice and found that TNF inhibits macrophage phagocytosis efficiency following 
activation by IFNγ/LPS and LPS.   
  
Materials and Methods  
Animals    
The gene-targeted C57BL/6 (B6.TNF-/-) mouse strains deficient for TNF were generated on a 
genetically pure C57BL/6 (B6.WT) background as described [13].  The screening procedure 
followed the protocols described previously [13]. All animals were housed in pathogen-free 
conditions. Mice aged 8-16 weeks were used in all experiments following approval of the 
Animal Ethics Committee of University of Tasmania (UTAS) under the ethics number 
A13934.   
Cell culture  
Bone marrow derived macrophages (BMDMs) from B6.WT and B6.TNF-/- mice were 
generated from pelvic and femoral bones. BMDMs were cultured in RPMI 1640 medium 
(Gibco, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, 
USA), 10% L929-conditioned medium (containing M-CSF), 5% horse serum (Gibco, USA), 
1% penicillin and streptomycin (Gibco, USA), 1% nonessential amino acids (Gibco, USA) 
and 2-mercaptotoethanol (Gibco, USA). After culture for 7 days, BMDMs were untreated or 
treated with the following substances: 20 ng/ml IFNγ (Peprotech, USA), 100 ng/ml LPS 
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(Sigma, USA) or a combination of IFNγ and LPS for 24 hours or 5 ng/ml IL-4 (Peprotech, 
USA) for 48 hours. The purity of macrophages obtained was always at least 90%.  
The Devil Facial Tumour Disease cell line, C5065, was established from primary tumour 
samples [14]. Cells were grown in RPMI-1640 medium (Gibco, USA) supplemented with 10% 
FBS (Bovogen Biological, Australia) and 5mM L-glutamine (Sigma, USA). DFTD cells were 
maintained in a humidified 5% CO2 incubator at 35 C. Phagocytosis assays required 
coculturing of mouse macrophages with DFTD cells were maintained at 37 °C.  
Flow cytometry phagocytosis assay and calculations  
BMDMs (effector cells) were labelled with CellTrace™ Violet (CTV, Invitrogen, USA), 
DFTD cells (target cells) were labelled with 5(6)-Carboxyfluorescein diacetate Nsuccinimidyl 
ester (CFSE, Invitrogen, USA) according to manufacturer’s instruction. BMDMs were 
resuspended in cell culture medium at 106/ml. Serial dilution of 100 µl BMDMs were 
performed to obtain effector to target ratios of 10:1, 5:1 with 104 target cells. The phagocytosis 
assays were performed using duplicates or triplicates and incubated for 4 hours, 24 hours at 
37 °C and for 4 hours at 4 °C for negative control. The plates were analysed on a BD Canto II 
flow cytometer and data were analysed with Flowjo V10.1 software (Tree star, USA), and 
Graphpad Prism 5 for graphic display. To calculate phagocytosis, three gates were identified. 
R1, total CFSE+ tumour cells = total tumour cells. R2, CFSE+/CTV+ cells = tumour cells 
phagocytized by macrophages. The formula used for calculating phagocytosis was: percentage 
of phagocytosis= R2/R1 x100. For the 24 hours incubation (to avoid complication of cell 
division), the absolute numbers of DFTD cells were calculated by including all events (i.e. 
cells) or enumerating with a known number of cell count beads (eBioscience, USA).  For the 
bead count method, the number of DFTD cells = (number of beads added/ number of beads 
collected) x number of CFSE+ CTV- DFTD cells.  
Cell staining and confocal microscopy for evidence of phagocytosis  
CTV labelled BMDMs were grown in 24 well plates on 0.2% gelatine (BD Bioscience, USA) 
coated 12 mm coverslips. CFSE labelled DFTD cells were added when the coverslip was 
almost confluent with BMDMs. After 4 and 24 hours incubation, cells were gently washed 
with PBS. Cells were permeabilized with 0.25% Triton X-100 (Sigma, USA)  for 20 min and 
blocked with a 1% BSA (Sigma, USA) in PBS solution for 20 min. Antibody staining was 
conducted for 30 min with a rabbit anti-mouse-LAMP1 antibody (BD Bioscience, USA). The 
goat anti rabbit Alexa Fluor 594 (BD Pharmingen, USA) secondary antibody was applied for 
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30 min. The cells were washed three times in PBS and mounted using Dako mounting medium 
(DakoCytomation, Australia). Confocal microscopy was performed using spinning disk and 
z-stacks were taken in slices of 1 µm.   
Griess assay  
The contents of nitrate and nitrite in the cell culture media were determined by Griess assay 
as described previously [15]. 50 µl cell culture medium was mixed with equal volumes of 
Griess reagents (1% sulphanilamide in 2.5% H3PO4, Sigma, USA), then 50 µl Griess reagent 
(0.1% napthylenediamide dihydrochloride, Sigma, USA) was added and incubated at room 
temperature for 10 min. The absorbance at 540 nm was measured by a microplate reader (Bio-
Rad, USA) and compared to a standard nitrite curve using sodium nitrite (Sigma, USA).  
 Statistical analysis   
Flow cytometry was conducted at least three times in duplicate or triplicate wells. Statistical 
significance was determined by Student’s unpaired t-test. P values of less than 0.05 were 
considered statistically significant.   
  
Results  
DFTD cells can be phagocytosed by B6.WT and B6.TNF-/- macrophages.   
To determine if DFTD cells could be phagocytosed, BMDMs from B6.WT and B6.TNF-/- 
mice (CTV labelled; blue) were co-incubated with DFTD C5065 cells (CFSE-labelled; green). 
After 4 hours and 24 hours culture, phagocytosis was analysed by confocal microscopy 
(Figure 1). Green DFTD cells could be identified within the blue macrophages from both 
B6.WT and B6.TNF-/- mice. When z-stacks were analysed the green fragments were identified 
inside the macrophages, suggesting the tumour cells had been engulfed (Fig 1). The 
degradation of phagocytosed cellular material involves the process of phagosome maturation 
through homotypic and heterotypic fusion of early endosomes, late endosomes and lysosomes 
[16]. The presence of lysosomal-associated membrane protein 1 (LAMP1) was used to 
discriminate a late phase of phagocytosis, after phagosomes/lysosome fusion [17]. LAMP1 
and engulfed tumour fragments were co-localized with LAMP1, confirming phagocytosis. As 
BMDMs from B6.WT and B6.TNF-/- mice can phagocytose DFTD cells, it suggests that TNF 
is not essential for phagocytosis and that DFTD cells are not resistant to phagocytosis.   
                                              





Figure 1. Confocal microscope analysis of macrophage phagocytosing DFTD cells. Co-
incubate CTV labelled BMDMs with CFSE labelled DFTD cells for 4 hours and 24 hours, 
cells were fixed and permeabilized, then labelled with anti-LAMP1 antibody. Phagocytosis 
was analysed in confocal microscopy. The z-stack demonstrated that tumour cells inside 
B6.WT and B6.TNF-/- macrophages after 4 hours and 24 hours incubation (Green, DFTD cells; 
Blue, macrophages; Red, LAMP1).    
  
TNF deficiency results in reduced phagocytic capacity in IFNγ/LPS treated macrophages.  
Confocal microscopy showed that DFTD cells are phagocytosed by BMDMs from B6.WT 
and B6.TNF-/- mice, but to determine phagocytic efficiency flow cytometry was used. 
BMDMs were labelled with CTV and DFTD cells were labelled with CFSE, then incubated 
at ratios of BMDMs: DFTD cells (10:1 and 5:1) at 37 ºC or 4 ºC for 4 hours. The phagocytosed 
DFTD cells were recognized as CFSE and CTV double positive cells. In the absence of 
stimulation (control) the phagocytic efficiencies of BMDMs from B6.WT and B6.TNF-/- mice 
were similar at both 10:1 (Fig 2A) and 5:1 (Fig 2B) ratios, indicating that DFTD cells can be 
phagocytosed. It also suggests that TNF is not required for macrophage phagocytosis of DFTD 
cells under steady-state conditions.   
In order to determine TNF involvement in phagocytosis following macrophage activation, 
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BMDMs were stimulated with IFNγ and LPS, IFNγ alone, LPS alone or IL-4 alone. Following 
IFNγ/LPS activation, macrophages from B6.TNF-/- mice displayed enhanced phagocytosis 
efficiency at both 10:1 (Fig 2A) and 5:1 (Fig 2B) ratios, compared with macrophages from 
B6.WT mice. However, BMDM macrophages from B6.TNF-/- mice stimulated with IFNγ or 
IL-4 did not show a significant difference in phagocytic efficiency, compared with BMDM 
from B6.WT mice (Fig 2A, 2B). Compared to untreated BMDMs, LPS treatment enhanced 
the phagocytic efficiency of BMDMs from wild-type and B6.TNF-/- mice (Fig 2A, 2B). But 
no significant difference was shown between BMDMs from wildtype and B6.TNF-/- mice 
following LPS activation.  
To confirm that the CFSE and CTV double positive cells represented phagocytosis rather than 
cell binding, DFTD cells and macrophages were co-incubated at 4 ºC for 4 hours (Fig 2C, 2D). 
The proportion of double positive cells was substantially reduced providing support for 
phagocytosis at 37 ºC rather than just binding to the cell surface.                                                                   
 
Figure 2. IFNγ/LPS treated B6.TNF-/- BMDMs exhibited enhanced phagocytic 
efficiency of DFTD cells compared to B6.WT BMDMs. B6.WT and B6.TNF-/- 
BMDMs were treated with IFNγ/LPS, IFNγ alone, LPS alone, or IL-4 alone. BMDMs 
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were labelled with CTV and DFTD cells were labelled with CFSE. After labelling, 
BMDMs were co-incubated with DFTD cells for 4 hours. The percentage of 
phagocytosed DFTD cells in the incubation of 37 C (A, B) and 4 C (C, D) was 
investigated by flow cytometry. Data were from 3-7 mice of two or three independent 
experiments, error bars indicate SEM, ΔP< 0.05 versus WT control, #P< 0.05 versus 
B6.TNF-/- control, *P< 0.05 versus WT versus B6.TNF-/-, NS not significantly.  
  
IFNγ/LPS, LPS activated BMDM from B6.TNF-/- mice phagocytose and kill DFTD cells 
more effectively than BMDM from B6.WT mice following 24 hours incubation.  
DFTD cell phagocytosis and killing was analysed with flow cytometry after 24 hours 
incubation by enumerating the number of viable DFTD cells remaining. The absolute number 
of free DFTD cells was calculated using cell count beads. IFNγ/LPS and LPS alone activated 
BMDMs from B6.TNF-/- mice cultured with DFTD cells for 24 hours resulted in fewer DFTD 
cells remaining compared to BMDMs from B6.WT mice at 10:1 and 5:1 ratios (Fig 3A, 3B). 
However, IFNγ or IL-4 activated BMDMs from B6.TNF-/- mice had similar number of DFTD 
cells with wild-type controls at 10:1 and 5:1 ratios (Fig 3A, 3B). These results indicate that 
LPS and potentially IFNγ/LPS activated macrophages from B6.TNF-/- mice phagocytosed 
more DFTD cells than macrophages from the B6.WT mice. Thus, although phagocytosis by 
activated BMDMs was observed in the presence of TNF, the absence of TNF appeared to 
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Figure 3: IFNγ/LPS, LPS activated B6.TNF-/- BMDMs are more effective at removing 
DFTD cells after 24 hours incubation than B6.WT BMDMs. BMDMs from B6.WT and 
B6.TNF-/- mice were treated with IFNγ/LPS, IFNγ alone, LPS alone, or IL-4 alone. BMDMs 
were labelled with CTV and DFTD cells were labelled with CFSE. After labelling, BMDMs 
were incubated with DFTD cells for 24 hours, and the absolute number of free DFTD cells 
was calculated using flow cytometry with cell count beads. Data were from 3-7 mice of two 
or three independent experiments, error bars indicate SEM, * P< 0.05.  
  
Less nitric oxide is released from IFNγ/LPS, LPS activated B6.TNF-/- macrophages after 
incubation with DFTD cells for 24 hours.  
Nitric oxide is an essential effector molecule in macrophages and is cytotoxic to tumour cells 
[18]. As TNF regulates the production of NO in macrophages [19], we determined whether 
NO is related to TNF regulation of macrophage phagocytosis of DFTD cells. IFNγ/LPS, IFNγ 
or LPS treated macrophages from B6.WT, B6.TNF-/- mice were co-incubated with DFTD cells 
for 24 hours and the NO contents in the cell culture supernatant were measured. As shown in 
Fig 4, untreated macrophages from both mouse genotypes did not release any detectable NO. 
In response to IFNγ/LPS activation, BMDMs from B6.TNF-/- mice released less NO than wild 
type controls. This was evident at 10:1 (Fig 4A) and 5:1 (Fig 4B) ratios. Similarly, less NO 
was released from LPS activated BMDMs from B6.TNF-/- mice than wild type controls (Fig 
4A, 4B). The IFNγ treatment did not alter NO production of B6.WT, B6.TNF-/- macrophages 
after incubation with DFTD cells for 24 hours (Fig 4A, 4B). The release of NO might associate 
with the alteration of phagocytosis in IFNγ/LPS and LPS alone treated B6.TNF-/- macrophages.  
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 Figure 4. Reduced NO production from IFNγ/LPS, LPS activated B6.TNF-/- 
macrophages phagocytosis of DFTD cells. B6.WT and B6.TNF-/- macrophages were 
stimulated with IFNγ/LPS, IFNγ or LPS overnight. Macrophages were co-incubated with 
DFTD cells at 10:1(A) and 5:1 (B) ratios, the concentration of NO in the cell culture 
supernatant was analysed in Griess assay. Data were from 3 mice, error bars indicate SEM, 
ΔΔ P< 0.01 versus WT control, ## P< 0.01 versus B6.TNF-/control, *P<0.05 versus WT versus 
B6.TNF-/-.   
  
NO is not required for TNF regulation of macrophage phagocytosis of DFTD cells.    
To determine the association of NO with increased phagocytic activity in IFNγ/LPS and LPS 
alone treated B6.TNF-/- macrophages. The NO release was blocked by the inhibitor of nitric 
oxide synthesis, L-N6- (1-Iminoethyl) lysine dihydrochlorideinducible (L-NIL). After the 
incubation with IFNγ/LPS or IFNγ/LPS and L-NIL for 24 hours, BMDMs from B6.WT and 
B6.TNF-/- mice were co-incubated with DFTD cells for 24 hours. The number of DFTD cells 
was measured by flow cytometry and cell counting beads. As shown in Fig 5, L-NIL did not 
alter phagocytosis following stimulation with IFNγ/LPS of macrophages from B6.WT or B6. 
TNF-/- mice. In addition, compared to IFNγ/LPS treatment, L-NIL treatment did not alter the 
phagocytic ability of macrophages from B6.WT or B6.TNF-/- mice (Fig 5). Thus, it suggests 
that NO was unrelated to the altered phagocytic ability of IFNγ/LPS treated macrophages from 
B6.TNF-/- mice.  
  
Figure 5. NO is unrelated to TNF involved macrophage phagocytosis of DFTD cells. 
B6.WT and B6.TNF-/- BMDMs were treated with IFNγ/LPS or IFNγ/LPS with L-NIL 
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overnight. After incubation with BMDMs and DFTD cells for 24 hours, the numbers of DFTD 
cells at E: T 10:1 (A), 5:1 (B) ratios were analysed by flow cytometry and cell counting beads. 
The numbers of DFTD cells were calculated as methods described. Data were from 3-5 mice 




The key points of our study are that DFTD cells are phagocytosed effectively by bone marrow 
derived macrophages from mice and that TNF reduced this phagocytosis. The main 
consequences of these findings are two-fold. DFTD avoidance of phagocytosis is unlikely to 
contribute to immune escape. Secondly, TNF is not required for phagocytosis, but it appears 
to negatively regulate phagocytosis by activated macrophages.   
The absence of MHC-I expression on DFT1 cells prevents the activation CD8+ T cell adaptive 
immune response [12]. This would prevent an adaptive cell mediated immune response. An 
enhancement of innate immune response to DFTD such as macrophage phagocytosis may 
provide a mechanism to promote anti-DFTD immune responses. This could be either naturally 
or artificially such as vaccination. The evidence that immunised devils [20, 21] and some wild 
devils [22] can produce antibodies against DFTD cells is in line with antibody mediated 
opsonisation of DFT1 cells and subsequent phagocytosis. For this to occur, DFT1 cells would 
need the capacity to be phagocytosed. Tumour cells can avoid phagocytosis by expressing 
inhibitory molecules such as the ‘don't eat me signal’, which is part of the immune checkpoint 
inhibitory pathway, preventing phagocytosis [23]. RNA transcriptome analysis identified 
CD47 from devil mononuclear cells, which aligned closely with other species [24]. Hence 
there is the potential for DFT1 cells to express this molecule to avoid phagocytosis. In the 
absence of monoclonal antibodies to identify such molecules and the unavailability of devil 
macrophages, we conducted phagocytosis of DFT1 cells using bone marrow derived mouse 
macrophages. If mouse derived macrophages could phagocytose DFT1 cells, then devil 
macrophages should also have this ability. We showed the phagocytosis of DFTD cells by 
mouse macrophages by two independent mechanisms, flow cytometry and confocal 
microscopy. The confocal microscopy, provided the additional evidence of destruction of the 
DFT1 tumour cells. The susceptibility of DFT1 cells to phagocytosis has at least two important 
implications. Firstly, wild devils that have the capacity to make antibodies against DFT1 cells 
could promote phagocytosis of antibody opsonised DFT1 cells [22]. Secondly, devil 
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immunised with DFT1 cells that produce antibody [20, 21] could also opsonise the DFT1 cells 
and target them for phagocytosis. In both situations, promotion of a specific immune response 
could follow due to the interaction of the macrophages and cytokines produced during 
phagocytosis. This could result in cytokines upregulating MHC-I [12]and the DFT1 cells 
becoming targets for CD8 T cells, as shown with immunotherapy [20].  
After determining that mouse macrophages effectively phagocytose DFT1 tumour cells we 
then investigated whether TNF was required. In the absence of stimulation, the presence of 
TNF made no difference to the phagocytic efficiency. But following activation with IFNγ/LPS 
or LPS (but not IFNγ), the presence of TNF reduced phagocytic activity. Although TNF is 
regarded as a master regulator of inflammatory cytokine production (reviewed in [25]) there 
are reports that TNF can inhibit macrophage phagocytic activity. Exogenous TNF has been 
shown to reduce the macrophage capacity to ingest apoptotic cells [26]. This inhibition 
appears specific for apoptotic cells as it is not seen with beads or antibody-opsonized cells 
[26]. The authors propose that within the inflammatory environment, the reduced phagocytic 
ability may ‘contribute to the local intensity of the inflammatory response’. Macrophages 
stimulated with LPS produce TNF and this would inhibit macrophage phagocytosis of 
apoptotic cells in an autocrine manner [27]. TNF is also produced by IFNγ/LPS activated 
macrophages [28, 29]. IFNγ on its own is unable to activate macrophages to produce TNF, 
but can do so in the presence of LPS [30]. The situation can be somewhat murky as some 
studies showed IFNγ primed macrophages [6, 31] can produce TNF. Furthermore, IFNγ 
appears to restore an impaired ability of macrophages to phagocytose apoptotic cells in a nitric 
oxide-dependent manner that required TNF production [6, 31]. But these might be due to the 
macrophages coming from different sources and at different stages of maturation. For example, 
although TNF-α has no effect on phagocytosis by immature macrophages, it reduces 
phagocytosis by mature macrophages [26].  
Phagocytosis of pathogens by macrophages requires NO and TNF dependent NO production 
is required for the enhanced phagocytosis of apoptotic cells by IFNγ activated macrophages 
[6]. However, NO can impair phagocytosis of fluoresecent particles by affecting cytoskeletal 
assembly and pseudopod formation [32]. TNF is definitely involved in NO production as it 
induces iNOS expression via NF- B [19, 29]. Furthermore, the expression of iNOS in 
IFNγ/LPS activation macrophages requires TNF [33]. TNF dependent NO production is 
required for the enhanced phagocytosis of apoptotic cells by IFNγ activated macrophages [6]. 
We blocked NO release by using L-NIL, but inhibition of NO did not alter phagocytosis 
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efficiency in IFNγ/LPS treated macrophages. It suggests the NO is independent of in TNF 
related IFNγ/LPS treated macrophages. Moreover, actin polymerization is an essential event 
in the process of macrophage phagocytosis. It has been suggested that exogenous TNF 
decreases actin reorganization in J774 macrophages [34]. The involvement of actin and TNF 
inhibition of phagocytosis activity in IFNγ/LPS activated macrophages needs to be further 
investigated.   
In this study, TNF is inhibitory in macrophage phagocytosis under activation. The orchestration 
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